

KODA-KIMBLE & YOUNG'S

APPLIED THERAPEUTICS

The Clinical Use of Drugs

TENTH EDITION

BRIAN K. ALLDREDGE

ROBIN L. CORELLI

MICHAEL E. ERNST

B. JOSEPH GUGLIELMO

PAMALA A. JACOBSON

WAYNE A. KRADJAN

BRADLEY R. WILLIAMS



Wolters Kluwer
Health

Lippincott
Williams & Wilkins

Applied Therapeutics

The Clinical Use of Drugs

TENTH EDITION

Edited By

Brian K. Alldredge, PHARM D

Professor of Clinical Pharmacy and Associate
Dean, Academic Affairs
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Robin L. Corelli, PHARM D

Professor of Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Michael E. Ernst, PHARM D, BCPS, FCCP

Professor (Clinical)
Department of Pharmacy Practice and Science
College of Pharmacy
Department of Family Medicine
Carver College of Medicine
The University of Iowa
Iowa City, Iowa

B. Joseph Guglielmo, PHARM D

Professor and Chair
TA Oliver Chair in Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Pamala A. Jacobson, PHARM D

Associate Professor
Department of Experimental and Clinical Pharmacology
College of Pharmacy
University of Minnesota
Minneapolis, Minnesota

Wayne A. Kradjan, PHARM D, BCPS

Dean Emeritus and Professor Emeritus
College of Pharmacy
Oregon State University
Oregon Health & Science University
Corvallis, Oregon

Bradley R. Williams, PHARM D, FASCP, CGP

Professor of Clinical Pharmacy and Clinical Gerontology
Titus Family Department of Clinical Pharmacy and
Pharmaceutical Economics and Policy
Schools of Pharmacy and Gerontology
University of Southern California
Los Angeles, California

Acquisitions Editor: David B. Troy
Project Manager: Meredith L. Brittain
Marketing Manager: Joy Fisher-Williams
Designer: Doug Smock
Compositor: Aptara, Inc.

© 2013, 2009, 2005 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER business
Two Commerce Square
2001 Market Street
Philadelphia, PA 19103 USA
LWW.com

Tenth Edition

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright.

Printed in China

Library of Congress Cataloging-in-Publication Data

Koda-Kimble and Young's applied therapeutics : the clinical use of drugs.

– 10th ed. / edited by Brian K. Alldredge . . . [et al.].

p. ; cm.

Applied therapeutics

Rev. ed. of: Applied therapeutics : the clinical use of drugs / edited

by Mary Anne Koda-Kimble ... [et al.]. 9th ed. c2009.

Includes bibliographical references and index.

ISBN 978-1-60913-713-7

I. Koda-Kimble, Mary Anne. II. Alldredge, Brian K. III. Applied therapeutics.

IV. Title: Applied therapeutics.

[DNLM: 1. Drug Therapy--methods. WB 330]

615.5'8--dc23

2011047631

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of the information in a particular situation remains the professional responsibility of the practitioner.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in the publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice.

To purchase additional copies of this book, call our customer service department at (800) 638-3030 or fax orders to (301) 223-2320. International customers should call (301) 223-2300.

Visit Lippincott Williams & Wilkins on the Internet: at LWW.com. Lippincott Williams & Wilkins customer service representatives are available from 8:30 am to 6 pm, EST.

9 8 7 6 5 4 3 2 1

The Editors wish to express their sincere thanks and longstanding admiration to the creators of Applied Therapeutics, Drs. Mary Anne Koda-Kimble and Lloyd Young. They are truly educational visionaries whom we deeply respect as the innovators and pioneers in the teaching of patient-centered drug therapeutics. Their passion has touched the lives of countless health care professional students, clinicians, and patients throughout the world. As their colleagues and friends, we are forever indebted for their contributions and we consider it a privilege to carry forward their legacy—renamed as Koda-Kimble and Young’s Applied Therapeutics—into future editions.

Preface

It has been nearly 40 years since the first edition of *Applied Therapeutics: The Clinical Use of Drugs* was published. The landscape of health care has evolved radically during this time, much of it spurred by remarkable advancements in drug discovery and clinical therapeutics. Despite these changes, the founding principle for this innovative text—a patient-centric, case-based approach to learning—remains integral to the current edition. Our authors present more than 860 patient cases that stimulate the reader to integrate and apply therapeutic principles in the context of specific clinical situations. Students and practitioners are provided with a glimpse into the minds of clinicians as they assess and solve therapeutic problems toward the development of their own critical-thinking and problem-solving skills. Every chapter in this edition has been revised and updated to reflect our ever-changing knowledge of drugs and the application of this knowledge to the individualized therapy of patients. Additionally, content within several sections has been extensively reorganized, with new chapters introduced to expand important topics. Among these are new chapters in the Arthritic Disorders, Women's Health, Neurologic Disorders, Neoplastic Disorders, and Pediatrics sections.

Readers familiar with past editions of the text will notice some welcome changes in the tenth edition. The overall design has been updated for visual appeal and to allow the reader to more quickly distinguish cases from surrounding text. In lieu of the traditional chapter outline, all chapters now contain a Core Principles section at the beginning, which provides the most important “take home” information from the chapter. Each Core Principle is mapped to specific cases within the chapter where the principle is discussed in detail. Key references and websites are listed at the end of each chapter, whereas the full reference lists for each chapter have been moved online.

A particularly significant change to the tenth edition is the incorporation of online multimedia content, much of it author-created, for many of the chapters. These include images, videos, narrated presentations, animations, and podcasts, which can be found on the textbook's website (see the “Additional Resources” section, which follows this preface, for more information). The incorporation of supplemental multimedia into the tenth edition marks a commitment on the part of the editorial team to ensure that *Koda-Kimble and Young's Applied Therapeutics* increases its role as a viable and dynamic resource that can appeal to multiple learning styles and future generations. We welcome your feedback as we undertake planning for the next edition.

The authors have drawn on information from the literature, current standards, and their own clinical experiences to share the process involved in making sound and thoughtful therapeutic decisions. *However, it remains the responsibility of every practitioner to evaluate the appropriateness of a particular opinion in the context of the actual clinical situation, bearing in mind any recent developments in the field. We strongly urge students and practitioners to consult*

several appropriate information sources when working with new and unfamiliar drugs.

ACKNOWLEDGMENTS

We are deeply indebted to the many dedicated people who have given of themselves to complete the tenth edition of *Koda-Kimble and Young's Applied Therapeutics*. As always, we are most grateful to our contributing authors who have been attentive to meeting our stringent time deadlines and unique writing format. We especially thank those authors who graciously provided multimedia to accompany their chapter, and we gratefully recognize the additional time and effort this entailed. We hold their creativity in the highest regard. The exceptional work of our section editors, Judith Beizer, Marcia Buck, Shareen El-Ibiary, Marcus Ferrone, Patrick Finley, Timothy Ives, Mark Kirstein, Lisa Kroon, Kelly Lee, Myrna Munar, Jean Nappi, Tricia Russell, and Joseph Saseen, cannot be overstated. These content experts gave us critical feedback necessary in both the organizational structure of the textbook and in the individual editing of chapters; without their dedication and assistance, this edition would not be possible. We would also like to thank Facts and Comparisons for allowing us to use their data for the construction of some of our tables.

Two individuals from Lippincott Williams and Wilkins, Meredith Brittain and Loftin (Paul) Montgomery, Jr., deserve special recognition for their efforts. Their exceptional patience, attention to detail, and firm guidance helped us all stay on task. This edition would not have come to completion without their partnership. Mary Tod (copyediting), Ed Schultes, Jr. (multimedia production), and Jeri Litteral (typesetting) all played key roles in the production of the tenth edition, and we sincerely thank them for their assistance in completing this edition. Most importantly, we would be remiss not to acknowledge the love, understanding, and support of our spouses, children, and in some cases, grandchildren. They selflessly gave to us the many early mornings, late nights, and weekends we spent writing and editing.

As in past editions, we continue to dedicate our work to our students who inspire us and to the many patients we have been privileged to care for. Our patients have repeatedly taught us how critical it is to tailor our knowledge to their specific circumstances, to listen well, and to welcome them as true partners in their care.

Brian K. Alldredge
Robin L. Corelli
Michael E. Ernst
B. Joseph Guglielmo
Pamala A. Jacobson
Wayne A. Kradjan
Bradley R. Williams

Additional Resources

The Tenth Edition of *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs* includes additional resources for both instructors and students, available on the book's companion website at <http://thepoint.lww.com/AT10e>.

STUDENT RESOURCES

Students who have purchased *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*, Tenth Edition have access to the following additional resources for each chapter:

- An audio recording of that chapter's core principles
- A full online reference list for that chapter

In addition, at least one of the following supplements each chapter to enhance the chapter content:

- Audio files (most recorded by author)
- PowerPoints (most created by author)
- PowerPoints with audio (most created/recorded by author)
- Animations

- Videos (some created by author)
- Additional content (created by author)
- Interactive versions of the algorithms found in the book
- Full-color images

INSTRUCTOR RESOURCES

Approved adopting instructors will be given access to the following additional resources:

- PowerPoint slides
- Image bank (includes all images and tables in the book)
- Pathophysiology image collection

In addition, purchasers of the text can access the searchable Full Text On-line by going to the *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*, Tenth Edition website at <http://thepoint.lww.com/AT10e>. See the inside front cover for more details, including the passcode you will need to gain access to the website.

Section Editors

Judith L. Beizer, PharmD, CGP, FASCP

Clinical Professor
Department of Clinical Pharmacy Practice
College of Pharmacy & Allied Health Professions
St. John's University
Jamaica, New York

Marcia L. Buck, PharmD, FCCP, FPPAG

Associate Professor, Pediatrics
School of Medicine
Clinical Coordinator, Pediatrics
Department of Pharmacy
University of Virginia
Charlottesville, Virginia

Shareen Y. El-Ibiary, PharmD, BCPS

Associate Professor of Pharmacy Practice
Department of Pharmacy Practice
Midwestern University, College of Pharmacy—Glendale
Glendale, Arizona

Marcus Ferrone, PharmD, BCNSP

Associate Professor of Clinical Pharmacy
Director, Drug Products Services Laboratory
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Patrick R. Finley, PharmD, BCPP

Professor of Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Timothy J. Ives, PharmD, MPH, FCCP, BCPS

Professor
Eshelman School of Pharmacy
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Mark N. Kirstein, PharmD

Associate Professor
Department of Experimental and Clinical Pharmacology
College of Pharmacy
University of Minnesota
Minneapolis, Minnesota

Lisa A. Kroon, PharmD, CDE

Professor of Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
Clinical Pharmacist, General Internal Medicine and
Diabetes Clinics
University of California, San Francisco Medical Center
San Francisco, California

Kelly C. Lee, PharmD, BCPP

Assistant Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of California, San Diego
La Jolla, California

Myrna Y. Munar, PharmD

Associate Professor
Department of Pharmacy Practice
College of Pharmacy
Oregon State University
Oregon Health and Science University
Portland, Oregon

Jean M. Nappi, PharmD, FCCP, BCPS

Professor
Clinical Pharmacy and Outcome Sciences
South Carolina College of Pharmacy
Clinical Pharmacy Specialist in Cardiology
Medical University of South Carolina
Charleston, South Carolina

Tricia M. Russell, PharmD, BCPS, CDE

Assistant Professor
Department of Pharmacy Practice
Wilkes University, Nesbitt College of Pharmacy & Nursing
Wilkes-Barre, Pennsylvania

Joseph J. Saseen, PharmD, FCCP, FASHP, BCPS

Professor
University of Colorado Anschutz Medical Campus
Schools of Pharmacy and Medicine
Director, PGY2 Ambulatory Care/Family Medicine
Residency
Clinical Pharmacy Specialist
Department of Family Medicine
Aurora, Colorado

Steven R. Abel, PharmD, FASHP

Associate Dean for Clinical Programs
Bucke Professor and Head
Department of Pharmacy Practice
Purdue University College of Pharmacy
West Lafayette, Indiana

Jessica L. Adams, PharmD

Human Immunodeficiency Virus Pharmacology Fellow
Eshelman School of Pharmacy
University of North Carolina Chapel Hill
Chapel Hill, North Carolina

Brian K. Alldredge, PharmD

Professor and Associate Dean
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Judith A. Alsop, PharmD

Health Sciences Clinical Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
Director, Sacramento Division, California Poison Control System
University of California, Davis Health System
San Francisco and Sacramento, California

J.V. Anandan, PharmD

Adjunct Associate Professor
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University
Pharmacy Specialist
Department of Pharmacy Services
Henry Ford Hospital
Detroit, Michigan

Heather M. Arnold, PharmD, BCPS

Critical Care Clinical Pharmacist
Department of Pharmacy
Barnes-Jewish Hospital
St. Louis, Missouri

Magdalene M. Assimon, PharmD

Nephrology Pharmacotherapy Research Fellow
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York

Francesca T. Aweeka, PharmD

Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Jennifer H. Baggs, PharmD, BCPS

Clinical Staff Pharmacist
Department of Pharmacy
University Medical Center
Tucson, Arizona

Maria Ballod, PharmD

Nutrition Support Pharmacist
Department of Pharmacy
Instructor of Pharmacy
College of Medicine
Mayo Clinic
Jacksonville, Florida

Andrew D. Barnes, PharmD

Clinical Professor
School of Pharmacy
University of Washington
Director, Critical Care Residency, Pharmacy Services
University of Washington Medicine
Seattle, Washington

David T. Bearden, PharmD

Clinical Associate Professor
Department of Pharmacy Practice
College of Pharmacy
Oregon State University
Portland, Oregon

Sandra Benavides, PharmD

Assistant Professor
Pharmacy Practice
College of Pharmacy
Nova Southeastern University
Clinical Pharmacist
Department of Pharmacy
Joe DiMaggio Children's Hospital
Fort Lauderdale and Hollywood, Florida

Rosemary R. Berardi, PharmD, FCCP, FASHP, FAPhA

Professor of Pharmacy
College of Pharmacy
University of Michigan
Ann Arbor, Michigan

Paul M. Beringer, PharmD, FASHP, FCCP

Associate Professor
Department of Clinical Pharmacy
University of Southern California
Los Angeles, California

Jeff F. Binkley, PharmD, BCNSP, FASHP

Assistant Professor
Department of Clinical Pharmacy
University of Tennessee College of Pharmacy
Director of Pharmacy
Maury Regional Medical Center
Memphis and Columbia, Tennessee

KarenBeth H. Bohan, PharmD, BCPS

Associate Professor
Department of Pharmacy Practice
Wilkes University
Clinical Pharmacist
Department of Pharmacy
Wilkes-Barre General Hospital
Wilkes-Barre, Pennsylvania

Laura M. Borgelt, PharmD, BCPS, FCCP

Associate Professor
 Departments of Clinical Pharmacy and Family
 Medicine
 University of Colorado Anschutz Medical Campus
 Aurora, Colorado

Jolene R. Bostwick, PharmD, BCPS, BCPP

Clinical Assistant Professor
 Department of Clinical, Social, and Administrative
 Sciences
 University of Michigan College of Pharmacy
 Clinical Pharmacist in Psychiatry
 Department of Pharmacy Services
 University of Michigan Health System
 Ann Arbor, Michigan

Nicole J. Brandt, PharmD, CGP, BCPP, FASCP

Associate Professor
 Department of Pharmacy Practice and Science
 University of Maryland, Baltimore
 Clinical Pharmacist, Geriatrics
 Veterans Affairs
 Baltimore, Maryland

Tina Penick Brock, MSPharm, EdD

Professor and Associate Dean
 Department of Clinical Pharmacy
 School of Pharmacy
 University of California, San Francisco
 San Francisco, California

Michael R. Brodeur, PharmD, CGP, FASCP

Associate Professor
 Department of Pharmacy Practice
 Albany College of Pharmacy and Health Sciences
 Albany, New York

Glen R. Brown, PharmD

Clinical Professor
 Faculty of Pharmaceutical Sciences
 University of British Columbia
 Clinical Pharmacy Specialist, Critical Care
 Department of Pharmacy
 St. Paul's Hospital
 Vancouver, British Columbia, Canada

Marcia L. Buck, PharmD, FCCP, FPPAG

Associate Professor, Pediatrics
 School of Medicine
 University of Virginia
 Clinical Coordinator, Pediatrics
 Department of Pharmacy
 University of Virginia
 Charlottesville, Virginia

Jamie J. Cavanaugh, PharmD

Clinical Instructor
 Division of Pharmacy Practice and Experiential Education
 Eshelman School of Pharmacy
 University of North Carolina at Chapel Hill
 Chapel Hill, North Carolina

Stanley W. Chapman, PharmD, MD

Professor Emeritus
 Department of Medicine
 University of Mississippi Medical Center
 Jackson, Mississippi

Steven W. Chen, PharmD, FASHP

Associate Professor
 Department of Clinical Pharmacy and Pharmaceutical
 Economics and Policy
 Hygeia Centennial Chair in Clinical Pharmacy
 University of Southern California School of Pharmacy
 Los Angeles, California

Michael F. Chicella, PharmD

Clinical Coordinator
 Department of Pharmacy
 Children's Hospital of The King's Daughters
 Norfolk, Virginia

Jennifer W. Chow, PharmD

Pediatric Clinical Specialist
 Department of Pharmacy
 Children's Hospital of The King's Daughters
 Norfolk, Virginia

Cary R. Chrisman, PharmD

Assistant Professor
 Department of Clinical Pharmacy
 University of Tennessee College of Pharmacy
 Clinical Pharmacist, Department of Pharmacy
 Methodist Medical Center
 Memphis and Oak Ridge, Tennessee

Thomas E. Christian, BSPHarm, BCPS

Pharmacy Therapeutics Manager, Infectious
 Disease Coordinator
 Department of Pharmacy
 PeaceHealth Southwest
 Vancouver, Washington

John D. Cleary, PharmD

Professor and Vice Chair of Research
 Department of Pharmacy Practice
 Assistant Professor, Medicine
 Department of Infectious Diseases
 University of Mississippi Schools of Pharmacy and Medicine
 Jackson, Mississippi

Michelle Condren, PharmD, AE-C, CDE

Associate Professor and Vice Chair
 Department of Clinical and Administrative Sciences—Tulsa
 College of Pharmacy
 Associate Professor, Pediatrics
 School of Community Medicine
 University of Oklahoma
 Tulsa, Oklahoma

Amanda H. Corbett, PharmD, BCPS, FCCP, AAHIVE

Clinical Assistant Professor
 Eshelman School of Pharmacy
 University of North Carolina
 Chapel Hill, North Carolina

Robin L. Corelli, PharmD

Professor of Clinical Pharmacy
 Department of Clinical Pharmacy
 School of Pharmacy
 University of California, San Francisco
 San Francisco, California

Timothy W. Cutler, PharmD, CGP

Associate Professor of Clinical Pharmacy
 Department of Clinical Pharmacy
 School of Pharmacy
 University of California, San Francisco
 San Francisco, California

Larry H. Danziger, PharmD

Professor of Pharmacy Practice
Department of Pharmacy Practice
University of Illinois at Chicago
Chicago, Illinois

Eli N. Deal, PharmD, BCPS

Clinical Pharmacist, Internal Medicine
Department of Pharmacy
Barnes-Jewish Hospital
St. Louis, Missouri

Ellen R. DeGrasse, PharmD, BCPS

Clinical Assistant Professor
Department of Pharmacy
University of Washington School of Pharmacy
Seattle, Washington

Philip T. Diaz, MD

Professor
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Betty J. Dong, PharmD, FASHP, FCCP

Professor of Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
Clinical Pharmacist, Thyroid Clinic
University of California, San Francisco
San Francisco, California

Andrew J. Donnelly, PharmD, MBA, FASHP

Clinical Professor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Director of Pharmacy Services
Department of Pharmacy
University of Illinois Medical Center at Chicago
Chicago, Illinois

Julie A. Dopheide, PharmD, BCPP

Associate Professor of Clinical Pharmacy, Psychiatry and the
Behavioral Sciences
University of Southern California Schools of Pharmacy and Medicine
Los Angeles County and University of Southern California Medical
Center
Los Angeles, California

Richard H. Drew, PharmD, MS, BCPS, FCCP

Professor
Campbell University College of Pharmacy and Health Sciences
Associate Professor of Medicine (Infectious Diseases)
Duke University School of Medicine
Duke Medical Center
Durham, North Carolina

Arkadiusz Z. Dudek, MD, PhD

Associate Professor
Department of Medicine
Division of Hematology-Oncology Transplantation
University of Minnesota
Minneapolis, Minnesota

Julie B. Dumond, PharmD, BCPS, AAHIVE

Research Assistant Professor
Division of Pharmacotherapy and Experimental Therapeutics
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Robert E. Dupuis, PharmD

Clinical Associate Professor
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Shareen Y. El-Ibiary, PharmD, BCPS

Associate Professor of Pharmacy Practice
Department of Pharmacy Practice
Midwestern University, College of Pharmacy—Glendale
Glendale, Arizona

Rene A. Endow-Eyer, PharmD, BCPP

Psychiatric Clinical Pharmacy Specialist
Department of Pharmacy Service
Veterans Affairs San Diego Healthcare System
San Diego, California

Michael E. Ernst, PharmD, BCPS, FCCP

Professor (Clinical)
Department of Pharmacy Practice and Science
College of Pharmacy
Department of Family Medicine
Carver College of Medicine
The University of Iowa
Iowa City, Iowa

Gregory A. Eschenauer, PharmD, BCPS

Clinical Pharmacist
Infectious Diseases
Department of Pharmacy
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Sanaz Farhadian, PharmD

Academic Detailing Pharmacist
Department of Pharmacy
Veterans Affairs San Diego Healthcare System
San Diego, California

Elizabeth Farrington, PharmD, FCCP, FCCM, FPPAG, BCPS

Clinical Assistant Professor
Department of Pharmacotherapy and Experimental
Education
Eshelman School of Pharmacy
University of North Carolina
Chapel Hill, North Carolina
Pharmacist III
Pediatrics
New Hanover Regional Medical Center
Betty H. Cameron Women's and Children's Hospital
Wilmington, North Carolina

Jonathan D. Ference, PharmD, BCPS

Associate Professor
Department of Pharmacy Practice
Wilkes University Nesbitt College of Pharmacy
and Nursing
Director of Pharmacotherapy Education
Wyoming Valley Family Medical Residency Program
Wilkes-Barre, Pennsylvania

Victoria F. Ferraresi, PharmD, FASHP, FCSHP

Associate Professor of Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
Director of Pharmacy Services
Pathways Home Health and Hospice
San Francisco and Sunnyvale, California

Christopher K. Finch, PharmD, BCPS

Associate Professor
Department of Clinical Pharmacy
University of Tennessee
Assistant Director
Clinical Pharmacy Services
Department of Pharmacy
Methodist University Hospital
Memphis, Tennessee

Patrick R. Finley, PharmD, BCPP

Professor of Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Douglas N. Fish, PharmD

Professor and Chair
Department of Clinical Pharmacy
University of Colorado School of Pharmacy
Clinical Specialist in Critical Care/Infectious Diseases
Department of Pharmacy
University of Colorado Hospital
Aurora, Colorado

Randolph V. Fugit, PharmD, BCPS

Clinical Assistant Professor
Department of Clinical Pharmacy Practice
University of Colorado at Denver Health Sciences Center
Internal Medicine Clinical Specialist
Department of Pharmacy
Denver Veterans Affairs Medical Center
Denver, Colorado

Mark W. Garrison, PharmD, FCCP

Assistant Dean and Associate Professor
Department of Pharmacotherapy
College of Pharmacy
Washington State University
Deaconess Medical Center
Spokane, Washington

James J. Gasper, PharmD

Assistant Clinical Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
Psychiatric Clinical Pharmacist
Community Behavioral Health Services
San Francisco Department of Public Health
San Francisco, California

Katherine R. Gerrald, PharmD, BCPS

Assistant Professor of Pharmacy Practice
Department of Pharmacy Practice
Presbyterian College School of Pharmacy
Clinton, South Carolina

Jane M. Gervasio, PharmD, BCNSP, FCCP

Vice Chair and Associate Professor
Department of Pharmacy Practice
Butler University
Indianapolis, Indiana

Virginia L. Ghafoor, PharmD

Clinical Pharmacy Specialist
Pain Management
University of Minnesota Medical Center
Division of Fairview Health Services
Minneapolis, Minnesota

Jeffery A. Goad, PharmD, MPH

Associate Professor of Clinical Pharmacy
Department of Clinical Pharmacy and Pharmaceutical
Economics and Policy
School of Pharmacy
University of Southern California
Los Angeles, California

Julie A. Golembiewski, PharmD

Clinical Associate Professor
Pharmacy Practice and Anesthesiology
University of Illinois at Chicago
Clinical Pharmacist
Hospital Pharmacy and Anesthesiology
University of Illinois Medical Center
Chicago, Illinois

Luis S. Gonzalez, III, PharmD, BCPS

Associate Clinical Preceptor of Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy
Manager, Clinical Pharmacy Services
Pharmaceutical Care Services
Conemaugh Memorial Medical Center
Pittsburgh and Johnstown, Pennsylvania

Mildred D. Gottwald, PharmD

Director
Clinical Research
Gilead Sciences
Foster City, California

Kathleen G.E. Green, MS, PharmD

Clinical Assistant Professor
Experimental and Clinical Pharmacology
University of Minnesota College of Pharmacy
Pharmacy Clinical Leader, Oncology/Bone Marrow Transplantation
Department of Pharmacy
University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota

B. Joseph Guglielmo, PharmD

Professor and Chair
TA Oliver Chair in Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
San Francisco, California

Karen M. Gunning, PharmD, BCPS, FCCP

Associate Professor (Clinical)
Departments of Pharmacotherapy and Family and Preventive
Medicine
University of Utah College of Pharmacy & School of Medicine
Clinical Pharmacist
University of Utah Sugarhouse Family Health Center
University of Utah Healthcare
Salt Lake City, Utah

Sally K. Guthrie, PharmD

Associate Professor
Department of Clinical and Social Administrative Sciences
College of Pharmacy
University of Michigan
Ann Arbor, Michigan

Mark R. Haase, PharmD, FCCP, BCPS

Associate Professor
Department of Pharmacy Practice
Health Sciences Center School of Pharmacy
Texas Tech University
Amarillo, Texas

Mary F. Hebert, PharmD, FCCP

Professor
Department of Pharmacy
University of Washington
Seattle, Washington

Emily L. Heil, PharmD, BCPS

Infectious Diseases Clinical Pharmacy Specialist
Department of Pharmacy
University of Maryland Medical Center
Baltimore, Maryland

David W. Henry, PharmD, MS, BCOP, FASHP

Associate Professor and Chair
Department of Pharmacy Practice
University of Kansas School of Pharmacy
Pediatric Hematology/Oncology Pharmacy Specialist
University of Kansas Hospital
Lawrence and Kansas City, Kansas

Richard N. Herrier, PharmD

Clinical Professor
Department of Pharmacy Practice and Science
College of Pharmacy
University of Arizona
Tucson, Arizona

Karl M. Hess, PharmD, FCPHA

Assistant Professor of Pharmacy Practice and Administration
Western University of Health Sciences
College of Pharmacy
Pomona, California

Mark T. Holdsworth, PharmD

Associate Professor of Pharmacy and Pediatrics and
Pharmacy Practice Head
College of Pharmacy
Executive Chair, Human Research Review Committee
University of New Mexico Health Sciences Center
Albuquerque, New Mexico

Curtis D. Holt, PharmD

Clinical Professor
Department of Surgery
University of California, Los Angeles
Los Angeles, California

Priscilla P. How, PharmD, BCPS

Assistant Professor
Department of Pharmacy, Faculty of Science
National University of Singapore
Principal Clinical Pharmacist
Department of Medicine, Division of Nephrology
National University Hospital
Singapore, Singapore

Karen Suchanek Hudmon, DrPH, MS, RPh

Associate Professor
Department of Pharmacy Practice
Purdue University
West Lafayette, Indiana

Matthew K. Ito, PharmD, FCCP, FNLA, CLS

Professor
Department of Pharmacy Practice
Oregon State University/Oregon Health Sciences
University
College of Pharmacy
Portland, Oregon

Gail S. Itokazu, PharmD

Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois, Chicago
Clinical Pharmacist
Department of Pharmacy
John H. Stroger Jr. Hospital of Cook County
Chicago, Illinois

Timothy J. Ives, PharmD, MPH, FCCP, BCPS

Professor
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Kellie L. Jones, PharmD, BCOP

Clinical Associate Professor
Department of Pharmacy Practice
Purdue University
Indianapolis, Indiana

Nicole A. Kaiser, RPh, BCOP

Clinical Assistant Professor
School of Pharmacy, The University of Colorado
Oncology Clinical Pharmacy Specialist
Department of Pharmacy
The Children's Hospital
Denver, Colorado

James S. Kalus, PharmD, BCPS

Senior Pharmacy Manager
Department of Pharmacy Services
Henry Ford Hospital
Detroit, Michigan

Angela D.M. Kashuba, BScPharm, PharmD, DABCP

Associate Professor
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Michael B. Kays, PharmD, FCCP

Associate Professor
Department of Pharmacy Practice
Purdue University College of Pharmacy
Indianapolis, Indiana

George A. Kenna, PhD, RPh

Assistant Professor of Psychiatry
Warren Alpert Medical School
Center for Alcohol Addiction Studies
Brown University
Clinical Pharmacist
Department of Pharmacy
Westerly Hospital
Providence and Westerly, Rhode Island

Jiwon Kim, PharmD, BCPS

Assistant Professor
Department of Clinical Pharmacy and Pharmaceutical Economics and
Policy
University of Southern California School of Pharmacy
Clinical Pharmacist
Department of Pharmacy
University of Southern California University Hospital
Los Angeles, California

Mark N. Kirstein, PharmD

Associate Professor
Department of Experimental and Clinical Pharmacology
College of Pharmacy
University of Minnesota
Minneapolis, Minnesota

Katie L. Kiser, PharmD, BCPS

Assistant Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Baltimore, Maryland

Daren L. Knoell, PharmD, FCCP

Professor
Departments of Pharmacy and Internal Medicine
Davis Heart and Lung Research Institute
The Ohio State University
Columbus, Ohio

Lee A. Kral, PharmD, BCPS

Adjunct Assistant Professor
Department of Anesthesia
The University of Iowa Carver College of Medicine
Clinical Pharmacy Specialist, Pain Management
Department of Pharmaceutical Care
The University of Iowa Hospitals and Clinics
Iowa City, Iowa

Bridgette L. Kram, PharmD

Surgical/Trauma Intensive Care Unit Clinical Pharmacist
Department of Pharmacy
Wesley Medical Center
Wichita, Kansas

Robert A. Kratzke, MD

Associate Professor
Department of Medicine
Division of Hematology-Oncology Transplantation
University of Minnesota
Minneapolis, Minnesota

Donna M. Kraus, PharmD, FAPhA, FPPAG

Pediatric Clinical Pharmacist
Associate Professor of Pharmacy Practice
Departments of Pharmacy Practice and Pediatrics
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, Illinois

Lisa A. Kroon, PharmD, CDE

Professor of Clinical Pharmacy
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
Clinical Pharmacist, General Internal Medicine and
Diabetes Clinics
University of California, San Francisco Medical Center
San Francisco, California

Jonathan P. Lacro, PharmD, BCPS, BCPP

Associate Clinical Professor
Departments of Pharmacy & Pharmaceutical Science
and Psychiatry
University of California, San Diego
Director, Pharmacy Education and Training
Department of Pharmacy
Veterans Affairs San Diego Healthcare System
San Diego, California

Alan H. Lau, PharmD

Professor
Director, International Clinical Pharmacy Education
College of Pharmacy
University of Illinois at Chicago
Chicago, Illinois

Kelly C. Lee, PharmD, BCPP

Assistant Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of California, San Diego
La Jolla, California

Michelle Lee, PharmD

Infectious Disease Pharmacist
Department of Pharmacy
Methodist Hospital of Southern California
Arcadia, California

Susan H. Lee, PharmD

Surgery/Critical Care Clinical Pharmacist
Department of Pharmacy
Veterans Affairs Puget Sound Medical Center
Seattle, Washington

Lisa K. Lohr, PharmD, BCPS, BCOP

Clinical Assistant Professor
College of Pharmacy
University of Minnesota
Oncology Pharmacy Specialist/Oncology Medication Therapy
Management Provider
Masonic Cancer Center (University of Minnesota/Fairview)
Minneapolis, Minnesota

Rex S. Lott, PharmD, BCPP

Professor
Department of Pharmacy Practice & Administrative Sciences
Idaho State University College of Pharmacy
Mental Health Clinical Pharmacist
Department of Pharmacy and Mental Health
Boise Veterans Affairs Medical Center, Boise, Idaho
Clinical Associate Professor
University of Washington School of Medicine
Department of Psychiatry and Behavioral Sciences
Seattle, Washington

Sherry Luedtke, PharmD, FPPAG

Associate Professor
Department of Pharmacy Practice
Texas Tech Health Sciences Center School of Pharmacy
Amarillo, Texas

May Mak, PharmD

Assistant Professor
Department of Clinical Pharmacy and Pharmaceutical
Economics and Policy
University of Southern California
Los Angeles, California

Joel C. Marrs, PharmD, BCPS (AQ Cardiology), CLS

Assistant Professor
University of Colorado Anschutz Medical Campus
School of Pharmacy
Clinical Pharmacy Specialist
Department of Pharmacy
Denver Health
Aurora, Colorado

Darius L. Mason, PharmD, BCPS

Assistant Professor
Department of Pharmacy Practice
Albany College of Pharmacy and Health Science
Albany, New York

James W. McAuley, PhD, FAPhA

Associate Professor
Departments of Pharmacy Practice and
Neurology
The Ohio State University College of Pharmacy
Columbus, Ohio

James P. McCormack, BSc(Pharm), PharmD

Professor
Faculty of Pharmaceutical Sciences
University of British Columbia
Vancouver, British Columbia, Canada

Jennifer McNulty, MD

Associate Clinical Professor
Department of Obstetrics and Gynecology
Division of Maternal Fetal Medicine
University of California, Irvine
Staff Perinatologist
Long Beach Memorial Medical Center
Long Beach, California

Scott T. Micek, PharmD, BCPS, FCCP

Clinical Pharmacist, Critical Care
Department of Pharmacy
Barnes-Jewish Hospital
St. Louis, Missouri

Robert K. Middleton, PharmD

Director of Pharmacy
Department of Pharmacy
Ministry Saint Clare's Hospital
Weston, Wisconsin

Molly G. Minze, PharmD

Assistant Professor
Department of Pharmacy Practice
Texas Tech Health Sciences Center
School of Pharmacy
Abilene, Texas

Myrna Y. Munar, PharmD

Associate Professor
Department of Pharmacy Practice
College of Pharmacy
Oregon State University
Oregon Health and Science University
Portland, Oregon

Milap C. Nahata, PharmD, MS

Professor and Division Chair
Director, Institute of Therapeutic Innovations and
Outcomes
College of Pharmacy
Professor of Internal Medicine and Pediatrics
College of Medicine
Associate Director, Pharmacy
Ohio State University Medical Center
The Ohio State University
Columbus, Ohio

Jean M. Nappi, PharmD, FCCP, BCPS

Professor
Clinical Pharmacy and Outcome Sciences
South Carolina College of Pharmacy
Clinical Pharmacy Specialist in Cardiology
Medical University of South Carolina
Charleston, South Carolina

Paul E. Nolan, Jr., PharmD

Professor
Department of Pharmacy Practice & Science
College of Pharmacy
University of Arizona
Cardiovascular Clinical Pharmacist
University Medical Center
Tucson, Arizona

Edith A. Nutescu, PharmD, FCCP

Clinical Professor
Pharmacy Practice and Center for Pharmacoeconomic Research
University of Illinois at Chicago College of Pharmacy
Director, Antithrombosis Center
University of Illinois at Chicago Medical Center
Chicago, Illinois

Cindy L. O'Bryant, PharmD, BCOP

Associate Professor
Department of Clinical Pharmacy
University of Colorado
Oncology Clinical Specialist
Department of Pharmacy
University of Colorado Cancer Center
Aurora, Colorado

Rory E. O'Callaghan, PharmD

Clinical Pharmacist
Adjunct Assistant Professor of Pharmacy Practice
University of Southern California School of Pharmacy
Los Angeles, California

Julie L. Olenak, PharmD

Associate Professor
Department of Pharmacy Practice
Wilkes University
Nesbitt College of Pharmacy and Nursing
Wilkes-Barre, Pennsylvania

Neeta Bahal O'Mara, PharmD, BCPS, CCP

Clinical Pharmacist
Dialysis Clinic, Inc.
North Brunswick, New Jersey

Makala B. Pace, PharmD, BCOP

Clinical Pharmacy Specialist
Division of Pharmacy
Thoracic/Head & Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Robert Lee Page, II, PharmD, MSPH, FCCP, FASHP, FAHA, FASCP, BCPS, CGP

Associate Professor
Departments of Clinical Pharmacy & Physical Medicine
University of Colorado Schools of Pharmacy and Medicine
Clinical Specialist
Division of Cardiology
University of Colorado Hospital
Aurora, Colorado

Louise Parent-Stevens, PharmD, BCPS

Clinical Assistant Professor
 Department of Pharmacy Practice
 College of Pharmacy
 University of Illinois at Chicago
 Clinical Pharmacist
 Department of Family Medicine
 University of Illinois Medical Center
 Chicago, Illinois

Patricia L. Parker, PharmD, BCPS

Health Sciences Associate Clinical Professor
 Department of Clinical Pharmacy
 School of Pharmacy
 University of California, San Francisco
 Clinical Coordinator
 Department of Pharmacy
 University of California, Davis Medical Center
 Sacramento, California

Katherine Tipton Patel, PharmD, BCOP

Clinical Pharmacy Specialist
 Division of Pharmacy
 Thoracic/Head and Neck Medical Oncology
 The University of Texas
 MD Anderson Cancer Center
 Houston, Texas

Margaret M. Pearson, PharmD, MS

Director, Department of Pharmacy
 Mississippi State Department of Health
 Jackson, Mississippi

Jennifer Tran Pham, PharmD, BCPS

Clinical Assistant Professor
 Departments of Pharmacy Practice and Pediatrics
 University of Illinois at Chicago College of Pharmacy
 Neonatal Clinical Pharmacist
 Department of Pharmacy
 University of Illinois at Chicago Medical Center at Chicago
 Chicago, Illinois

Brian A. Potoski, PharmD

Assistant Professor
 Departments of Pharmacy and Therapeutics
 University of Pittsburgh School of Pharmacy
 Associate Director, Antibiotic Management Program
 University of Pittsburgh Medical Center
 Presbyterian University Hospital
 Pittsburgh, Pennsylvania

David J. Quan, PharmD

Clinical Professor of Pharmacy
 Department of Clinical Pharmacy
 School of Pharmacy
 University of California, San Francisco
 Clinical Pharmacist
 Department of Pharmaceutical Services
 University of California, San Francisco Medical Center
 San Francisco, California

Ralph H. Raasch, PharmD, FCCP, BCPS

Associate Professor
 Department of Pharmacy Practice and Experiential Education
 Eshelman School of Pharmacy
 University of North Carolina at Chapel Hill
 Chapel Hill, North Carolina

Andrei M. Rakic, MD

Assistant Professor of Clinical Anesthesiology
 Department of Anesthesiology
 University of Illinois at Chicago
 Anesthesiologist and Pain Physician
 Department of Anesthesiology
 University of Illinois Medical Center
 Chicago, Illinois

Erin C. Raney, PharmD, BCPS

Associate Professor
 Department of Pharmacy Practice
 Midwestern University College of Pharmacy—Glendale
 Campus
 Clinical Pharmacist
 Midwestern University Multispecialty Clinic
 Glendale, Arizona

Alison M. Reta, PharmD

Clinical Pharmacist
 Adjunct Assistant Professor of Pharmacy Practice
 University of Southern California School of Pharmacy
 Los Angeles, California

John R. Rogosheske, PharmD

Clinical Assistant Professor
 College of Pharmacy
 University of Minnesota
 Clinical Pharmacist
 Department of Pharmacy Services
 University of Minnesota Medical Center, Fairview
 Minneapolis, Minnesota

Carol J. Rollins, PharmD, MS, RD, BCNSP

Clinical Associate Professor
 Department of Pharmacy Practice and Science
 The University of Arizona
 Interim Assistant Director, Clinical Pharmacy
 Department of Pharmacy, University Medical Center
 Tucson, Arizona

Rebecca A. Rottman-Sagebiel, PharmD, BCPS, CGP

Clinical Assistant Professor
 Pharmacy Education and Research Center
 University of Texas at Austin
 Geriatric Clinical Pharmacy Specialist
 Department of Pharmacy
 South Texas Veterans Health Care System
 San Antonio, Texas

Melody Ryan, PharmD, MPH

Associate Professor
 Department of Pharmacy Practice and Science
 College of Pharmacy
 Department of Neurology
 College of Medicine
 University of Kentucky
 Clinical Pharmacy Specialist
 Department of Pharmacy
 Veterans Affairs Medical Center
 Lexington, Kentucky

Joseph J. Saseen, PharmD, FCCP, FASHP, BCPS

Professor
 University of Colorado Anschutz Medical Campus
 Schools of Pharmacy and Medicine
 Director, PGY2 Ambulatory Care/Family Medicine Residency
 Clinical Pharmacy Specialist
 Department of Family Medicine
 Aurora, Colorado

Eric F. Schneider, PharmD, BCPS

Associate Dean, Northwest Campus
Associate Professor of Pharmacy Practice
Associate Professor of Family and Preventive Medicine
University of Arkansas for Medical Sciences
Fayetteville, Arkansas

Patricia M. Schuler, PharmD

Associate Professor
Department of Clinical Pharmacy and Outcome
Sciences
South Carolina College of Pharmacy
Clinical Specialist—Cardiology
Department of Pharmacy
The Medical University of South Carolina
Charleston, South Carolina

Catrina R. Schwartz, PharmD

Clinical Assistant Professor
Department of Pharmacotherapy
Washington State University College of Pharmacy
Spokane, Washington

Timothy H. Self, PharmD

Professor of Clinical Pharmacy
College of Pharmacy
University of Tennessee Health Science Center
Director, PGY2 Internal Medicine Pharmacy Residency
Department of Pharmacy
Methodist University Hospital
Memphis, Tennessee

Amy Hatfield Seung, PharmD, BCOP

Clinical Specialist, Hematologic Malignancies
Department of Pharmacy
Johns Hopkins Hospital
Baltimore, Maryland

Sachin R. Shah, PharmD, BCOP, FCCP

Associate Professor
Department of Pharmacy Practice
Texas Tech University Health Science Center—School
of Pharmacy
Advanced Clinical Pharmacist
Department of Pharmacy
Veterans Administration North Texas Health Care System
Dallas, Texas

Carrie A. Sincak, PharmD, BCPS

Vice Chair of Acute Care and Associate Professor
Department of Pharmacy Practice
Midwestern University Chicago College of Pharmacy
Downer's Grove, Illinois
Clinical Pharmacist
Department of Internal Medicine
Loyola University Medical Center
Maywood, Illinois

Harleen Singh, PharmD

Clinical Associate Professor
Department of Pharmacy Practice
Oregon State University
Clinical Specialist Pharmacist
Department of Pharmacy
Veterans Affairs Medical Center
Portland, Oregon

Julian Hoyt Slade, III, PharmD, BCOP

Clinical Pharmacy Specialist
Gastrointestinal Medical Oncology
Division of Pharmacy
University of Texas
MD Anderson Cancer Center
Houston, Texas

Jessica C. Song, MA, PharmD

Clinical Pharmacy Supervisor
PGY1 Pharmacy Residency Coordinator
Department of Pharmacy Services
Santa Clara Valley Medical Center
San Jose, California

Suellyn J. Sorensen, PharmD, BCPS

Clinical Pharmacist Specialist
Infectious Diseases, Pulmonary, and Neurology
Director, Midwest AIDS Education and Training
Center Indiana
Department of Pharmacy
University Hospital of Indiana University Health
Indianapolis, Indiana

Marilyn R. Stebbins, PharmD

Health Sciences Clinical Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
Pharmacy Utilization Director
CHW Medical Foundation Mercury Medical Group
Department of Pharmacy
Catholic Healthcare West Medical Foundation
San Francisco and Sacramento, California

Glen L. Stimmel, PharmD, BCPP

Professor of Clinical Pharmacy, Psychiatry and the
Behavioral Sciences
University of Southern California School of Pharmacy
Keck School of Medicine
Los Angeles, California

Steve Stricker, PharmD, MS, BCOP

Assistant Professor
Department of Pharmacy Practice
Samford University McWhorter School of Pharmacy
Birmingham, Alabama

David J. Taber, PharmD, BCPS

Clinical Assistant Professor
Department of Clinical Pharmacy and Outcomes Sciences
South Carolina College of Pharmacy
Clinical Pharmacy Specialist
Department of Pharmacy Services
Medical University of South Carolina
Charleston, South Carolina

**Kimberly B. Tallian, PharmD, BCPP, FASHP,
FCCP, FCSHP**

Associate Clinical Professor, Pharmacy
University of California, San Francisco and University
of California, San Diego
Pharmacy Clinical Manager
Department of Pharmacy
Scripps Memorial Hospital—La Jolla
La Jolla, California

Yasar O. Tasnif, PharmD

Clinical Assistant Professor
Cooperative Pharmacy Program
University of Texas—Pan American
Edinburg, Texas

Daniel J. G. Thirion, PharmD, FCSHP

Clinical Associate Professor
Faculte de Pharmacie
University of Montreal
Pharmacist
Department of Pharmacy
McGill University Health Center
Montreal, Quebec, Canada

Lisa A. Thompson, PharmD

Assistant Professor
Department of Clinical Pharmacy
University of Colorado School of Pharmacy
Oncology Clinical Specialist
Department of Pharmacy
University of Colorado Cancer Center
Aurora, Colorado

Dominick P. Trombetta, PharmD, BCPS, CGP, FASCP

Associate Professor
Department of Pharmacy Practice
Wilkes University
Wilkes-Barre, Pennsylvania

Toby C. Trujillo, PharmD, BCPS

Associate Professor
Department of Clinical Pharmacy
University of Colorado School of Pharmacy
Clinical Specialist, Cardiology/Anticoagulation
Department of Pharmacy
University of Colorado Hospital
Aurora, Colorado

Kimey D. Ung, PharmD, BCPS

Clinical Pharmacy Specialist
Center for Women Obstetrics Division
Long Beach Memorial Medical Center and Miller
Children's Hospital
Assistant Clinical Professor
Department of Clinical Pharmacy
School of Pharmacy
University of California, San Francisco
Long Beach and San Francisco, California

Geoffrey C. Wall, PharmD, FCCP, BCPS, CGP

Professor of Clinical Sciences
Department of Clinical Sciences
Drake University College of Pharmacy
Clinical Pharmacist
Iowa Inflammatory Bowel Disease Center
Des Moines, Iowa

Sheila K. Wang, PharmD, BCPS (AQ-ID)

Assistant Professor
Department of Pharmacy Practice
Midwestern University Chicago College of Pharmacy
Clinical Pharmacist, Infectious Disease
Department of Pharmacy
Rush University Medical Center
Chicago, Illinois

Brian Watson, PharmD, BCPS

Clinical Pharmacy Specialist, Critical Care
Department of Pharmacy
Union Memorial Hospital
Clinical Assistant Professor
University of Maryland School of Pharmacy
Baltimore, Maryland

Kristin Watson, PharmD, BCPS

Assistant Professor
Department of Pharmacy Practice and Sciences
University of Maryland School of Pharmacy
Baltimore, Maryland

C. Wayne Weart, PharmD, BCPS, FASHP, FAPhA

Professor of Clinical Pharmacy and Outcome Sciences
South Carolina College of Pharmacy
Professor of Family Medicine
Medical University of South Carolina
Charleston, South Carolina

Lynn Weber, PharmD, BCOP

Clinical Pharmacist in Oncology/Hematology
Pharmacy Residency Coordinator and PGY-1 Residency Director
Department of Pharmacy
Hennepin County Medical Center
Minneapolis, Minnesota

Timothy E. Welty, PharmD, FCCP

Professor
Department of Pharmacy Practice
University of Kansas School of Pharmacy
Lawrence, Kansas

C. Michael White, PharmD, FCP, FCCP

Professor and Head
Department of Pharmacy Practice
University of Connecticut
Director, Evidence-based Practice Center
University of Connecticut/Hartford Hospital
Storrs and Hartford, Connecticut

Bradley R. Williams, PharmD, FASCP, CGP

Professor of Clinical Pharmacy and Clinical Gerontology
Titus Family Department of Clinical Pharmacy and
Pharmaceutical Economics and Policy
Schools of Pharmacy and Gerontology
University of Southern California
Los Angeles, California

Casey B. Williams, PharmD, BCOP

Adjunct Clinical Assistant Professor
Department of Pharmacy Practice
University of Kansas School of Pharmacy
Hematology/Oncology Clinical Coordinator and Residency Director
Department of Pharmacy
University of Kansas Hospital
Lawrence and Kansas City, Kansas

Craig Williams, PharmD

Associate Professor
Department of Pharmacy Practice
Oregon State University
Clinical Specialist
Department of Family Medicine
Oregon Health Sciences University Hospital
Portland, Oregon

Dennis M. Williams, PharmD

Associate Professor
Division of Pharmacotherapy and Experimental Therapeutics
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Clinical Specialist
Department of Pharmacy
University of North Carolina Hospitals
Chapel Hill, North Carolina

Ann K. Wittkowsky, PharmD, CACP, FASHP, FCCP

Clinical Professor
Department of Pharmacy
University of Washington School of Pharmacy
Director, Anticoagulation Services
Department of Pharmacy
University of Washington Medical Center
Seattle, Washington

Katie A. Won, PharmD, BCOP

Clinical Associate
College of Pharmacy
University of Minnesota
Clinical Pharmacist, Oncology
Department of Pharmacy
Hennepin County Medical Center
Minneapolis, Minnesota

Annie Wong-Beringer, PharmD, FCCP, FIDSA

Associate Professor
Department of Clinical Pharmacy
University of Southern California
Infectious Diseases Pharmacist
Department of Pharmacy
Huntington Hospital
Los Angeles, California

Wendy O. Zizzo, PharmD

Associate Professor
Behavior Sciences/Alcohol and Other
Drug Studies
San Diego City College
San Diego, California

Paolo V. Zizzo, DO

Assistant Clinical Professor
Department of Medicine
University of California, San Diego
Medical Staff, Department of Medicine
Tri City Medical Center
San Diego and Oceanside, California

Reviewers

Steven R. Abel, PharmD, FASHP

Associate Dean for Clinical Programs
College of Pharmacy
Head, Department of Pharmacy Practice
Bucke Professor of Pharmacy Practice
Purdue University
Indianapolis, Indiana

Saafan Al-Safi, BScPharm, RPh, PhD

Professor in Clinical Pharmacy & Therapeutics
International Advisor in Clinical Pharmacy
Ontario College of Pharmacists
Toronto, Canada

William L. Baker, PharmD, BCPS

Assistant Clinical Professor of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut

Veronica Bandy, PharmD, MS, FCPA, FCSHP

Director of IPP Programs
Assistant Clinical Professor
Department of Pharmacy Practice
University of the Pacific
Stockton, California

John D. Bowman, MS

Associate Professor
Department of Pharmacy Practice
Texas A&M HSC Rangel College of Pharmacy
Kingsville, Texas

Elias B. Chahine, PharmD, BCPS

Assistant Professor of Pharmacy Practice
Clinical Pharmacists
Palm Beach Atlantic University Gregory School of Pharmacy
West Palm Beach, Florida

Eunice P. Chung, PharmD

Associate Professor of Pharmacy Practice and Administration
Director of Curriculum Development Pharmacy Practice
Western University of Health Sciences, College of Pharmacy
Pomona, California

Charles C. Collins, BS, PhD

Professor of Pharmaceutical Sciences
Bill Gatton College of Pharmacy
East Tennessee State University
Johnson City, Tennessee

Stephanie Counts, PharmD

Associate Professor
Pharmacy Practice
Midwestern University—Glendale
Glendale, Arizona

Monika N. Daftary, PharmD

Associate Professor
Clinical and Pharmacy Administrative Sciences
Howard University College of Pharmacy
Washington, District of Columbia

Sudip Das, PhD

Associate Professor
Pharmacy
Butler University
Indianapolis, Indiana

Crystal Deas, PharmD, BCPS

Assistant Professor of Pharmacy Practice
Pharmacy Practice Primary Care Residency
Harding University
Searcy, Arkansas

Lea S. Eiland, PharmD, BCPS

Associate Clinical Professor and Associate Department Head
Pharmacy Practice
Auburn University
Huntsville, Alabama

Glen E. Farr, PharmD

Professor and Associate Dean for Continuing Education
The University of Tennessee Health Science Center
Knoxville, Tennessee

Rebecca S. Finley, PharmD

Founding Dean
Pharmacy
Thomas Jefferson University Jefferson School of Pharmacy
Philadelphia, Pennsylvania

Jill Fitzgerald, PhD

Professor of Literacy
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Gina Garrison, BS, PharmD

Associate Professor
Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York

Nicole Harder, RN, BN, MPA

Coordinator, Simulation Learning Centers
University of Manitoba Faculty of Nursing
Winnipeg, Canada

Arthur F. Harralson, PharmD, BCPS

Professor and Chairman
Pharmacogenomics
Associate Dean for Academic Affairs Administration
Shenandoah University
Winchester, Virginia

Angela Kim-Sing, PharmD, ACPR, FCSHP

Director, Office of Experiential Education
Faculty of Pharmaceutical Sciences
The University of British Columbia
Vancouver, Canada

Chris King-Talley, PhD

Interdisciplinary Graduate Studies
University of Calgary
Calgary, Alberta, Canada

Harold Kirschenbaum, MS, PharmD

Associate Dean for Professional Affairs
Professor of Pharmacy Practice
Arnold & Marie Schwartz College of Pharmacy and Health Sciences
Long Island University
Long Island, New York

Brian M. Matayoshi, PhD

Professor of Physiology
Philadelphia College of Osteopathic Medicine - Georgia Campus
Suwanee, Georgia

Laurie Mauro, PharmD

Professor of Clinical Pharmacy
Director of Educational Assessment
Department of Pharmacy Practice
College of Pharmacy and Pharmaceutical Sciences
The University of Toledo
Toledo, Ohio

Beverly C. Mims, PharmD

Associate Professor
Pharmacy Practice
Howard University School of Pharmacy
Washington, District of Columbia

Stefanie Nigro, PharmD

Assistant Professor of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, Connecticut

Kathleen Pace Murphy, MBA

Professor
University of Texas Health Science Center
Health Careers
Houston, Texas

Nathan Painter, PharmD, CDE

Assistant Clinical Professor
UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences
La Jolla, California

Michael J. Peeters, PharmD, MEd, BCPS

Clinical Associate Professor
Department of Pharmacy Practice
University of Toledo College of Pharmacy & Pharmaceutical Sciences
Toledo, Ohio

Helen Pervanas, PharmD, RPh

Assistant Professor of Pharmacy Practice
Department of Pharmacy Practice-Worcester/Manchester
Massachusetts College of Pharmacy and Health Sciences
Worcester, Massachusetts

Christine M. Petraglia, RPh, MSED

Holyoke Medical Center
Clinical Pharmacist
Holyoke, Massachusetts

John Poon, PharmD

Inpatient Pharmacist
Clinical Pharmacist
Kaiser Permanente Antioch Medical Center
Antioch, California

Keith Rodvold, PharmD

Professor
Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Jessica Rogers

Academic Coordinator
Education
Trillium College
Oshwa, Ontario, Canada

Martha Zervopoulos Siomos, DNP, MSN, ADM-BC, FNP-BC

Assistant Professor
Family Nurse Practitioner
Rush University College of Nursing
Chicago, Illinois

Candace Smith, PharmD

Associate Clinical Professor and Chair
Clinical Pharmacy Practice Department
Clinical Pharmacy Practice
St. John's University and Allied Health Professions
Queens, New York

Linda Spooner, PharmD, BCPS

Associate Professor of Pharmacy Practice
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Worcester, Massachusetts

Michael Steinberg, PharmD, BCOP

Associate Professor of Pharmacy Practice
Department of Pharmacy Practice Worcester/Manchester School of
Pharmacy
Massachusetts College of Pharmacy and Health Sciences
Worcester, Massachusetts

Michael C. Thomas, PharmD, BCPS

Assistant Professor
Pharmacy Practice (Emergency Medicine)
South University-Savannah
Savannah, Georgia

Andrea Traina, PharmD

Assistant Professor
St. John Fisher College Wegmans School of Pharmacy
Rochester, New York

April Vallerand, BSN, MSN, PhD Nursing

Associate Professor
Wayne State University College of Nursing
Detroit, Michigan

Arun Verma, PhD, MSc

Instructor
Division of Pharmacy Practice
The University of British Columbia
Vancouver, British Columbia, Canada

Kristina Ward, PharmD, BCPS

Clinical Associate Professor
Department of Pharmacy Practice
University of Rhode Island College of Pharmacy
Kingston, Rhode Island

Kathy Zaiken, PharmD

Assistant Professor
Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Boston, Massachusetts

Brief Table of Contents

SECTION 1: GENERAL CARE 1

- 1 Assessment of Therapy and Medication Therapy Management 1**
Marilyn R. Stebbins, Timothy W. Cutler, and Patricia L. Parker
- 2 Interpretation of Clinical Laboratory Tests 16**
Catrina R. Schwartz and Mark W. Garrison
- 3 Anaphylaxis and Drug Allergies 42**
Robert K. Middleton
- 4 Managing Drug Overdoses and Poisonings 65**
Judith A. Alsop
- 5 End-of-Life Care 88**
Victoria F. Ferraresi
- 6 Nausea and Vomiting 98**
Lisa K. Lohr
- 7 Pain and Its Management 112**
Lee A. Kral and Virginia L. Ghafoor
- 8 Perioperative Care 147**
Andrew J. Donnelly, Julie A. Golembiewski, and Andrei M. Rakic
- 9 Acid-Base Disorders 175**
Luis S. Gonzalez, III and Raymond W. Hammond
- 10 Fluid and Electrolyte Disorders 188**
Alan H. Lau and Priscilla P. How
- 11 Vaccinations 217**
Sherry Luedtke and Molly G. Minze
- 12 Anemias 232**
Cindy L. O'Bryant and Lisa A. Thompson

SECTION 2: CARDIAC AND VASCULAR DISORDERS 252

Section Editors: Joseph J. Saseen and Jean M. Nappi

- 13 Dyslipidemias, Atherosclerosis, and Coronary Heart Disease 252**
Matthew K. Ito
- 14 Essential Hypertension 291**
Joseph J. Saseen
- 15 Peripheral Vascular Disorders 331**
Patricia M. Schuler and C. Wayne Weart
- 16 Thrombosis 345**
Ann K. Wittkowsky and Edith A. Nutescu
- 17 Chronic Stable Angina 377**
Toby C. Trujillo and Paul E. Nolan
- 18 Acute Coronary Syndrome 407**
Robert Lee Page, II and Jean M. Nappi
- 19 Heart Failure 436**
Harleen Singh and Joel C. Marrs

- 20 Cardiac Arrhythmias 489**
C. Michael White, Jessica C. Song, and James S. Kalus
- 21 Hypertensive Crises 520**
Kristin Watson, Brian Watson, Kelly Summers, and Robert Michocki
- 22 Shock 536**
Andrew D. Barnes and Susan H. Lee

SECTION 3: PULMONARY DISORDERS 565

- 23 Asthma 565**
Timothy H. Self, Cary R. Chrisman, and Christopher K. Finch
- 24 Chronic Obstructive Pulmonary Disease 601**
Philip T. Diaz and Daren L. Knoell
- 25 Acute and Chronic Rhinitis 619**
Tina Penick Brock and Dennis M. Williams
- 26 Cystic Fibrosis 644**
Paul M. Beringer and Michelle Condren

SECTION 4: GASTROINTESTINAL DISORDERS 660

- 27 Upper Gastrointestinal Disorders 660**
Randolph V. Fugit and Rosemary R. Berardi
- 28 Lower Gastrointestinal Disorders 699**
Geoffrey C. Wall
- 29 Complications of End-Stage Liver Disease 720**
Yasar O. Tasnif and Mary F. Hebert

SECTION 5: RENAL DISORDERS 743

Section Editor: Myrna Y. Munar

- 30 Acute Kidney Injury 743**
Myrna Y. Munar and Donald F. Brophy
- 31 Chronic Kidney Disease 764**
Darius L. Mason and Magdalene M. Assimon
- 32 Renal Dialysis 797**
Myrna Y. Munar
- 33 Dosing of Drugs in Renal Failure 811**
David J. Quan and Francesca T. Aweeka

SECTION 6: SOLID ORGAN TRANSPLANTATION 827

- 34 Kidney and Liver Transplantation 827**
David J. Taber and Robert E. Dupuis

SECTION 7: NUTRITION ISSUES 861

Section Editor: Marcus Ferrone

- 35 Basics of Nutrition and Patient Assessment 861**
Jeff F. Binkley
- 36 Obesity 872**
Maria Ballod

37 Adult Enteral Nutrition 884
Carol J. Rollins and Jennifer H. Baggs

38 Adult Parenteral Nutrition 908
Jane M. Gervasio and Jennifer L. Ash

SECTION 8: DERMATOLOGIC DISORDERS 925

Section Editor: Timothy J. Ives

39 Dermatotherapy and Drug-Induced Skin Disorders 925
Richard N. Herrier

40 Acne 944
Ellen R. DeGrasse and Jamie J. Cavanaugh

41 Psoriasis 956
Katie L. Kiser and Timothy J. Ives

42 Photosensitivity, Photoaging, and Burn Injuries 968
Katherine R. Gerrald and Timothy J. Ives

SECTION 9: ARTHRITIC DISORDERS 989

Section Editor: Tricia M. Russell

43 Osteoarthritis 989
Dominick P. Trombetta

44 Rheumatoid Arthritis 1002
Steven W. Chen, Rory E. O'Callaghan, and Alison M. Reta

45 Gout and Hyperuricemia 1039
KarenBeth H. Bohan

46 Connective Tissue Disorders 1054
Julie L. Olenak and Jonathan D. Ference

SECTION 10: WOMEN'S HEALTH 1066

Section Editor: Shareen Y. El-Ibiary

47 Contraception 1066
Shareen Y. El-Ibiary and Jennifer L. Hardman

48 Infertility 1090
Erin C. Raney

49 Obstetric Drug Therapy 1107
Kimey D. Ung and Jennifer McNulty

50 Disorders Related to the Menstrual Cycle 1149
Laura M. Borgelt and Karen M. Gunning

51 The Transition Through Menopause 1175
Louise Parent-Stevens

SECTION 11: ENDOCRINE DISORDERS 1186

Section Editor: Lisa A. Kroon

52 Thyroid Disorders 1186
Betty J. Dong and Eric F. Schneider

53 Diabetes Mellitus 1223
Lisa A. Kroon and Craig Williams

SECTION 12: EYE DISORDERS 1301

54 Eye Disorders 1301
Steven R. Abel and Suellen J. Sorensen

SECTION 13: NEUROLOGIC DISORDERS 1323

55 Multiple Sclerosis 1323
Melody Ryan

56 Headache 1337
Brian K. Alldredge

57 Parkinson Disease and Other Movement Disorders 1358
Michael E. Ernst and Mildred D. Gottwald

58 Seizure Disorders 1387
James W. McAuley, Rex S. Lott, and Brian K. Alldredge

59 Cerebrovascular Disorders 1419
Timothy E. Welty

SECTION 14: INFECTIOUS DISEASE 1437

60 Principles of Infectious Diseases 1437
B. Joseph Guglielmo

61 Antimicrobial Prophylaxis for Surgical Procedures 1461
Daniel J. G. Thirion

62 Central Nervous System Infections 1468
Gregory A. Eschenauer, Brian A. Potoski, and Victoria J. Dudas

63 Endocarditis 1489
Annie Wong-Beringer and Michelle Lee

64 Respiratory Tract Infections 1513
Heather M. Arnold, Eli N. Deal, Steven Gelone, and Scott T. Micek

65 Tuberculosis 1534
Michael B. Kays

66 Infectious Diarrhea 1559
Gail S. Itokazu, David T. Bearden, and Larry H. Danziger

67 Intra-Abdominal Infections 1581
Carrie A. Sincak and Sheila K. Wang

68 Urinary Tract Infections 1594
Douglas N. Fish

69 Sexually Transmitted Diseases 1619
Jeffery A. Goad and Karl M. Hess

70 Osteomyelitis and Septic Arthritis 1648
Bridgette L. Kram and Ralph H. Raasch

71 Traumatic Skin and Soft Tissue Infections 1661
James P. McCormack and Glen R. Brown

72 Prevention and Treatment of Infections in Neutropenic Cancer Patients 1672
Richard H. Drew

73 Pharmacotherapy of Human Immunodeficiency Virus Infection 1690
Jessica L. Adams, Julie B. Dumond, and Angela D.M. Kashuba

74 Opportunistic Infections in HIV-Infected Patients 1717
Amanda H. Corbett and Emily L. Heil

75 Fungal Infections 1746
John D. Cleary, Stanley W. Chapman, and Margaret M. Pearson

76 Viral Infections 1772
Milap C. Nahata, Neeta Bahal O'Mara, and Sandra Benavides

77 Viral Hepatitis 1790
Curtis D. Holt

78 Parasitic Infections 1828
J.V. Anandan

79 Tick-Borne Diseases 1846

Thomas E. Christian

SECTION 15: PSYCHIATRIC DISORDERS 1863

Section Editors: Patrick R. Finley and Kelly C. Lee

80 Anxiety Disorders 1863

Sally K. Guthrie and Jolene R. Bostwick

81 Sleep Disorders 1900

Julie A. Dopheide and Glen L. Stimmel

82 Schizophrenia 1921

Jonathan P. Lacro, Sanaz Farhadian, and Rene A. Endow-Eyer

83 Mood Disorders I: Major Depressive Disorders 1949

Patrick R. Finley and Kelly C. Lee

84 Mood Disorders II: Bipolar Disorders 1983

James J. Gasper

85 Attention Deficit Hyperactivity Disorder in Children, Adolescents, and Adults 1999

Kimberly B. Tallian, Patrick R. Finley, Paul Perry, and Samuel Kuperman

SECTION 16: SUBSTANCE ABUSE 2011**86 Drug Abuse 2011**

Wendy O. Zizzo and Paolo V. Zizzo

87 Alcohol Use Disorders 2033

George A. Kenna

88 Tobacco Use and Dependence 2055

Robin L. Corelli and Karen Suchanek Hudmon

SECTION 17: NEOPLASTIC DISORDERS 2080

Section Editor: Mark N. Kirstein

89 Neoplastic Disorders and Their Treatment: General Principles 2080

Makala B. Pace and Katherine Tipton Patel

90 Adverse Effects of Chemotherapy and Targeted Agents 2109

Amy Hatfield Seung

91 Pediatric Malignancies 2143

David W. Henry, Mark T. Holdsworth, and Nicole A. Kaiser

92 Adult Hematologic Malignancies 2172

Lynn Weber, Steve Stricker, Casey B. Williams, and Katie A. Won

93 Breast Cancer 2197

Kellie L. Jones

94 Lung Cancer 2210

Mark N. Kirstein, Robert A. Kratzke, and Arkadiusz Z. Dudek

95 Colorectal Cancer 2223

Sachin R. Shah and Julian Hoyt Slade, III

96 Hematopoietic Cell Transplantation 2236

Kathleen G. E. Green and John R. Rogosheske

SECTION 18: PEDIATRICS 2265

Section Editor: Marcia L. Buck

97 Pediatric Pharmacotherapy 2265

Marcia L. Buck

98 Pediatric Fluid, Electrolytes, and Nutrition 2277

Michael F. Chicella and Jennifer W. Chow

99 Common Pediatric Illnesses 2293

Michelle Condren and Mark R. Haase

100 Neonatal Therapy 2307

Donna M. Kraus and Jennifer Tran Pham

101 Care of the Critically Ill Child 2337

Elizabeth Anne Farrington and Marcia L. Buck

SECTION 19: GERIATRIC THERAPY 2359

Section Editor: Judith L. Beizer

102 Geriatric Drug Use 2359

Jiwon Kim and May Mak

103 Geriatric Dementias 2375

Nicole J. Brandt and Bradley R. Williams

104 Geriatric Urologic Disorders 2395

Michael R. Brodeur

105 Osteoporosis 2417

Rebecca A. Rottman-Sagebiel

*Drug Index 2434**Subject Index 2466*

Detailed Table of Contents

SECTION 1: GENERAL CARE 1

1 Assessment of Therapy and Medication Therapy Management 1

Marilyn R. Stebbins, Timothy W. Cutler, and Patricia L. Parker

Sources of Patient Information 2

Effective Communication and the Patient Interview 4

Obtaining A Patient History 5

Case 1-1, Questions 1–3 5

Approach to and Assessment of Patient Therapy 7

Case 1-2, Question 1 8

Case 1-3, Question 1 8

Case 1-4, Question 1 9

Medication Therapy Management Services in the Community

Pharmacy or Ambulatory Setting 10

Case 1-5, Questions 1–4 12

Medication Therapy Management in the Acute

Care Setting 14

Case 1-5, Question 5 14

Conclusion 14

Acknowledgment 15

Key References and Websites 15

2 Interpretation of Clinical Laboratory Tests 16

Catrina R. Schwartz and Mark W. Garrison

General Principles 16

Fluids and Electrolytes 20

Case 2-1, Questions 1–3 20

Case 2-2, Questions 1–2 24

Case 2-3, Question 1 25

Multichemistry Panels 25

Case 2-4, Question 1 26

Proteins 27

Cardiac Markers 27

Case 2-5, Question 1 28

Liver Function Tests 29

Case 2-6, Question 1 30

Case 2-7, Question 1 30

Miscellaneous Tests 31

Hematology 32

Case 2-8, Question 1 34

Case 2-9, Question 1 35

Case 2-10, Question 1 35

Urinalysis 36

Case 2-11, Question 1 40

Therapeutic Drug Monitoring 40

Patient-Directed Monitoring and Testing 41

Key References and Websites 41

3 Anaphylaxis and Drug Allergies 42

Robert K. Middleton

Case 3-1, Questions 1–4 46

Generalized Reactions 49

Case 3-2, Questions 1–3 49

Case 3-3, Questions 1–3 52

Case 3-4, Questions 1–3 54

Case 3-5, Questions 1–4 55

Organ-Specific Reactions 56

Pseudoallergic Reactions 57

Case 3-6, Questions 1–5 57

Case 3-7, Questions 1–3 59

Latex Allergy 61

Prevention and Management of Allergic Reactions 61

Case 3-8, Question 1 61

Case 3-9, Questions 1–5 62

Key References and Websites 63

4 Managing Drug Overdoses and Poisonings 65

Judith A. Alsop

General Management 68

Assessment of Salicylate Ingestion 70

Case 4-1, Questions 1–3 70

Case 4-2, Questions 1–6 71

Assessment of Iron Ingestion 74

Case 4-3, Questions 1–14 74

Assessment of Central Nervous System Depressant versus

Antidepressant Ingestion 78

Case 4-4, Questions 1–17 78

Assessment of Acetaminophen Ingestion 83

Case 4-5, Questions 1–15 83

Summary 87

Key References and Websites 87

5 End-of-Life Care 88

Victoria F. Ferraresi

Hospice and Palliative Care 88

Case 5-1, Questions 1–2 90

Symptom Management 93

Case 5-1, Questions 3–4 93

Pain Management 95

Case 5-2, Question 1 95

Case 5-3, Questions 1–3 96

Key References and Websites 97

6 Nausea and Vomiting 98

Lisa Lohr

Definition 99

Epidemiology and Clinical Presentation 99

Pathophysiology 99

Diagnosis 99

Motion Sickness 100

Case 6-1, Questions 1–2 100

Chemotherapy-Induced Nausea and Vomiting 101

Case 6-2, Questions 1–3 101

Radiation-Induced Nausea and Vomiting 107

Case 6-3, Question 1 107

Postoperative Nausea and Vomiting 109

Case 6-4, Question 1 109

Key References and Websites 111

7 Pain and Its Management 112

Lee A. Kral and Virginia L. Ghafoor

- Low Back Pain 117
- Case 7-1, Questions 1–6 119
- Fibromyalgia and Myofascial Pain 123
- Case 7-2, Questions 1–3 125
- Neuropathic Pain and Postherpetic Neuralgia 126
- Case 7-3, Questions 1–4 128
- Complex Regional Pain Syndrome 130
- Case 7-4, Questions 1–2 131
- Pharmacotherapy Options for Chronic Pain in the Elderly 132
- Case 7-5, Questions 1–4 132
- Functional Abdominal Pain Syndrome 135
- Case 7-6, Questions 1–6 135
- Cancer Pain and Symptom Management 138
- Case 7-7, Questions 1–9 139
- Key References and Websites 146

8 Perioperative Care 147

Andrew J. Donnelly, Julie A. Golembiewski, and Andrei M. Rakic

- Preoperative Medications 148
- Case 8-1, Question 1 150
- Case 8-2, Question 1 151
- Intravenous Anesthetic Agents 152
- Case 8-3, Question 1 153
- Case 8-4, Question 1 153
- Case 8-5, Question 1 153
- Case 8-6, Question 1 154
- Volatile Inhalation Agents 154
- Case 8-7, Question 1 156
- Case 8-8, Question 1 157
- Neuromuscular Blocking Agents 157
- Case 8-9, Questions 1–2 158
- Case 8-10, Question 1 159
- Local Anesthetics 160
- Case 8-11, Question 1 161
- Case 8-12, Question 1 162
- Antiemetic Agents and Postoperative Nausea and Vomiting 162
- Case 8-13, Question 1–4 163
- Analgesic Agents and Postoperative Pain Management 166
- Case 8-14, Questions 1–7 167
- Case 8-15, Questions 1–6 170
- Case 8-16, Question 1 172
- Key References and Websites 173

9 Acid–Base Disorders 175

Luis S. Gonzalez, III and Raymond W. Hammond

- Acid–Base Physiology 175
- Evaluation of Acid–Base Disorders 178
- Metabolic Acidosis 178
- Case 9-1, Questions 1–6 179
- Case 9-2, Questions 1–4 180
- Metabolic Alkalosis 182
- Case 9-3, Questions 1–4 183
- Respiratory Acidosis 184
- Case 9-4, Questions 1–4 184
- Respiratory Alkalosis 185
- Case 9-5, Questions 1–4 185
- Mixed Acid–Base Disorders 186
- Case 9-6, Questions 1–3 186
- Key References and Websites 187

10 Fluid and Electrolyte Disorders 188

Alan H. Lau and Priscilla P. How

- Basic Principles 190
- Case 10-1, Question 1 190
- Disorders in Volume Regulation 192
- Case 10-2, Questions 1–2 192
- Case 10-3, Questions 1–2 193
- Disorders in Osmoregulation 194
- Case 10-4, Question 1 195
- Case 10-5, Questions 1–2 195
- Case 10-6, Question 1 197
- Case 10-7, Question 1–5 197
- Clinical Use of Diuretics 201
- Potassium 202
- Case 10-8, Questions 1–3 203
- Case 10-9, Question 1 205
- Case 10-10, Questions 1–2 206
- Calcium 207
- Case 10-11, Questions 1–3 208
- Phosphorus 211
- Case 10-12, Questions 1–4 212
- Magnesium 213
- Case 10-13, Questions 1–4 214
- Case 10-14, Questions 1–3 216
- Key References and Websites 216

11 Vaccinations 217

Sherry Luedtke and Molly G. Minze

- Vaccine Principles 219
- Case 11-1, Question 1 219
- Guidelines 221
- Case 11-2, Question 1 221
- Case 11-3, Question 1 221
- Inactivated Vaccines 221
- Case 11-4, Question 1–2 221
- Case 11-5, Question 1 222
- Case 11-6, Question 1 223
- Case 11-7, Question 1 224
- Case 11-8, Question 1 224
- Case 11-9, Question 1 224
- Case 11-10, Question 1 225
- Case 11-11, Question 1 225
- Case 11-12, Questions 1–2 226
- Case 11-13, Question 1 227
- Live Attenuated Vaccines 227
- Case 11-14, Question 1 227
- Case 11-15, Question 1 228
- Case 11-16, Questions 1–2 229
- Administration Techniques 229
- Case 11-17, Question 1 230
- Legal Requirements 230
- Case 11-18, Question 1 230
- Key References and Websites 231

12 Anemias 232

Cindy L. O'Bryant and Lisa A. Thompson

- Iron Deficiency Anemia 235
- Case 12-1, Questions 1–10 235
- Megaloblastic Anemias 238
- Case 12-2, Questions 1–3 239
- Case 12-3, Question 1 241
- Case 12-4, Questions 1–2 241
- Case 12-5, Questions 1–2 242

| | |
|------------------------------------|------------|
| Sickle Cell Anemia | 243 |
| Case 12-6, Questions 1–3 | 244 |
| Case 12-7, Questions 1–6 | 245 |
| Anemia of Chronic Disease | 247 |
| Case 12-8, Question 1 | 248 |
| Case 12-9, Question 1 | 249 |
| Case 12-10, Question 1–2 | 249 |
| Acknowledgment | 250 |
| Key References and Websites | 250 |

SECTION 2: CARDIAC AND VASCULAR DISORDERS 252

Section Editors: Joseph J. Saseen and Jean M. Nappi

13 Dyslipidemias, Atherosclerosis, and Coronary Heart Disease 252

Matthew K. Ito

| | |
|------------------------------------|------------|
| Hypercholesterolemia | 267 |
| Case 13-1, Questions 1–10 | 267 |
| Case 13-2, Questions 1–6 | 274 |
| Case 13-3, Questions 1–4 | 281 |
| Mixed Hyperlipidemia | 282 |
| Case 13-4, Questions 1–12 | 282 |
| Case 13-5, Questions 1–2 | 288 |
| Case 13-6, Question 1 | 289 |
| Key References and Websites | 289 |

14 Essential Hypertension 291

Joseph J. Saseen

| | |
|------------------------------------|------------|
| Introduction | 291 |
| Clinical Evaluation | 301 |
| Case 14-1, Questions 1–6 | 301 |
| Principles of Treatment | 303 |
| Case 14-1, Questions 7–10 | 303 |
| Hypertension Management | 304 |
| Case 14-1, Questions 11–17 | 304 |
| Case 14-2, Questions 1–4 | 306 |
| Case 14-3, Questions 1–6 | 307 |
| Clinical Scenarios | 311 |
| Case 14-4, Questions 1–10 | 311 |
| Case 14-5, Question 1 | 316 |
| Case 14-6, Questions 1–10 | 317 |
| Case 14-7, Questions 1–2 | 321 |
| Case 14-8, Question 1 | 322 |
| Case 14-9, Questions 1–3 | 322 |
| Case 14-10, Questions 1–10 | 323 |
| Case 14-11, Questions 1–3 | 325 |
| Case 14-12, Questions 1–4 | 326 |
| Case 14-13, Questions 1–3 | 327 |
| Case 14-14, Questions 1–4 | 328 |
| Case 14-15, Questions 1–4 | 329 |
| Key References and Websites | 329 |

15 Peripheral Vascular Disorders 331

Patricia M. Schuler and C. Wayne Weart

| | |
|------------------------------------|------------|
| Peripheral Arterial Disease | 331 |
| Case 15-1, Questions 1–11 | 333 |
| Raynaud's Phenomenon | 339 |
| Case 15-2, Questions 1–4 | 340 |
| Nocturnal Leg Muscle Cramps | 342 |
| Case 15-3, Questions 1–5 | 342 |
| Key References and Websites | 344 |

16 Thrombosis 345

Ann K. Wittkowsky and Edith A. Nutescu

| | |
|--|------------|
| General Principles | 345 |
| Deep Venous Thrombosis | 352 |
| Case 16-1, Questions 1–12 | 352 |
| Case 16-2, Question 1 | 356 |
| Case 16-3, Questions 1–2 | 357 |
| Case 16-4, Question 1 | 358 |
| Pulmonary Embolism | 359 |
| Case 16-5, Questions 1–6 | 359 |
| Case 16-6, Questions 1–6 | 363 |
| Case 16-7, Question 1 | 367 |
| Case 16-8, Question 1 | 368 |
| Prevention of Cardiogenic Thromboembolism | 369 |
| Case 16-9, Questions 1–3 | 369 |
| Case 16-10, Question 1 | 371 |
| Case 16-11, Question 1 | 371 |
| Bridge Therapy | 371 |
| Case 16-12, Question 1 | 371 |
| Case 16-13, Question 1 | 373 |
| Drug Interactions | 373 |
| Case 16-14, Question 1 | 373 |
| Case 16-15, Question 1 | 374 |
| Case 16-16, Question 1 | 375 |
| Case 16-17, Question 1 | 375 |
| Key References and Websites | 375 |

17 Chronic Stable Angina 377

Toby C. Trujillo and Paul E. Nolan

| | |
|---|------------|
| Chronic Stable Angina | 378 |
| Overview of Drug and Nondrug Therapy | 384 |
| Clinical Presentation of Chronic Stable Angina | 388 |
| Case 17-1, Questions 1–24 | 388 |
| Case 17-2, Questions 1–4 | 395 |
| Case 17-3, Questions 1–3 | 398 |
| Revascularization | 399 |
| Case 17-3, Questions 4–8 | 399 |
| Variant Angina (Coronary Artery Spasm) | 403 |
| Case 17-4, Questions 1–4 | 403 |
| Microvascular Ischemia (Syndrome X) | 405 |
| Case 17-5, Question 1 | 405 |
| Key References and Websites | 405 |

18 Acute Coronary Syndrome 407

Robert Lee Page, II and Jean M. Nappi

| | |
|--|------------|
| Acute Coronary Disease | 408 |
| Overview of Drug and Nondrug Therapy | 413 |
| Clinical Presentation of ACS | 422 |
| Case 18-1, Questions 1–6 | 422 |
| Treatment for ST Segment Elevation Myocardial Infarction | 424 |
| Case 18-1, Questions 7–23 | 424 |
| Treatment for Unstable Angina or Non-ST Segment Elevation Myocardial Infarction | 430 |
| Case 18-2, Questions 1–4 | 430 |
| Long-Term Therapy | 432 |
| Case 18-3, Questions 1–9 | 432 |
| Lifestyle Modifications | 434 |
| Case 18-3, Questions 10 | 434 |
| Summary | 434 |
| Key References and Websites | 434 |

19 Heart Failure 436

Harleen Singh and Joel C. Marrs

Patient Evaluation 449**Case 19-1**, Questions 1–5 449**Treatment 452****Case 19-1**, Questions 6–20 452**Case 19-2**, Questions 1–9 468**Case 19-3**, Questions 1–2 474**Case 19-4**, Questions 1–3 476**Case 19-5**, Questions 1–4 480**Case 19-6**, Questions 1–2 483**Heart Failure With Preserved Left Ventricular Ejection****Fraction 484****Case 19-7**, Question 1 484**Case 19-8**, Question 1 487**Key References and Websites 488****20 Cardiac Arrhythmias 489**

C. Michael White, Jessica C. Song, and James S. Kalus

Electrophysiology 490**Supraventricular Arrhythmias 493****Case 20-1**, Questions 1–13 493**Case 20-2**, Question 1 502**Case 20-3**, Questions 1–3 502**Case 20-4**, Questions 1–6 503**Case 20-5**, Questions 1–2 505**Conduction Blocks 505****Case 20-6**, Questions 1–2 505**Ventricular Arrhythmias 506****Case 20-7**, Questions 1–2 508**Case 20-8**, Question 1 509**Case 20-9**, Questions 1–3 509**Case 20-10**, Questions 1–5 512**Cardiopulmonary Arrest 515****Case 20-11**, Questions 1–4 515**Case 20-12**, Question 1 518**Case 20-13**, Question 1 518**Key References And Websites 518****21 Hypertensive Crises 520**

Kristin Watson, Brian Watson, Kelly Summers, and Robert Michocki

Clinical Presentation of Hypertensive Urgency 521**Clinical Presentation of Hypertensive Emergency 521****Overview of Treatment 522****Hypertensive Urgencies 522****Case 21-1**, Questions 1–6 522**Hypertensive Emergencies 527****Case 21-2**, Questions 1–11 527**Case 21-3**, Questions 1–6 530**Case 21-4**, Questions 1–2 531**Case 21-5**, Questions 1–3 532**Case 21-6**, Questions 1–3 534**Case 21-7**, Question 1 535**Key References and Websites 535****22 Shock 536**

Andrew D. Barnes and Susan H. Lee

Introduction 536**Causes 537****Pathophysiology 537****Clinical Presentation and diagnosis 537****Treatment Overview 538****Hemodynamic Monitoring 538****Etiologic Classification of Shock and
Common Mechanisms 540****Hypovolemic Shock 540****Case 22-1**, Questions 1–13 541**Cardiogenic Shock 547****Case 22-2**, Questions 1–10 547**Case 22-3**, Questions 1–5 552**Septic Shock 555****Case 22-4**, Questions 1–8 556**Disseminated Intravascular Coagulation 562****Case 22-4**, Questions 9–12 562**Glossary 564****SECTION 3: PULMONARY DISORDERS 565****23 Asthma 565**

Timothy H. Self, Cary R. Chrisman, and Christopher K. Finch

Asthma 566**Acute Asthma 573****Case 23-1**, Questions 1–9 573**Case 23-2**, Questions 1–12 580**Chronic Asthma 584****Case 23-3**, Questions 1–4 584**Case 23-4**, Question 1 585**Case 23-5**, Questions 1–6 585**Case 23-6**, Question 1 590**Case 23-7**, Questions 1–3 590**Case 23-8**, Question 1 592**Case 23-9**, Question 1 592**Case 23-10**, Question 1 593**Exercise-Induced Asthma 593****Case 23-11**, Question 1 593**Case 23-12**, Question 1 594**Patient Education 594****Case 23-13**, Questions 1–3 594**Nocturnal Asthma 596****Case 23-14**, Question 1 596**Drug-Induced Asthma 598****Case 23-15**, Question 1 598**Outcomes 599****Case 23-16**, Questions 1–3 599**Complementary Alternative Therapies 600****Case 23-16**, Question 4 600**Key References and Websites 600****24 Chronic Obstructive Pulmonary Disease 601**

Philip T. Diaz and Daren L. Knochel

Diagnosis and Patient Assessment 607**General Management Considerations 609****Pharmacotherapy 609****Pharmacologic Therapy by Disease Severity 611****COPD Exacerbation 611****Stage I (Mild) COPD 612****Case 24-1**, Questions 1–3 612**Stage II (Moderate) COPD 613****Case 24-2**, Questions 1–5 613**Stage III (Severe) COPD 615****Case 24-3**, Questions 1–3 615**Stage IV (Very Severe) COPD 616****Case 24-4**, Question 1 616**Case 24-5**, Questions 1–2 617**Key References and Website 618**

25 Acute and Chronic Rhinitis 619

Tina Penick Brock and Dennis M. Williams

- Definition 619
- Causes and Classifications 620
- Epidemiology and Impact 621
- Anatomy and Physiology 621
- Etiology of Allergic Rhinitis 622
- Pathophysiology 622
- Clinical Presentation and Assessment of Rhinitis 623
- General Management of Rhinitis 625
- Specific Therapeutic Options 628
 - Case 25-1, Questions 1–8 628
 - Case 25-2, Questions 1–3 632
 - Case 25-3, Questions 1–9 633
 - Case 25-4, Questions 1–2 636
 - Case 25-5, Question 1 636
 - Case 25-6, Questions 1–6 637
- Drug-Induced Nasal Congestion: Rhinitis Medicamentosa 639
 - Case 25-7, Questions 1–2 639
- Idiopathic Rhinitis 641
 - Case 25-8, Questions 1–2 641
- Mixed Allergic-Nonallergic Rhinitis 642
 - Case 25-9, Questions 1–2 642
- Summary 642
- Acknowledgments 642
- Key References and Websites 642

26 Cystic Fibrosis 644

Paul M. Beringer and Michelle Condren

- Genetic Basis 645
- Clinical Manifestations 646
- Diagnosis 649
 - Case 26-1, Question 1 650
- Early Interventions and Therapy 650
 - Case 26-1, Questions 2–3 650
 - Case 26-2, Questions 1–3 653
 - Case 26-3, Questions 1–3 656
- Lung Transplantation 658
- Key References and Websites 659

SECTION 4: GASTROINTESTINAL DISORDERS 660**27 Upper Gastrointestinal Disorders 660**

Randolph V. Fugit and Rosemary R. Berardi

- Upper Gastrointestinal Disorders 661
- Physiology of the Upper Gastrointestinal Tract 661
- Pharmacotherapy of Drugs Used to Treat Acid-Related Disorders 663
- Dyspepsia 667
- Peptic Ulcer Disease 669
 - Helicobacter Pylori*-Related Peptic Ulcer 675
 - Case 27-1, Questions 1–10 675
- Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer 679
 - Case 27-2, Questions 1–10 679
- Zollinger-Ellison Syndrome 682
- Gastroesophageal Reflux Disease 683
 - Case 27-3, Questions 1–4 685
 - Case 27-4, Questions 1–3 687
 - Case 27-5, Questions 1–2 690
- Upper Gastrointestinal Bleeding 692
 - Case 27-6, Questions 1–4 695
- Key References 697

28 Lower Gastrointestinal Disorders 699

Geoffrey C. Wall

- Overview of Inflammatory Bowel Disease 700
- Ulcerative Colitis 705
 - Case 28-1, Questions 1–13 705
 - Case 28-2, Question 1 710
- Crohn's Disease 710
 - Case 28-3, Questions 1–7 710
- Irritable Bowel Syndrome 714
 - Case 28-4, Questions 1–4 715
 - Case 28-5, Questions 1–2 717
- Key References and Websites 718

29 Complications of End-Stage Liver Disease 720

Yasar O. Tasnif and Mary F. Hebert

- Overview 721
- Pathogenesis of Cirrhosis 721
- Complications of Cirrhosis 722
 - Case 29-1, Question 1 724
- Ascites 724
 - Case 29-1, Questions 2–12 724
- Esophageal Varices 730
 - Case 29-2, Questions 1–6 730
- Hepatic Encephalopathy 735
 - Case 29-3, Questions 1–6 735
- Hepatorenal Syndrome 739
 - Case 29-3, Questions 7–8 739
- Key References and Websites 742

SECTION 5: RENAL DISORDERS 743

Section Editor: Myrna Y. Munar

30 Acute Kidney Injury 743

Myrna Y. Munar and Donald F. Brophy

- Definition 744
- Epidemiology 744
- Prognosis 745
- Clinical Course 745
- Pathogenesis 745
- Clinical Evaluation 746
- Prerenal and Functional Acute Kidney Injury 750
 - Case 30-1, Questions 1–3 750
 - Case 30-2, Questions 1–4 751
- Intrinsic Acute Kidney Injury 752
 - Case 30-3, Questions 1–5 752
- Tubulointerstitial Diseases 754
 - Case 30-4, Question 1 754
 - Case 30-5, Questions 1–4 755
 - Case 30-6, Questions 1–3 756
 - Case 30-7, Questions 1–2 758
- Postrenal Acute Kidney Injury 759
 - Case 30-8, Questions 1–2 760
- Supportive Management of Acute Kidney Injury 761
 - Case 30-9, Questions 1–2 761
- Key References and Websites 763

31 Chronic Kidney Disease 764

Darius L. Mason and Magdalene M. Assimon

- Introduction 765
- End-Stage Renal Disease (Stage 5 Chronic Kidney Disease) 772
- Diabetic Nephropathy 773
 - Case 31-1, Questions 1–4 773

| | |
|--|-----|
| Fluid and Electrolyte Complications | 775 |
| Case 31-1, Questions 5–9 | 775 |
| Anemia of Chronic Kidney Disease | 777 |
| Case 31-1, Questions 10–12 | 777 |
| Cardiovascular Complications | 782 |
| Case 31-2, Questions 1–3 | 782 |
| Mineral and Bone Disorders | 783 |
| Case 31-3, Questions 1–2 | 783 |
| Other Complications of CKD | 789 |
| Case 31-3, Questions 3–6 | 789 |
| Case 31-4, Questions 1–2 | 790 |
| Glomerular Disease | 791 |
| Case 31-5, Questions 1–2 | 792 |
| Case 31-6, Questions 1–2 | 793 |
| Case 31-7, Question 1 | 794 |
| Key References and Websites | 795 |

32 Renal Dialysis 797

Myrna Y. Munar

| | |
|------------------------------------|-----|
| Hemodialysis | 799 |
| Case 32-1, Questions 1–2 | 801 |
| Peritoneal Dialysis | 806 |
| Case 32-2, Questions 1–7 | 807 |
| Key References and Websites | 810 |

33 Dosing of Drugs in Renal Failure 811

David J. Quan and Francesca T. Aweeka

| | |
|---|-----|
| Basic Principles | 811 |
| Pharmacokinetics and Pharmacodynamics of Specific Drugs in Renal Failure | 814 |
| Case 33-1, Questions 1–8 | 814 |
| Case 33-2, Questions 1–2 | 819 |
| Case 33-3, Questions 1–4 | 819 |
| Case 33-4, Questions 1–2 | 820 |
| Case 33-5, Questions 1–4 | 821 |
| Case 33-6, Question 1 | 823 |
| Case 33-7, Question 1 | 823 |
| Effect of Renal Failure on Metabolized Drugs | 824 |
| Case 33-8, Questions 1–4 | 824 |
| Case 33-9, Question 1 | 825 |
| Summary | 826 |
| Key References and Websites | 826 |

SECTION 6: SOLID ORGAN TRANSPLANTATION 827

34 Kidney and Liver Transplantation 827

David J. Taber and Robert E. Dupuis

| | |
|--|-----|
| Introduction to Transplantation | 828 |
| Transplantation Immunology | 829 |
| Immunosuppressive Agents | 831 |
| Kidney Transplantation | 837 |
| Case 34-1, Questions 1–10 | 837 |
| Case 34-2, Questions 1–4 | 842 |
| Case 34-3, Questions 1–2 | 844 |
| Case 34-4, Question 1 | 845 |
| Case 34-5, Questions 1–3 | 846 |
| Case 34-6, Questions 1–3 | 847 |
| Case 34-7, Questions 1–9 | 849 |
| Case 34-8, Question 1 | 853 |
| Case 34-9, Question 1 | 854 |
| Case 34-10, Questions 1–4 | 855 |

| | |
|------------------------------------|-----|
| Case 34-11, Questions 1–2 | 858 |
| Liver Transplantation | 849 |
| Key References and Websites | 860 |

SECTION 7: NUTRITION ISSUES 861

Section Editor: Marcus Ferrone

35 Basics of Nutrition and Patient Assessment 861

Jeff F. Binkley

| | |
|---|-----|
| Nutrition Basics | 862 |
| Malnutrition | 864 |
| Nutrition Screening | 864 |
| Patient Assessment: Woman with Crohn's Disease | 867 |
| Case 35-1, Questions 1–7 | 867 |
| Acknowledgments | 870 |
| Key References and Websites | 870 |

36 Obesity 872

Maria Ballod

| | |
|-------------------------------------|-----|
| Definitions | 872 |
| Epidemiology | 873 |
| Etiology and Pathophysiology | 874 |
| Clinical Features | 876 |
| Case 36-1, Questions 1–3 | 876 |
| Management and Treatment | 878 |
| Case 36-1, Questions 8–10 | 880 |
| Key References and Websites | 883 |

37 Adult Enteral Nutrition 884

Carol J. Rollins and Jennifer H. Baggs

| | |
|--|-----|
| Case 37-1, Questions 1–2 | 884 |
| Case 37-2, Question 1 | 886 |
| Formula Selection | 887 |
| Case 37-2, Questions 2–7 | 887 |
| Case 37-3, Questions 1–2 | 893 |
| Renal Failure | 897 |
| Case 37-3, Question 3 | 897 |
| Case 37-4, Question 1 | 898 |
| Monitoring Enteral Nutrition Support | 899 |
| Case 37-4, Question 2 | 899 |
| Medications and Enteral Nutrition by Tube | 902 |
| Case 37-4, Questions 3–4 | 902 |
| Case 37-5, Question 1 | 905 |
| Case 37-6, Question 1 | 905 |
| Key References and Websites | 907 |

38 Adult Parenteral Nutrition 908

Jane M. Gervasio and Jennifer L. Ash

| | |
|--|-----|
| Venous Access Sites | 909 |
| Components of Parenteral Nutrient Formulations | 909 |
| Parenteral Nutrition | 910 |
| Case 38-1, Questions 1–9 | 910 |
| Case 38-2, Questions 1–16 | 913 |
| Case 38-3, Questions 1–3 | 919 |
| Use of Parenteral Nutrition in Special Disease States | 920 |
| Case 38-4, Questions 1–2 | 920 |
| Case 38-5, Questions 1–4 | 922 |
| Case 38-6, Questions 1–3 | 923 |
| Case 38-7, Questions 1–2 | 924 |
| Key References and Websites | 924 |

39 Dermatotherapy and Drug-Induced Skin Disorders 925

Richard N. Herrier

- Anatomy and Physiology of the Skin 925
- Inflammatory Lesions 926
- Dermatologic Drug Delivery Systems 926
- Assessing the Dermatologic Patient 929
- Case 39-1, Question 1 929
- Topical Corticosteroids 931
- Case 39-2, Questions 1–10 933
- Case 39-3, Questions 1–2 938
- Xerosis 938
- Case 39-4, Question 1 938
- Drug Eruptions 938
- Case 39-5, Question 1 941
- Allergic Contact Dermatitis: Poison Ivy, Poison Oak, or Poison Sumac 941
- Case 39-6, Question 1 942
- Case 39-7, Questions 1–3 942
- Key References and Websites 943

40 Acne 944

Ellen R. DeGrasse and Jamie J. Cavanaugh

- Clinical Assessment 947
- Case 40-1, Questions 1–7 947
- Case 40-2, Questions 1–3 950
- Case 40-3, Questions 1–8 952
- Case 40-4, Question 1 955
- Acknowledgment 955
- Key References and Websites 955

41 Psoriasis 956

Katie L. Kiser and Timothy J. Ives

- Epidemiology 956
- Case 41-1, Questions 1–3 957
- Treatment of Mild Psoriasis 959
- Case 41-1, Questions 4–6 959
- Treatment of Severe Psoriasis 962
- Case 41-2, Question 1 962
- Systemic Pharmacotherapy 963
- Case 41-2, Questions 2–3 964
- Psoriatic Arthritis 965
- Case 41-3, Questions 1–2 965
- Key References and Websites 967

42 Photosensitivity, Photoaging, and Burn Injuries 968

Katherine R. Gerrald and Timothy J. Ives

- Ultraviolet Radiation (UVR) Exposure 969
- Case 42-1, Questions 1–9 972
- Case 42-2, Questions 1–3 978
- Case 42-3, Question 1 979
- Case 42-4, Questions 1–3 980
- Photoaging 981
- Case 42-5, Questions 1–5 981
- Burn Injuries 982
- Case 42-6, Question 1 984
- Key References and Websites 988

43 Osteoarthritis 989

Dominick P. Trombetta

- Incidence, Prevalence, and Epidemiology 990
- Etiology 990
- Pathogenesis 991
- Overview of Drug Therapy 991
- Clinical Manifestations 992
- Case 43-1, Questions 1–3 992
- Treatment of Osteoarthritis 993
- Case 43-1, Questions 4–7 994
- Case 43-2, Questions 1–6 995
- Case 43-3, Questions 1–3 1000
- Key References and Websites 1000

44 Rheumatoid Arthritis 1002

Steven W. Chen, Rory E. O'Callaghan, and Alison M. Reta

- Early and Progressive Rheumatoid Arthritis 1013
- Case 44-1, Questions 1–5 1013
- Case 44-2, Question 1 1019
- Case 44-3, Questions 1–2 1019
- Case 44-4, Question 1 1019
- Case 44-5, Questions 1–7 1020
- Case 44-6, Questions 1–9 1022
- Case 44-7, Questions 1–13 1025
- Case 44-8, Question 1 1030
- Case 44-9, Questions 1–5 1033
- Juvenile Idiopathic Arthritis 1034
- Case 44-10, Questions 1–4 1034
- Case 44-11, Questions 1–2 1036
- Case 44-12, Question 1 1036
- Case 44-13, Questions 1–2 1036
- Case 44-14, Questions 1–2 1037
- Key References and Websites 1038

45 Gout and Hyperuricemia 1039

KarenBeth H. Bohan

- Pathophysiology 1040
- Acute Gout 1040
- Case 45-1, Questions 1–3 1041
- Case 45-2, Questions 1–6 1042
- Case 45-3, Questions 1–2 1048
- Hyperuricemia 1048
- Case 45-3, Questions 3–5 1048
- Case 45-4, Question 1 1051
- Case 45-5, Question 1 1052
- Case 45-6, Question 1 1052
- Key References and Websites 1052

46 Connective Tissue Disorders 1054

Julie L. Olenak and Jonathan D. Ference

- Introduction 1055
- General Signs and Symptoms 1055
- Selected Connective Tissue Diseases 1055
- Lupus Erythematosus 1055
- Case 46-1, Questions 1–3 1056
- Case 46-2, Questions 1–2 1059
- Systemic Sclerosis (Scleroderma) 1060
- Case 46-3, Questions 1–3 1060
- Polymyalgia Rheumatica and Temporal Arteritis (Giant Cell Arteritis) 1061

- Case 46-4, Questions 1–3 1062
- Reiter Syndrome 1063
- Case 46-5, Question 1 1063
- Polymyositis and Dermatomyositis 1063
- Case 46-6, Question 1 1064
- Key References and Websites 1065

SECTION 10: WOMEN'S HEALTH 1066

Section Editor: Shareen Y. El-Ibiary

47 Contraception 1066

Shareen Y. El-Ibiary and Jennifer L. Hardman

- Epidemiology 1067
- Hormonal Contraception Background and Pharmacology 1067
- Combination Hormonal Contraceptives 1067
 - Case 47-1, Questions 1–6 1067
- Contraceptive Patch and Ring 1076
 - Case 47-1, Questions 7–8 1076
 - Case 47-2, Questions 1–8 1079
 - Case 47-3, Questions 1–2 1082
- Progestin-Only Contraceptives 1083
 - Case 47-3, Questions 3–6 1083
- Intrauterine Device and Intrauterine System 1085
 - Case 47-3, Question 7 1085
- Other Nonhormonal Contraception 1085
 - Case 47-4, Questions 1–2 1085
- Emergency Contraception 1088
 - Case 47-4, Question 3 1088
- Medical Abortion 1088
- Key References and Websites 1089

48 Infertility 1090

Erin C. Raney

- Introduction 1091
- Pathophysiology and Diagnosis 1091
 - Case 48-1, Questions 1–7 1091
- Treatment Approaches 1095
 - Case 48-1, Questions 8–12 1095
 - Case 48-2, Questions 1–11 1098
- Key References and Websites 1106

49 Obstetric Drug Therapy 1107

Kimey D. Ung and Jennifer McNulty

- Case 49-1, Questions 1–5 1109
- Teratogenicity 1112
 - Case 49-1, Question 6 1112
- Management of Conditions in Pregnancy 1116
 - Case 49-1, Questions 7–11 1116
- Urinary Tract Infections 1118
 - Case 49-1, Questions 12–13 1120
- Diabetes Mellitus 1120
 - Case 49-2, Questions 1–4 1120
 - Case 49-3, Questions 1–2 1122
 - Case 49-4, Questions 1–4 1123
- Hypertension and Pre-Eclampsia 1125
 - Case 49-5, Questions 1–13 1125
- Drug Therapy Management in Labor and Delivery 1131
 - Case 49-6, Questions 1–5 1131
 - Case 49-7, Questions 1–11 1134
 - Case 49-8, Questions 1–2 1140
- Postpartum Hemorrhage 1141
 - Case 49-8, Questions 3–4 1141
- Prevention of Rh D Alloimmunization 1143
 - Case 49-9, Questions 1–5 1143

Lactation 1144

- Case 49-10, Questions 1–2 1144
- Case 49-11, Question 1 1145
- Drug Excretion in Human Milk 1145
 - Case 49-12, Question 1 1146
 - Case 49-13, Question 1 1147
- Acknowledgment 1147
- Key References and Websites 1147
- Medication Use in Pregnancy and Lactation 1148
- General Information 1148

50 Disorders Related to the Menstrual Cycle 1149

Laura M. Borgelt and Karen M. Gunning

- Menstrual Cycle Physiology 1150
- Polycystic Ovary Syndrome 1150
 - Case 50-1, Questions 1–7 1153
- Dysmenorrhea 1159
 - Case 50-2, Questions 1–8 1159
- Endometriosis 1162
 - Case 50-3, Questions 1–4 1163
 - Case 50-4, Question 1 1167
 - Case 50-5, Question 1 1168
- Premenstrual Syndrome and Premenstrual Dysphoric Disorder 1169
 - Case 50-6, Questions 1–4 1170
- Key References and Websites 1173

51 The Transition Through Menopause 1175

Louise Parent-Stevens

- Incidence, Prevalence, and Epidemiology 1175
- Pathophysiology 1176
- Clinical Presentation 1176
 - Case 51-1, Questions 1–6 1177
 - Case 51-2, Questions 1–3 1183
- Key References and Websites 1185

SECTION 11: ENDOCRINE DISORDERS 1186

Section Editor: Lisa Kroon

52 Thyroid Disorders 1186

Betty J. Dong and Eric F. Schneider

- Overview 1187
- Thyroid Function Tests 1191
 - Case 52-1, Questions 1–2 1194
 - Case 52-2, Question 1 1195
 - Case 52-3, Question 1 1195
 - Case 52-4, Question 1 1195
- Hypothyroidism 1196
 - Case 52-5, Questions 1–5 1196
 - Case 52-6, Question 1 1199
 - Case 52-7, Question 1 1199
 - Case 52-8, Questions 1–2 1199
 - Case 52-9, Questions 1–2 1201
 - Case 52-10, Questions 1–2 1202
 - Case 52-11, Questions 1–3 1202
 - Case 52-12, Question 1 1204
 - Case 52-13, Question 1 1204
- Hyperthyroidism 1205
 - Case 52-14, Questions 1–4 1205
 - Case 52-15, Questions 1–12 1206
 - Case 52-16, Question 1 1212
 - Case 52-17, Question 1 1212
 - Case 52-18, Question 1 1213
 - Case 52-19, Question 1 1213
 - Case 52-20, Questions 1–2 1214

Case 52-21, Question 1 1215
 Case 52-22, Questions 1–2 1215
 Case 52-23, Questions 1–2 1216
Drug-Induced Thyroid Disease 1217
 Case 52-24, Question 1 1217
 Case 52-25, Question 1 1218
 Case 52-26, Question 1 1218
 Case 52-27, Question 1 1219
 Case 52-28, Question 1 1219
Nodules 1220
 Case 52-29, Question 1 1220
 Case 52-30, Question 1 1220
 Case 52-31, Question 1 1220
 Case 52-32, Question 1 1220
Key References and Websites 1221

53 Diabetes Mellitus 1223

Lisa A. Kroon and Craig Williams

Case 53-1, Questions 1–2 1231
Insulin 1236
Treatment of Type 1 Diabetes: Clinical Use of Insulin 1239
 Case 53-2, Questions 1–17 1239
 Case 53-3, Question 1 1251
 Case 53-4, Questions 1–7 1252
 Case 53-5, Question 1 1254
 Case 53-6, Question 1 1254
 Case 53-7, Question 1 1255
 Case 53-8, Question 1 1256
 Case 53-9, Question 1 1256
 Case 53-10, Question 1 1256
 Case 53-11, Questions 1–3 1258
 Case 53-12, Question 1 1260
Diabetic Ketoacidosis 1261
 Case 53-13, Questions 1–5 1261
Treatment of Type 2 Diabetes: Antidiabetic Agents 1264
Treatment of Patients With Type 2 Diabetes 1279
 Case 53-14, Questions 1–8 1279
 Case 53-15, Question 1 1284
 Case 53-16, Question 1 1285
 Case 53-17, Questions 1–7 1286
 Case 53-18, Question 1 1289
 Case 53-19, Question 1 1290
 Case 53-20, Questions 1–2 1290
 Case 53-21, Question 1 1291
 Case 53-22, Questions 1–6 1291
 Case 53-23, Question 1 1293
 Case 53-24, Questions 1–6 1294
 Case 53-25, Questions 1–3 1296
Drug-Induced Alterations in Glucose Homeostasis 1298
 Case 53-26, Question 1 1298
 Case 53-27, Question 1 1299
 Case 53-28, Question 1 1299
Key References and Websites 1299

SECTION 12: EYE DISORDERS 1301

54 Eye Disorders 1301

Steven R. Abel and Suellyn J. Sorensen

Ocular Anatomy and Physiology 1302
Glaucoma 1303
Primary Open-Angle Glaucoma 1303
 Case 54-1, Questions 1–7 1306
Angle-Closure Glaucoma 1311
 Case 54-2, Question 1 1311
Ocular Side Effects of Drugs 1312

Case 54-3, Question 1 1312
Ocular Emergencies 1312
 Case 54-4, Question 1 1312
Common Ocular Disorders 1317
 Case 54-5, Question 1 1317
 Case 54-6, Question 1 1317
 Case 54-7, Question 1 1318
Ophthalmic Corticosteroids 1318
 Case 54-8, Question 1 1318
 Case 54-9, Question 1 1319
Systemic Side Effects From Ophthalmic Medication 1319
 Case 54-10, Question 1 1319
Ocular Nonsteroidal Anti-Inflammatory Drugs 1319
 Case 54-11, Question 1 1319
Ocular Herpes Simplex Virus Infections 1320
 Case 54-12, Question 1 1320
Age-Related Macular Degeneration 1321
 Case 54-13, Question 1 1321
Key References and Websites 1322

SECTION 13: NEUROLOGIC DISORDERS 1323

55 Multiple Sclerosis 1323

Melody Ryan

Natural Course of the Disease and Prognosis 1324
Pathophysiology 1325
Epidemiologic and Genetic Features 1326
Clinical Presentation 1326
Diagnosis 1327
Overview of Treatment 1327
 Case 55-1, Questions 1–9 1330
 Case 55-2, Questions 1–3 1334
Key References and Website 1336

56 Headache 1337

Brian K. Alldredge

Migraine Headache 1340
 Case 56-1, Questions 1–15 1341
 Case 56-2, Question 1 1350
 Case 56-3, Question 1 1351
 Case 56-4, Question 1 1352
Cluster Headache 1352
 Case 56-5, Questions 1–3 1353
Tension-Type Headache 1355
 Case 56-6, Questions 1–2 1356
Key References and Websites 1357

57 Parkinson Disease and Other Movement Disorders 1358

Michael E. Ernst and Mildred D. Gottwald

Parkinson Disease 1359
Clinical Presentation of Parkinson disease 1360
 Case 57-1, Questions 1–2 1360
Treatment of Parkinson disease 1364
 Case 57-1, Questions 3–18 1364
 Case 57-2, Questions 1–3 1374
 Case 57-3, Questions 1–2 1377
 Case 57-4, Questions 1–2 1378
Restless Leg Syndrome and Periodic Limb Movements of Sleep 1380
 Case 57-5, Questions 1–4 1380
Essential tremor 1383
 Case 57-6, Questions 1–2 1383
Key References 1385

58 Seizure Disorders 1387

James W. McAuley, Rex S. Lott, and Brian K. Alldredge

Clinical Assessment and Treatment of Epilepsy 1395[Case 58-1](#), Questions 1–6 1395[Case 58-2](#), Questions 1–4 1397[Case 58-3](#), Questions 1–3 1402[Case 58-4](#), Question 1 1403[Case 58-5](#), Question 1 1403[Case 58-6](#), Question 1 1404[Case 58-7](#), Question 1 1404[Case 58-8](#), Questions 1–9 1405[Case 58-9](#), Question 1 1409[Case 58-10](#), Questions 1–3 1409**Antiepileptic Drug Interactions and Adverse Effects 1410**[Case 58-11](#), Question 1 1410[Case 58-12](#), Questions 1–3 1411[Case 58-13](#), Questions 1–2 1412**Women's Issues in Epilepsy 1413**[Case 58-14](#), Questions 1–2 1413**Status Epilepticus 1415**[Case 59-15](#), Questions 1–7 1415

Key References and Websites 1418

59 Cerebrovascular Disorders 1419

Timothy E. Welty

Transient Ischemic Attacks 1420**Primary prevention 1423**[Case 59-1](#), Questions 1–2 1423**Secondary Prevention and Transient Ischemic Attacks 1425**[Case 59-2](#), Questions 1–7 1425**Cerebral Infarction and Ischemic Stroke 1429**[Case 59-3](#), Questions 1–11 1429**Subarachnoid Hemorrhage 1434**[Case 59-4](#), Questions 1–4 1434

Key References and Websites 1436

SECTION 14: INFECTIOUS DISEASE 1437**60 Principles of Infectious Diseases 1437**

B. Joseph Guglielmo

Approaching the Problem 1437**Establishing the Presence of an Infection 1438**[Case 60-1](#), Question 1 1438**Establishing the Severity of an Infection 1438**[Case 60-1](#), Questions 2 1438**Problems in the Diagnosis of an Infection 1440**[Case 60-1](#), Questions 3 1440**Establishing the Site of the Infection 1441**[Case 60-1](#), Questions 4 1441**Determining Likely Pathogens 1441**[Case 60-1](#), Questions 5 1441**Microbiologic Tests and Susceptibility of Organisms 1443**[Case 60-1](#), Questions 6 1443**Determination of Isolate Pathogenicity 1448**[Case 60-1](#), Questions 7 1448**Antimicrobial Toxicities 1448**[Case 60-1](#), Questions 8 1448**Antimicrobial Costs of Therapy 1452**[Case 60-1](#), Questions 9 1452**Route of Administration 1452**[Case 60-1](#), Questions 10 1452**Antimicrobial Dosing 1452**[Case 60-1](#), Questions 11 1452**Pharmacokinetics and Pharmacodynamics 1457**[Case 60-1](#), Questions 12–13 1457**Antimicrobial Failure 1458**[Case 60-1](#), Questions 14–17 1458

Key References and Websites 1459

61 Antimicrobial Prophylaxis for Surgical Procedures 1461

Daniel J. G. Thirion

Risk Factors for Infection 1461**Classification of Surgical Site Infections 1462****Principles of Surgical Antimicrobial Prophylaxis 1462**[Case 61-1](#), Questions 1–4 1462[Case 61-2](#), Questions 1–3 1464[Case 61-3](#), Question 1 1465[Case 61-4](#), Questions 1–2 1465[Case 61-5](#), Questions 1–2 1466[Case 61-6](#), Question 1 1466[Case 61-7](#), Questions 1–2 1466**Optimizing Surgical Antimicrobial Prophylaxis 1467**

Key References and Websites 1467

62 Central Nervous System Infections 1468

Gregory A. Eschenauer, Brian A. Potoski, and Victoria J. Dudas

Review of Central Nervous System 1469**Meningitis 1469**[Case 62-1](#), Questions 1–12 1472[Case 62-2](#), Questions 1–5 1480[Case 62-3](#), Questions 1–3 1482[Case 62-4](#), Questions 1–4 1483**Brain Abscess 1485**[Case 62-5](#), Questions 1–3 1486

Key References and Websites 1488

63 Endocarditis 1489

Annie Wong-Beringer and Michelle Lee

Infective Endocarditis 1490***Streptococcus Viridans* Endocarditis 1491**[Case 63-1](#), Questions 1–4 1491***Staphylococcus Epidermidis*: Prosthetic Valve Endocarditis 1497**[Case 63-2](#), Questions 1–3 1497***Staphylococcus Aureus* Endocarditis 1500**[Case 63-3](#), Questions 1–4 1500**Enterococcal Endocarditis 1503**[Case 63-4](#), Questions 1–6 1503**Fungal Endocarditis Caused by *Candida Albicans* 1507**[Case 63-5](#), Questions 1–3 1507**Gram-Negative Bacillary Endocarditis Caused by *Pseudomonas Aeruginosa* 1508**[Case 63-5](#), Questions 5 1508**Culture-Negative Endocarditis 1509**[Case 63-5](#), Questions 6–7 1509**Prophylactic Therapy 1509**[Case 63-6](#), Questions 1–2 1509**Home Intravenous Antibiotic Therapy 1511**[Case 63-7](#), Question 1 1511

Key References 1511

64 Respiratory Tract Infections 1513

Heather M. Arnold, Eli N. Deal, Steven Gelone, and Scott T. Micek

Acute Bronchitis 1514[Case 64-1](#), Questions 1–8 1515

- Acute Exacerbation of Chronic Obstructive Pulmonary Disease 1516
- Case 64-2, Questions 1–7 1517
- Prevention of Common Respiratory Infections by Vaccination 1520
- Community-Acquired Pneumonia 1520
- Case 64-3, Questions 1–6 1521
- Case 64-4, Questions 1–3 1525
- Hospital-Acquired Pneumonia, Health Care–Associated Pneumonia, and Ventilator-Associated Pneumonia 1526
- Case 64-5, Questions 1–2 1527
- Case 64-6, Questions 1–3 1528
- Case 64-7, Questions 1–4 1530
- Key References and Websites 1532
- 65 Tuberculosis 1534**
- Michael B. Kays
- Case 65-1, Questions 1–7 1538
- Treatment of Active Disease 1541
- Case 65-1, Questions 8–14 1541
- Treatment of Latent Tuberculosis Infection 1548
- Case 65-2, Question 1 1548
- Adverse Drug Events 1549
- Case 65-2, Questions 2 1549
- Case 65-3, Questions 1–3 1549
- Case 65-4, Question 1 1551
- Special Treatment Considerations 1551
- Case 65-5, Question 1 1551
- Case 65-6, Questions 1–2 1552
- Case 65-7, Questions 1–5 1553
- Case 65-8, Question 1 1556
- Case 65-9, Question 1 1556
- Case 65-10, Question 1 1556
- Case 65-11, Question 1 1557
- Key References and Websites 1558
- 66 Infectious Diarrhea 1559**
- Gail S. Itokazu, David T. Bearden, and Larry H. Danziger
- Prevalence and Etiology 1560
- Definitions 1561
- Pathogenesis 1561
- Management Overview 1561
- Evaluation and Treatment of Patients with Infectious Diarrhea 1562
- Case 66-1, Questions 1–2 1562
- Clinical Presentation 1563
- Case 66-1, Questions 3 1563
- Viral Gastroenteritis 1563
- Case 66-1, Questions 4 1563
- Vibrio* Species 1563
- Case 66-2, Questions 1–3 1564
- Case 66-3, Questions 1–2 1564
- Staphylococcus Aureus*, *Bacillus Cereus*, and *Clostridium Perfringens* 1565
- Case 66-4, Question 1 1565
- Case 66-5, Question 1 1565
- Cryptosporidium Parvum* 1565
- Case 66-6, Question 1 1565
- Salmonella* 1566
- Case 66-7, Questions 1–7 1566
- Case 66-8, Questions 1–7 1568
- Shigella* species 1570
- Case 66-9, Questions 1–5 1570
- Case 66-10, Question 1 1571
- Campylobacter Jejuni* 1571
- Case 66-11, Questions 1–3 1571
- Travelers' Diarrhea (TD) 1572
- Case 66-12, Questions 1–5 1572
- Postinfectious Irritable Bowel Syndrome (PI-IBS) 1574
- Case 66-12, Questions 6–7 1574
- Escherichia coli* O157:H7 1575
- Case 66-13, Questions 1–5 1575
- Clostridium difficile*–Associated Diarrhea 1576
- Case 66-14, Questions 1–8 1576
- Case 66-15, Questions 1–6 1578
- Case 66-16, Questions 1–2 1579
- Key References and Websites 1580
- 67 Intra-Abdominal Infections 1581**
- Carrie A. Sincak and Sheila K. Wang
- Introduction 1581
- Infections of the Biliary Tract 1582
- Case 67-1, Questions 1–4 1582
- Primary Peritonitis 1585
- Case 67-2, Questions 1–4 1585
- Case 67-3, Questions 1–2 1587
- Secondary Peritonitis 1588
- Case 67-4, Questions 1–4 1589
- Case 67-5, Questions 1–4 1590
- Case 67-6, Question 1 1592
- Infections after Abdominal Trauma and Postoperative Complications 1592
- Case 67-7, Questions 1–2 1592
- Case 67-8, Question 1 1592
- Key References 1593
- 68 Urinary Tract Infections 1594**
- Douglas N. Fish
- Urinary Tract Infection 1595
- Lower Urinary Tract Infection 1599
- Case 68-1, Questions 1–6 1599
- Case 68-2, Questions 1–3 1605
- Case 68-3, Question 1 1606
- Treatment of Lower-Tract Infection in Renal Failure 1607
- Case 68-4, Question 1 1607
- Case 68-5, Questions 1–5 1607
- Recurrent Urinary Tract Infections 1609
- Case 68-6, Questions 1–11 1609
- Case 68-7, Questions 1–4 1612
- Symptomatic Abacteriuria 1613
- Case 68-8, Questions 1–2 1613
- Hospital-Acquired Acute Urinary Tract Infection 1613
- Case 68-9, Questions 1–2 1614
- Case 68-10, Questions 1–3 1614
- Asymptomatic Bacteriuria 1615
- Case 68-11, Questions 1–2 1615
- Prostatitis 1616
- Case 68-12, Questions 1–2 1617
- Key References and Websites 1617
- 69 Sexually Transmitted Diseases 1619**
- Jeffery A. Goad and Karl M. Hess
- Gonorrhea 1620
- Case 69-1, Questions 1–9 1621
- Case 69-2, Questions 1–4 1625
- Pelvic Inflammatory Disease 1625
- Case 69-3, Question 1 1626
- Complicated Gonorrhea 1627
- Case 69-4, Questions 1–4 1627

Chlamydia Trachomatis 1628
Case 69-5, Questions 1–5 1629
Case 69-6, Questions 1–2 1630
Syphilis 1630
Case 69-7, Questions 1–5 1631
Case 69-8, Questions 1–3 1634
Chancroid 1635
Case 69-9, Questions 1–2 1635
Vaginitis 1635
Case 69-10, Questions 1–2 1636
Case 69-11, Questions 1–12 1636
Case 69-12, Questions 1–3 1640
Case 69-13, Questions 1–2 1640
Genital Herpes 1641
Case 69-14, Questions 1–7 1641
Case 69-15, Question 1 1645
Case 69-16, Question 1 1645
Genital Warts 1645
Case 69-17, Question 1 1645
Key References and Websites 1646

70 Osteomyelitis and Septic Arthritis 1648

Bridgette L. Kram and Ralph H. Raasch

Osteomyelitis 1649
Case 70-1, Questions 1–7 1650
Case 70-2, Questions 1–4 1653
Case 70-3, Questions 1–2 1654
Case 70-4, Question 1 1655
Case 70-5, Questions 1–4 1655
Case 70-6, Questions 1–3 1656
Septic Arthritis 1657
Case 70-7, Questions 1–3 1658
Case 70-8, Questions 1–3 1659
Key References and Websites 1660

71 Traumatic Skin and Soft Tissue Infections 1661

James P. McCormack and Glen R. Brown

Cellulitis 1662
Case 71-1, Questions 1–6 1662
Case 71-2, Questions 1–4 1664
Case 71-3, Questions 1–3 1665
Soft Tissue Infections in Diabetic Patients 1666
Case 71-4, Questions 1–4 1666
Case 71-5, Question 1 1668
Erysipelas 1668
Case 71-6, Question 1 1668
Acute Traumatic Wounds 1668
Case 71-7, Question 1 1669
Case 71-8, Question 1 1669
Animal Bite Wounds 1669
Case 71-9, Questions 1–2 1669
Human Bite Wounds 1670
Case 71-10, Question 1 1670
Case 71-11, Question 1 1670
Key References and Websites 1671

72 Prevention and Treatment of Infections in Neutropenic Cancer Patients 1672

Richard H. Drew

Risk Factors for Infection 1673
Most Common Pathogens 1675
Case 72-1, Question 1675 1
RISK stratification 1675
Prophylaxis Against Infection 1675

Case 72-1, Questions 2–3 1675
Infections in Neutropenic Cancer Patients 1679
Case 72-1, Questions 4–6 1679
Empiric Antibiotic Therapy 1680
Case 72-1, Questions 7–10 1680
Case 72-2, Questions 1–3 1682
Antibiotic Dosing, Administration, and Monitoring Considerations 1684
Case 72-2, Questions 4–5 1684
Host Factors Influencing Response to Therapy 1684
Case 72-2, Question 6 1684
Modifying Initial Empiric Antibiotic Therapy 1684
Case 72-3, Questions 1–2 1684
Case 72-4, Questions 1–4 1685
Antimicrobial Adjuvants 1688
Case 72-4, Questions 5 1688
Key References and Websites 1689

73 Pharmacotherapy of Human Immunodeficiency Virus Infection 1690

Jessica L. Adams, Julie B. Dumond, and Angela D.M. Kashuba

Introduction 1691
Epidemiology 1691
Pathophysiology 1692
Pharmacotherapy 1695
Diagnosis 1699
Case 73-1, Question 1 1699
Surrogate Marker Data 1700
Case 73-1, Questions 2 1700
Antiretroviral Therapy 1701
Case 73-1, Question 3–10 1701
Case 73-2, Question 1 1709
Resistance, Viral Genotyping, Phenotyping, and Viral Fitness 1710
Case 73-2, Questions 2 1710
Special Circumstances 1711
Case 73-2, Questions 3 1711
Case 73-3, Question 1 1713
Case 73-4, Question 1 1714
Case 73-5, Question 1 1714
Case 73-6, Question 1 1714
Keeping Current 1715
Conclusions 1715
Key References and Websites 1716

74 Opportunistic Infections in HIV-Infected Patients 1717

Amanda H. Corbett and Emily L. Heil

***Pneumocystis jiroveci* Pneumonia** 1722
Case 74-1, Questions 1–3 1723
***Toxoplasma gondii* Encephalitis** 1726
Case 74-2, Questions 1–8 1726
Cytomegalovirus Disease 1728
Case 74-3, Questions 1–10 1728
Cryptococcosis 1735
Case 74-4, Questions 1–8 1735
Mycobacterium tuberculosis 1737
Case 74-5, Questions 1–2 1737
Case 74-6, Question 1 1738
Case 74-7, Question 1 1738
***Mycobacterium avium* Complex disease** 1740
Case 74-8, Questions 1–6 1740
Enteric Infections 1743
Case 74-9, Question 1 1743
Esophageal Disease 1745

Case 74-10, Question 1 1745
 Acknowledgments 1745
 Key References and Websites 1745

75 Fungal Infections 1746

John D. Cleary, Stanley W. Chapman, and Margaret M. Pearson

Mycology 1747
 Antimycotics 1749
 Superficial and Cutaneous Mycoses 1751
 Case 75-1, Questions 1–3 1751
 Subcutaneous Mycoses 1752
 Case 75-2, Questions 1–3 1752
 Systemic Mycoses 1754
 Case 75-3, Questions 1–11 1754
 Case 75-4, Question 1 1762
 Case 75-5, Questions 1–3 1763
 Case 75-6, Questions 1–3 1764
 Case 75-7, Questions 1–3 1767
 Case 75-8, Questions 1–3 1768
 Case 75-9, Questions 1–3 1769
 Key References and Websites 1771

76 Viral Infections 1772

Milap C. Nahata, Neeta Bahal O'Mara, and Sandra Benavides

Herpes Simplex Virus Infections 1773
 Case 76-1, Questions 1–4 1773
 Case 76-2, Questions 1–3 1775
 Case 76-3, Question 1 1777
 Case 76-4, Questions 1–2 1777
 Case 76-5, Question 1 1777
 Case 76-6, Question 1 1777
 Varicella-Zoster Infections 1778
 Case 76-7, Question 1 1778
 Case 76-8, Questions 1–2 1778
 Case 76-9, Questions 1–3 1779
 Case 76-10, Questions 1–2 1781
 Influenza 1781
 Case 76-11, Questions 1–2 1782
 Case 76-12, Questions 1–2 1783
 Respiratory Syncytial Virus Infections 1784
 Case 76-13, Questions 1–3 1784
 Case 76-14, Questions 1–2 1785
 Hantavirus Infections 1785
 Case 76-15, Questions 1–2 1786
 West Nile Virus 1786
 Case 76-16, Questions 1–2 1786
 Severe Acute Respiratory Distress Syndrome 1787
 Case 76-17, Questions 1–2 1787
 The Common Cold 1788
 Case 76-18, Question 1 1788
 Key References and Websites 1788

77 Viral Hepatitis 1790

Curtis D. Holt

Causative Agents and Characteristics 1791
 Hepatitis A Virus 1791
 Case 77-1, Questions 1–3 1793
 Case 77-2, Question 1 1795
 Case 77-3, Question 1 1796
 Hepatitis B Virus 1797
 Case 77-4, Questions 1–4 1800
 Case 77-5, Questions 1–2 1801
 Case 77-6, Questions 1–3 1802

Case 77-7, Question 1 1803
 Case 77-8, Question 1 1804
 Case 77-9, Question 1 1805
 Case 77-10, Questions 1–2 1805
 Case 77-11, Question 1 1805
 Case 77-12, Questions 1–14 1805
 Hepatitis C Virus 1814
 Case 77-13, Questions 1–9 1817
 Case 77-14, Question 1 1823
 Hepatitis D Virus 1823
 Hepatitis E Virus 1826
 Summary 1827
 Key References and Websites 1827

78 Parasitic Infections 1828

J.V. Anandan

Malaria 1829
 Case 78-1, Questions 1–2 1830
 Case 78-2, Questions 1–2 1833
 Case 78-3, Question 1 1835
 Case 78-4, Questions 1–2 1835
 Amebiasis 1835
 Case 78-5, Questions 1–2 1836
 Case 78-6, Questions 1–2 1837
 Case 78-7, Question 1 1837
 Giardiasis 1838
 Case 78-8, Questions 1–3 1838
 Enterobiasis 1839
 Case 78-9, Questions 1–3 1839
 Cestodiasis 1840
 Case 78-10, Questions 1–4 1841
 Case 78-11, Questions 1–3 1842
 Pediculosis 1842
 Case 78-12, Questions 1–3 1843
 Scabies 1844
 Case 78-13, Question 1 1844
 Key References and Websites 1844

79 Tick-Borne Diseases 1846

Thomas E. Christian

Overview 1847
 Lyme Disease 1847
 Case 79-1, Question 1 1849
 Erythema Migrans 1849
 Case 79-2, Questions 1–2 1849
 Lyme Disease Treatment 1850
 Case 79-2, Questions 3–4 1850
 Case 79-3, Question 1 1851
 Case 79-4, Question 1 1851
 Case 79-5, Question 1 1851
 Endemic Relapsing Fever (TBRE) 1852
 Case 79-6, Questions 1–2 1853
 Case 79-7, Question 1 1853
 Other Bacterial Diseases: Tularemia 1853
 The Rickettsia: Rocky Mountain Spotted Fever, *Rickettsia parkeri* Infection, Ehrlichiosis, and Anaplasmosis 1854
 Case 79-8, Question 1 1858
 The Protozoa: Babesiosis 1858
 Case 79-9, Questions 1–2 1859
 The Viruses: Colorado Tick Fever and Tick-Borne Encephalitis 1860
 Case 79-10, Question 1 1860
 The Toxins: Tick Paralysis 1861
 Case 79-11, Question 1 1861

Mixed Infections 1861
 Summary 1861
 Key References and Websites 1862

SECTION 15: PSYCHIATRIC DISORDERS 1863

Section Editors: Patrick R. Finley and Kelly C. Lee

80 Anxiety Disorders 1863

Sally K. Guthrie and Jolene R. Bostwick

Case 80-1, Question 1 1866
 Generalized Anxiety Disorder 1869
 Case 80-2, Questions 1–6 1872
 Case 80-3, Question 1 1876
 Case 80-4, Questions 1–2 1877
 Case 80-5, Question 1 1879
 Case 80-6, Questions 1–3 1879
 Panic Disorder 1882
 Case 80-7, Questions 1–4 1884
 Social Anxiety Disorder and Specific Phobias 1886
 Case 80-8, Questions 1–3 1888
 Posttraumatic Stress Disorder and Acute Stress Disorder 1889
 Case 80-9, Questions 1–3 1891
 Obsessive-Compulsive Disorder 1892
 Case 80-10, Questions 1–5 1895
 Case 80-11, Questions 1–3 1895
 Key References and Websites 1898

81 Sleep Disorders 1900

Julie A. Dopheide and Glen L. Stimmel

Societal Impact 1901
 Epidemiology 1901
 The Sleep Stages 1902
 Neurochemistry of Sleep-Wake Cycle 1903
 Patient Assessment 1903
 Case 81-2, Questions 1–9 1905
 Insomnia in a Medically Ill Patient 1908
 Case 81-2, Questions 1–4 1908
 Insomnia and Psychiatric Disorders 1911
 Case 81-3, Questions 1–4 1911
 Insomnia in the Elderly 1913
 Case 81-4, Questions 1–5 1913
 Pediatric Insomnia 1915
 Case 81-5, Questions 1–3 1915
 Pregnancy and Lactation 1916
 Case 81-6, Question 1 1916
 Formulary Management of Hypnotics 1917
 Case 81-7, Question 1 1917
 Sleep Apnea 1917
 Case 81-8, Questions 1–3 1917
 Narcolepsy 1918
 Case 81-9, Questions 1–4 1919
 Key References and Websites 1920

82 Schizophrenia 1921

Jonathan P. Lacro, Sanaz Farhadian, and Rene A. Endow-Eyer

Epidemiology 1921
 Economic Burden 1922
 Etiology (Neurobiology) 1922
 Clinical Presentation 1923
 Case 82-1, Questions 1–3 1926
 Treatment 1927
 Case 82-1, Questions 4–34 1928

Considerations in specific populations 1946
 Case 82-1, Questions 35–36 1946
 Key References and Websites 1947

83 Mood Disorders I: Major Depressive Disorders 1949

Patrick R. Finley and Kelly C. Lee

Introduction 1950
 Major Depressive Disorder 1959
 Case 83-1, Questions 1–2 1959
 Drug Management 1961
 Case 83-1, Questions 3–15 1961
 Case 83-2, Questions 1–4 1971
 Case 83-3, Questions 1–2 1974
 Case 83-4, Questions 1–4 1975
 Case 83-5, Question 1 1976
 Case 83-6, Question 1 1977
 Case 83-7, Questions 1–2 1978
 Case 83-8, Question 1 1978
 Case 83-9, Questions 1–5 1979
 Case 83-10, Questions 1–2 1981
 Key References and Websites 1982

84 Mood Disorders II: Bipolar Disorders 1983

James J. Gasper

Introduction 1983
 Clinical Assessment 1986
 Case 84-1, Questions 1–3 1986
 Treatment of Acute Mania 1987
 Case 84-1, Questions 1–8 1987
 Case 84-2, Questions 1–8 1989
 Case 84-3, Question 1 1991
 Case 84-4, Questions 1–2 1992
 Case 84-5, Questions 1–2 1993
 Case 84-6, Question 1 1994
 Treatment of Acute Bipolar Depression 1995
 Case 84-7, Question 1 1995
 Maintenance Therapy of Bipolar Disorder 1996
 Case 84-8, Questions 1–4 1996
 Key References and Websites 1998

85 Attention Deficit Hyperactivity Disorder in Children, Adolescents, and Adults 1999

Kimberly B. Tallian, Patrick R. Finley, Paul Perry, and Samuel Kuperman

Epidemiology 2000
 Pathophysiology 2000
 Diagnosis 2000
 Comorbidity and Prognosis 2001
 Signs and Symptoms 2001
 Case 85-1, Question 1 2001
 Treatment 2002
 Case 85-1, Questions 2–6 2008
 Case 85-2, Question 1 2008
 Case 85-3, Questions 1–2 2008
 Key References and Websites 2010

SECTION 16: SUBSTANCE ABUSE 2011

86 Drug Abuse 2011

Wendy O. Zizzo and Paolo V. Zizzo

Addiction 2012
 Case 86-1, Question 1 2012

Opioids 2012

- Case 86-2, Questions 1–3 2012
- Case 86-3, Question 1 2014
- Case 86-4, Question 1 2014
- Case 86-5, Question 1 2014
- Case 86-6, Question 1 2015
- Case 86-7, Questions 1–4 2015
- Case 86-8, Question 1 2017
- Case 86-9, Questions 1–4 2018
- Case 86-10, Questions 1–3 2018

Sedative-Hypnotics 2020

- Case 86-11, Questions 1–2 2020
- Case 86-12, Question 1 2021

Central Nervous System Stimulants 2022

- Case 86-13, Questions 1–5 2022
- Case 86-14, Questions 1–3 2024

Dissociative Drugs: Phencyclidine, Ketamine, and Dextromethorphan 2025

- Case 86-15, Questions 1–3 2025

Hallucinogens 2026

- Case 86-16, Questions 1–3 2026
- Case 86-17, Questions 1–3 2027

Marijuana 2028

- Case 86-18, Questions 1–3 2029

Inhalants 2030

- Case 86-19, Questions 1–3 2031

Acknowledgment 2031**Key References and Websites 2031****87 Alcohol Use Disorders 2033**

George A. Kenna

Alcohol Content and Definitions 2034**Neuroscience and Neurobehavior 2035****Alcohol Toxicity 2037**

- Case 87-1, Questions 1–5 3037

Alcohol Withdrawal 2039

- Case 87-2, Questions 1–4 2039

Adjunctive Treatments 2043

- Case 87-2, Questions 5 2043

Pharmacotherapy of Alcohol Dependence 2043

- Case 87-3, Questions 1–2 2043

Disulfiram 2045

- Case 87-4, Question 1 2047

Acamprosate 2047

- Case 87-4, Questions 2 2048

Naltrexone 2048**Combination Pharmacotherapy 2050**

- Case 87-4, Questions 3 2050

Alternative Pharmacotherapy 2050

- Case 87-5, Questions 1–3 2050

Drug Interactions 2052

- Case 87-6, Question 1 2052

Key References and Websites 2053**88 Tobacco Use and Dependence 2055**

Robin L. Corelli and Karen Suchanek Hudmon

Epidemiology of Tobacco Use and Dependence 2056**Pharmacotherapy for Treating Tobacco Use and Dependence 2067**

- Case 88-1, Questions 1–5 2067

- Case 88-2, Questions 1–4 2070

- Case 88-3, Question 1 2075

- Case 88-4, Questions 1–3 2076

- Case 88-5, Questions 2 2077

- Case 88-6, Questions 1–4 2078

Key References and Website 2079**SECTION 17: NEOPLASTIC DISORDERS 2080**

Section Editor: Mark N. Kirstein

89 Neoplastic Disorders and Their Treatment: General Principles 2080

Makala B. Pace and Katherine Tipton Patel

Introduction to Neoplastic Disorders 2081

- Case 89-1, Question 1 2085

- Case 89-2, Question 1 2086

- Case 89-3, Question 1 2087

- Case 89-4, Question 1 2088

- Case 89-5, Question 1 2088

Treatment 2090

- Case 89-6, Question 1 2090

- Case 89-7, Question 1 2099

- Case 89-8, Question 1 2100

- Case 89-9, Question 1 2100

- Case 89-10, Question 1 2101

- Case 89-11, Question 1 2106

Handling of Cytotoxic Drugs 2106

- Case 89-12, Questions 1–4 2106

Acknowledgment 2108**Key References and Website 2108****90 Adverse Effects of Chemotherapy and Targeted Agents 2109**

Amy Hatfield Seung

Common and Acute Toxicities 2110

- Case 90-1, Questions 1–6 2111

- Case 90-2, Questions 1–3 2115

- Case 90-3, Question 1 2118

- Case 90-4, Questions 1–7 2119

- Case 90-5, Question 1 2124

Specific Organ Toxicities 2126

- Case 90-6, Questions 1–4 2126

- Case 90-7, Questions 1–4 2129

- Case 90-8, Questions 1–2 2132

- Case 90-9, Questions 1–3 2134

- Case 90-10, Questions 1–4 2135

- Case 90-11, Question 1 2136

- Case 90-12, Questions 1–2 2139

- Case 90-13, Question 1 2140

- Case 90-14, Questions 1–2 2140

Key References and Websites 2141**91 Pediatric Malignancies 2143**

David W. Henry, Mark T. Holdsworth, and Nicole A. Kaiser

Pediatric Malignancies 2144**Pediatric Solid Tumors 2145**

- Case 91-1, Questions 1–5 2148

- Case 91-2, Questions 1–5 2150

- Case 91-3, Questions 1–4 2151

- Case 91-4, Questions 1–3 2153

Acute Lymphoblastic Leukemia of Childhood 2154**Overview of Treatment 2158**

- Case 91-5, Questions 1–15 2158

- Case 91-6, Questions 1–5 2164

- Case 91-7, Questions 1–3 2167

Pediatric Non-Hodgkin Lymphoma 2167

- Case 91-8, Questions 1–4 2169

Key References and Websites 2170

92 Adult Hematologic Malignancies 2172Lynn Weber, Steve Stricker, Casey B. Williams,
and Katie A. Won**Acute Myeloid Leukemia 2173**[Case 92-1](#), Questions 1–8 2175[Case 92-2](#), Questions 1–2 2178**Chronic Myelogenous Leukemia 2179**[Case 92-3](#), Questions 1–4 2180**Chronic Lymphocytic Leukemia 2182**[Case 92-4](#), Questions 1–5 2183**Multiple Myeloma 2185**[Case 92-5](#), Questions 1–5 2186**Lymphoma 2189**[Case 92-6](#), Questions 1–3 2191[Case 92-7](#), Questions 1–2 2193[Case 92-8](#), Questions 1–3 2194**Key References and Websites 2196****93 Breast Cancer 2197**

Kellie L. Jones

Breast Cancer 2197[Case 93-1](#), Questions 1–2 2199[Case 93-2](#), Question 1 2200[Case 93-3](#), Questions 1–9 2200**Metastatic Breast Cancer 2207**[Case 93-4](#), Questions 1–5 2207**Key References and Websites 2209****94 Lung Cancer 2210**

Mark N. Kirstein, Robert A. Kratzke, and Arkadiusz Z. Dudek

Lung Cancer 2210[Case 94-1](#), Questions 1–4 2212[Case 94-2](#), Questions 1–7 2215[Case 94-3](#), Questions 1–6 2219**Key References and Websites 2221****95 Colorectal Cancer 2223**

Sachin R. Shah and Julian Hoyt Slade, III

Colorectal Cancer 2224[Case 95-1](#), Questions 1–2 2225[Case 95-2](#), Questions 1–6 2226[Case 95-3](#), Questions 1–6 2231**Chemotherapy and Radiation for Early-Stage Rectal Cancer 2234****Key References and Websites 2235****96 Hematopoietic Cell Transplantation 2236**

Kathleen G.E. Green and John R. Rogosheske

Overview 2237**Autologous Hematopoietic Stem Cell Transplantation 2238**[Case 96-1](#), Questions 1–6 2238**Allogeneic Hematopoietic Stem Cell Transplantation 2242**[Case 96-2](#), Questions 1–7 2242**Comparison of Supportive Care Strategies Between Autologous and Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation 2246**[Case 96-2](#), Questions 8 2246**Comparison of Supportive Care Strategies Between Allogeneic Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation 2247**[Case 96-2](#), Questions 9 2247**Complications Associated with Hematopoietic Stem Cell Transplantation 2247**[Case 96-3](#), Questions 1–9 2247[Case 96-4](#), Question 1 2251**Graft-versus-Host Disease 2252**[Case 96-5](#), Questions 1–9 2252**Infectious Complications 2258**[Case 96-6](#), Questions 1–3 2258[Case 96-7](#), Questions 1–5 2261**Issues of Survivorship After Hematopoietic Stem Cell Transplantation 2263**[Case 96-8](#), Question 1 2263**Key References and Websites 2264****SECTION 18: PEDIATRICS 2265**

Section Editor: Marcia L. Buck

97 Pediatric Pharmacotherapy 2265

Marcia L. Buck

Growth and Development during Childhood 2266[Case 97-1](#), Question 1 2261**Pediatric Pharmacokinetic Differences 2267**[Case 97-2](#), Question 1 2267[Case 97-3](#), Questions 1–6 2267[Case 97-4](#), Questions 1–4 2270[Case 97-5](#), Questions 1–2 2272[Case 97-6](#), Question 1 2272[Case 97-7](#), Question 1 2273**Pediatric Pharmacodynamic Differences 2273**[Case 97-8](#), Question 1 2273[Case 97-9](#), Questions 1–2 2273**Medication Dosing in Children 2274**[Case 97-10](#), Question 1 2274**Preventing Medication Errors in Children 2274**[Case 97-10](#), Questions 2–3 2274**Increasing Availability of Pediatric Medication Information 2275**[Case 97-10](#), Questions 4 2275**Key References and Websites 2276****98 Pediatric Fluid, Electrolytes, and Nutrition 2277**

Michael F. Chicella and Jennifer W. Chow

Fluid and Electrolyte Maintenance 2278[Case 98-1](#), Questions 1–2 2278[Case 98-2](#), Questions 1–3 2280[Case 98-3](#), Questions 1–3 2281**Infant Enteral Nutrition 2283**[Case 98-4](#), Questions 1–5 2283[Case 98-5](#), Question 1 2285[Case 98-6](#), Questions 1–4 2286[Case 98-7](#), Questions 1–11 2288**Key References and Websites 2292****99 Common Pediatric Illnesses 2293**

Michelle Condren and Mark R. Haase

Administering Medication to Children 2294[Case 99-1](#), Question 1 2294**Infant Care 2295**[Case 99-2](#), Questions 1–2 2295[Case 99-3](#), Questions 1–2 2296[Case 99-4](#), Questions 1–2 2296[Case 99-5](#), Question 1 2297[Case 99-6](#), Question 1 2298**Viral Gastroenteritis 2299**[Case 99-7](#), Questions 1–3 2299

Gastroesophageal Reflux 2301
 Case 99-8, Questions 1–2 2302
 Common Pediatric Infections 2304
 Case 99-9, Questions 1–2 2304
 Case 99-10, Questions 1–2 2305
 Key References and Websites 2306

100 Neonatal Therapy 2307

Donna M. Kraus and Jennifer Tran Pham

Neonatal Therapy 2308
 Respiratory Distress Syndrome 2308
 Case 100-1, Questions 1–6 2309
 Bronchopulmonary Dysplasia 2312
 Case 100-2, Questions 1–5 2312
 Patent Ductus Arteriosus 2317
 Case 100-3, Questions 1–9 2319
 Necrotizing Enterocolitis 2322
 Case 100-4, Questions 1–6 2322
 Neonatal Sepsis and Meningitis 2326
 Case 100-5, Questions 1–2 2326
 Congenital Infections 2330
 Case 100-6, Question 1 2330
 Apnea of Prematurity 2331
 Case 100-7, Questions 1–3 2331
 Neonatal Seizures 2333
 Case 100-8, Questions 1–5 2333
 Key References and Websites 2336

101 Care of the Critically Ill Child 2337

Elizabeth Anne Farrington and Marcia L. Buck

Pediatric Cardiopulmonary Resuscitation 2338
 Case 101-1, Question 1 2339
 Respiratory Distress 2339
 Case 101-1, Questions 1–3 2339
 Medications for Intubation and Mechanical Ventilation 2341
 Case 101-1, Questions 4 2341
 Pediatric Shock 2344
 Case 101-3, Questions 1–3 2344
 Sepsis and Septic Shock in Infants and Children 2345
 Case 101-4, Questions 1–2 2346
 Initial Management of Pediatric Septic Shock 2348
 Case 101-4, Questions 3 2348
 Cardiovascular Drug Therapy 2349
 Case 101-4, Questions 4–5 2350
 Corticosteroid Administration in Pediatric Septic Shock 2352
 Case 101-4, Questions 6 2352
 Adjunctive Therapies 2352
 Congenital Heart Disease 2352
 Case 101-5, Question 1 2352
 Pediatric Traumatic Brain Injury 2353
 Case 101-6, Questions 1–6 2353
 Case 101-7, Question 1 2357
 Key References and Websites 2357

SECTION 19: GERIATRIC THERAPY 2359

Section Editor: Judith L. Beizer

102 Geriatric Drug Use 2359

Jiwon Kim and May Mak

Demographic and Economic Considerations 2360

Age-Related Physiological, Pharmacokinetic, and Pharmacodynamic Changes 2360

Case 102-1, Questions 1–4 2361

Pharmacodynamic Changes 2362

Problems Associated With Drug Use in Older Adults 2364

Case 102-2, Question 1 2364

Disease-Specific Geriatric Drug Therapy 2365

Case 102-3, Questions 1–11 2365

Case 102-4, Questions 1–2 2368

Case 102-5, Questions 1–6 2369

Case 102-6, Question 1 2371

Case 102-7, Questions 1–2 2371

Long-Term Care Facilities 2372

Case 102-8, Questions 1–2 2372

Key References and Websites 2373

103 Geriatric Dementias 2375

Nicole J. Brandt and Bradley R. Williams

Geriatric Dementias 2376

Alzheimer Disease 2378

Case 103-1, Questions 1–7 2379

Lewy Body Dementias 2386

Case 103-2, Questions 1–2 2386

Vascular Dementias 2387

Case 103-3, Questions 1–3 2387

Behavioral Disturbances in Dementia 2390

Case 103-4, Questions 1–5 2391

Pseudodementia 2393

Case 103-5, Questions 1–2 2393

Acknowledgement 2393

Key References and Websites 2394

104 Geriatric Urologic Disorders 2395

Michael R. Brodeur

Urinary Incontinence 2395

Case 104-1, Questions 1–4 2398

Case 104-2, Questions 1–2 2400

Benign Prostatic Hyperplasia 2401

Case 104-3, Questions 1–7 2402

Sexual Dysfunction 2408

Case 104-4, Questions 1–14 2410

Key References and Websites 2416

105 Osteoporosis 2417

Rebecca A. Rottman-Sagebiel

Incidence, Prevalence, and Epidemiology 2417

Case 105-1, Questions 1–3 2419

Case 105-2, Questions 1–8 2422

Case 105-3, Questions 1–2 2427

Case 105-4, Questions 1–3 2431

Osteoporosis in Men 2432

Case 105-5, Questions 1–5 2432

Key References and Websites 2433

Drug Index 2434

Subject Index 2466

Assessment of Therapy and Medication Therapy Management

Marilyn R. Stebbins, Timothy W. Cutler, and Patricia L. Parker

CORE PRINCIPLES

CHAPTER CASES

| | | |
|-----------|---|--|
| 1 | Medication Therapy Management Services (MTMS) are provided to patients in all care settings but were first described in the Medicare Modernization Act of 2003. | Case 1-5 (Questions 1, 5) |
| 2 | MTMS includes comprehensive medication therapy review, developing a personalized medication record, a medication action plan, and documentation of the encounter. | Case 1-5 (Questions 1-4) |
| 3 | Medication reconciliation and taking an accurate and complete medication history are crucial to a successful MTMS encounter. | Case 1-1 (Questions 1-3) |
| 4 | Data necessary to perform MTMS can be obtained from many sources, including the patient, the paper chart, the pharmacy information system, and the electronic health record. | Case 1-5 (Questions 1, 5) |
| 5 | A careful and complete patient interview should include a medical, medication, and social history and must be provided in a culturally sensitive manner. | Case 1-1 (Questions 1-3), Table 1-1, Online Content |
| 6 | A successful MTMS encounter must be well documented following the Problem Oriented Medical Record. | Case 1-5 (Question 1), Table 1-2 |
| 7 | The first step in documenting an MTMS encounter involves subjective and objective data collection to identify the primary problem. | Case 1-2 (Question 1), Case 1-3 (Question 1), Case 1-4 (Question 1) |
| 8 | Once the subjective and objective information is obtained, the clinician must assess the drug therapy or disease-specific problem. The assessment is the clinician's clinical justification for the plan. | Case 1-5 (Questions 1, 2) |
| 9 | The final step in documenting the MTMS encounter is developing the medication action plan and processing any billing requirements. | Case 1-5 (Questions 1, 2, 4) |
| 10 | To ensure the needs of the patient are met, communication of the plan with the patient and patient's other providers is required. | Case 1-5 (Question 3) |

With the passage of the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, pharmacists and other providers have tremendous opportunities in the implementation of health care reform.^{1,2} One of the hallmarks of this law is delivery system reform. As health care delivery systems change, pharmacists have an opportunity

to improve overall quality of care, to become involved in coordinated health care approaches such as medical home teams and accountable care organizations, and to collaborate to improve care for high-risk patients and those with chronic conditions in primary-care settings. Pharmacists practicing in acute care settings will have additional opportunities as hospitals will have

financial incentives to improve quality, reduce costs, and decrease hospital-acquired conditions.^{1,2} With the pharmacists' expertise in medication therapy management, their leadership and involvement are crucial as these collaborative practices are being developed and implemented.

This chapter presents several approaches to assessing drug therapy and provides the framework for medication therapy management services (MTMS) across the continuum of care. The illustrations in this chapter primarily focus on the pharmacist; however, the principles used to assess patient response to drug therapy are of value to all health care providers.

MTMS was first described in the Medicare Modernization Act of 2003 (MMA 2003), which also established the first outpatient prescription drug benefit (also known as Medicare Part D) for those eligible for Medicare.³ MTMS was defined in MMA 2003 as *a program of drug therapy management that may be furnished by a pharmacist and that is designed to assure . . . that covered Part D drugs under the prescription drug plan are appropriately used to optimize therapeutic outcomes through improved medication use, and to reduce the risk of adverse events, including adverse drug interactions.*

In 2003, the MMA defined eligibility criteria for MTMS, which were updated in 2010 to ensure that more Medicare beneficiaries would qualify for MTMS. MTMS-eligible beneficiaries must:

1. Take multiple Medicare Part D–covered drugs
2. Have multiple chronic diseases
3. Are likely to incur annual costs of at least \$3,000 for all covered Part D drugs

Although MTMS is the term used in MMA 2003 to describe medication management for those eligible under the Medicare Part D benefit, the same approach is appropriate for any patient taking medications for chronic conditions. To respond to the need for further clarification of the term MTMS, 11 professional pharmacy associations more formally defined MTMS in a consensus document published in 2004.⁴ According to this definition, MTMS can be applied to any patient in a variety of settings. Furthermore, this definition clarifies the type of activities involved in a medication therapy management (MTM) program.

MTMS has a direct relationship to pharmaceutical care. Pharmaceutical care has been described as *the responsible provision of drug therapy to achieve definite outcomes that are intended to improve a patient's quality of life.*^{5,6} In fact, MTMS has been described as a service provided in the practice of pharmaceutical care.⁷ However, unlike pharmaceutical care, MTMS is recognized by payers, has current procedural terminology (CPT) codes specifically for pharmacists, and has several clearly defined interventions. Therefore, MTMS will be the term used to describe the activity of MTM in various patient populations.

Both patient self-care and medication reconciliation are critical aspects of any MTMS encounter regardless of the setting (i.e., inpatient, community, ambulatory, or institutional). Patient self-care is defined by the World Health Organization as those *activities [that] individuals, families, and communities undertake with the intention of enhancing health, preventing disease, limiting illness, and restoring health. These activities are derived from knowledge and skills from the pool of both professional and lay experience. They are undertaken by lay people on their own behalf, either separately or in participative collaboration with professionals.*⁸ Patient self-care requires the patient to take responsibility for the illness; however, the help of a professional to structure healthy self-care is important. For example, patients with diabetes who monitor their blood glucose levels regularly and adjust their diet according to the guidelines published from the American Diabetes Association (ADA) would be practicing self-care. Self-care is often the work that the patient performs between visits with the provider. The patient

should be involved in his or her own care to ensure the best outcomes.

Medication reconciliation is the comprehensive evaluation of a patient's medication regimen any time there is a change in therapy in an effort to avoid medication errors such as omissions, duplications, dosing errors, or drug interactions, as well as to observe compliance and adherence patterns. This process should include a comparison of the existing and previous medication regimens and should occur at every transition of care in which new medications are ordered, existing orders are rewritten or adjusted, or when the patient has added nonprescription medications to his or her self-care.⁹ Although not a new concept to the profession of pharmacy, there has been heightened awareness and intensified effort in this area of practice as a result of the Joint Commission. The Joint Commission is the national accrediting body for hospitals and other health care delivery organizations that has committed to improving patient care through an inspection and evaluation process. In 2005, the Joint Commission announced its National Patient Safety Goal (NPSG) 8A and 8B to *accurately and completely reconcile medications across the continuum of care.* This goal requires institutions to develop and test processes for medication reconciliation in ambulatory and acute care settings.¹⁰ Currently, the Joint Commission is re-evaluating and refining the standards surrounding NPSG 8 so that they can be more readily and successfully implemented by institutions. The release of the new standards is anticipated in January 2011.

The general approach to an MTMS patient encounter in various clinical settings will be discussed in the next sections. Figure 1-1 provides an overview of a patient encounter that includes information gathering from various data sources; interviewing the patient while using effective communication skills; assessing the medical illness(es); developing a plan to manage the illness(es); documenting the service (including billing); and monitoring, follow-up, or referral for any additional issues that cannot be resolved during the encounter.

SOURCES OF PATIENT INFORMATION

Successful patient assessment and monitoring requires the gathering and organization of all relevant information.^{6,11} The patient (or family member or other representative) is always the primary source of information. The provider asks the patient a series of questions to obtain subjective information that is helpful in making a diagnosis or evaluating ongoing therapy. Likewise, pharmacists, home care nurses, and other providers without direct access to patient data also must obtain subjective data or measure objective physical data to guide recommendations for therapy and to monitor previously prescribed therapy.

Data-Rich Environment

In a "data-rich environment," such as a hospital, long-term care facility, or outpatient medical clinic, a wealth of information is available to practitioners from the medical record, pharmacy profile, and medication administration record (MAR). In these settings, physicians, nurses, and patients are readily available. This facilitates timely, effective communication among providers involved in the drug therapy decision-making process. Objective data (e.g., diagnosis, physical examination, laboratory and other test results, vital signs, weight, medications, medication allergies, intravenous flow rates, and fluid balance) are readily available. Likewise, the cases presented throughout this text usually provide considerable data on which to make more thorough assessments and therapeutic decisions. The patient record provides




FIGURE 1-1 General approach to a patient encounter. EHR, electronic health record; PIS, pharmacy information system; PMR, personal medication record.

readily available information that is needed to identify and assess medical problems, which is necessary to design patient-specific care plans and document MTMS. In some settings, patient insurance information is important to help understand the formulary choices and access to medications.

PAPER CHARTS

A paper chart may be a source of valuable patient information. Paper charts may exist in a variety of settings, including the hospital, outpatient clinic, or institutional setting. This source of information is considered data rich but does have limitations. Paper charts are organized differently by site and by setting. The information contained in a hospital chart will be different from that contained in an outpatient clinic. Furthermore, it may be difficult to obtain a paper chart, or access may be delayed if another professional is using the chart. Significant data delays may occur in paper charts, as information such as laboratory results, test results, and chart notes may not be placed in the

chart for several days after the test or documentation is complete. As a result, it is important to realize the limitations of this data-rich environment and that the information obtained during the patient interview is still extremely important.

ELECTRONIC HEALTH RECORD

An electronic health record (EHR) is an electronic version of the paper chart. These records are available in hospitals, clinics, and institutional settings, but the type of EHR and the organization of information will vary among the different settings and software applications. The EHR provides a wealth of information and is one of the most complete sources of reliable information. Unlike a paper chart, the EHR may be interfaced with the laboratory, pharmacy, and radiology systems so that data are available in real time with minimal delays. Unfortunately, clinicians may rely on the EHR too much for the patient information, and unless medication and problem lists are updated at every visit, this could lead to assumptions. For example, a patient who has metformin

500 mg twice daily listed in the EHR may actually be taking the medication once daily. Therefore, the data in the EHR are extremely useful, but it is still important to obtain information directly from the patient and to reconcile the medication and problem list and update the EHR accordingly.

Data-Poor Environment

In reality, clinicians are often required to make assessments with limited information. Even in a relatively data-poor environment, such as a community pharmacy, valuable sources of information are still available, including (a) the medication profile, (b) patient demographic data, (c) medication allergy history, and (d) the patient's insurance coverage information. In addition, it is often possible to consult with the prescriber (or the prescriber's office staff); however, contact may be delayed, and requests for information may be met with resistance owing to time constraints or other factors. As illustrated later in this chapter, the successful practitioner can make assessments and intervene on the patient's behalf even with limited information.

PHARMACY INFORMATION SYSTEMS

Pharmacy information systems (PIS) are generally considered data poor. When evaluating information available in PIS, it is important to appreciate differences between inpatient and outpatient PIS. Pharmacy billing and inventory management were the motivation behind the establishment of the early PIS. These initial systems provided fill lists, generated patient profiles, and produced medication labels, which were valuable to institutional pharmacies as the profession moved toward a unit dose medication distribution system. More modern functionalities allow for some limited documentation of clinical pharmacy activities, but still, this system is data poor. Increased emphasis on patient safety highlights the importance of integrating PIS with other computerized systems used throughout the inpatient setting. An initiative set forth by the US Department of Health and Human Services, called the EHR Incentive Program, exemplifies the importance of the integration of systems.¹² This initiative, commonly referred to as the "Meaningful Use of an EHR," allows Medicare and Medicaid to provide incentive payments to providers and hospitals for the "meaningful use" of certified health information technology products. Eligibility for these incentive payments involves transitioning PIS to a more data-rich clinical information system (CIS), which includes direct computerized physician order entry, clinical decision support, an EHR, an electronic medication administration record (eMAR), and integration of various ancillary information systems such as pharmacy and laboratory services. Additional functionality incorporates the use of bar code technology, which allows the ability to track and promote quality assurance during the medication administration process. Information generated by the CIS is electronically transmitted to the pharmacy in real time, eliminating lost, illegible, or incomplete medication orders. Improved communication among various health care providers, decreased medication turnaround time, enhanced compliance with medication use policies and formularies, and reductions in medication errors are potential benefits of the EHR Incentive Program. Although increasing numbers of institutions are incorporating this technology into their practice settings, implementation of CIS in hospitals has not occurred for numerous reasons, including expense and system complexity.

Especially in a data-poor environment, it is important that the clinician be a proactive interviewer; in many instances, the interviewer becomes an investigator. The investigative approach is direct and requires strong problem-solving abilities and active listening skills. Questions should be formulated to obtain infor-

mation such as the medication history, actual medication use, patient perception of care, use of over-the-counter (OTC) and natural or herbal products, and health beliefs (cultural or otherwise). This approach can help to verify and ensure the accuracy of other data sources. Clinicians should be mindful that not all patients are reliable historians, and some are poor sources of information. Even when the patient is a poor historian, the interview provides critical information (e.g., indicator of poor adherence, need for a caregiver or interpreter, etc.) that cannot be obtained from other sources.

EFFECTIVE COMMUNICATION AND THE PATIENT INTERVIEW

The ability to use effective communication principles and history-taking skills is crucial to a successful patient interaction.^{6,11} The importance of interviewing the patient, how to set the stage for the interview, general interview rules, and the essential information to be obtained from the interview are outlined in Table 1-1.

TABLE 1-1
Interviewing the Patient

Importance of Interviewing the Patient

Establishes professional relationship with the patient to:

- Obtain subjective data on medical problems
- Obtain patient-specific information on drug efficacy and toxicity
- Assess the patient's knowledge about, attitudes toward, and pattern of medication use
- Formulate a problem list
- Formulate plans for medication teaching and pharmaceutical care

How to Set the Stage for the Interview

- Have the patient complete a written health and medication questionnaire, if available
- Introduce yourself
- Make the setting as private as possible
- Do not allow friends or relatives without permission of the patient
- Do not appear rushed
- Be polite
- Be attentive
- Maintain eye contact
- Listen more than you talk
- Be nonjudgmental
- Encourage the patient to be descriptive
- Clarify by restatement or patient demonstration (e.g., of a technique)

General Interview Rules

- Read the chart or patient profile first
- Ask for the patient's permission to conduct an interview or make an appointment to do so
- Begin with open-ended questions
- Move to close-ended questions
- Document interaction

Information to Be Obtained

- History of allergies
- History of adverse drug reactions
- Weight and height
- Drugs: dose, route, frequency, and reason for use
- Perceived efficacy of each drug
- Perceived side effects
- Adherence to prescribed drug regimen
- Nonprescription medication use (including complementary and alternative medications)
- Possibility of pregnancy in women of childbearing age
- Family or other support systems

Source: Teresa O'Sullivan, PharmD, University of Washington.

Information obtained from the patient is critical for assessment and planning in medication therapy management.



For an example of a patient interview and medication history taking tips, please go to <http://thepoint.lww.com/AT10e>.

OBTAINING A PATIENT HISTORY

Those who provide MTMS should develop standardized forms to record patient information obtained from the patient interview. Standardization facilitates quick retrieval of information, minimizes the inadvertent omission of data, and enhances the ability of other practitioners to use shared records.^{6,11}

For convenience, the patient interview and record can be divided into sections with subjective and objective data as well as an assessment and plan (including expected outcomes). Components of subjective and objective data are the medical history, medication history, and social history. In some situations, these histories can be supplemented by the generation of flowchart diagrams to monitor changes in specific variables (e.g., blood glucose concentration, blood pressure, weight) with time. These charts and documentation systems may be incorporated into the EHR, PIS, or a similar electronic platform.

Medical History

The medical history is essential to the provision of MTMS. It can be as extensive as the medical records that are maintained in an institution or physician's office, or it can be a simple patient profile that is maintained in a community pharmacy. The purpose of the medical history is to identify significant past medical conditions or procedures; identify, characterize, and assess current acute and chronic medical conditions and symptoms; and gather all relevant health information that could influence drug selection or dosing (e.g., function of major organs such as the gastrointestinal tract, liver, and kidney, which are involved in the absorption and elimination of drugs; height and weight, including recent changes in either; age and sex; pregnancy and lactation status; and special nutritional needs). Not all interviews require the interviewer to ask for this much general information; however, in a data-poor environment, more information is required directly from the patient. A more focused interview may be appropriate in settings in which the information required is available electronically or is specific to a single disease state. For example, in an anticoagulation clinic, the information that is elicited from the patient is often specific to the patient's anticoagulation therapy (e.g., bleeding incidents, newly started medications, dietary changes, missed warfarin doses, etc.).

CASE 1-1

QUESTION 1: P.J., a 45-year-old woman of normal height and weight, states that she has diabetes. What questions might the practitioner ask of P.J. to determine whether type 1 or type 2 disease should be documented in her medical history?

Patients usually can enumerate their medical problems in a general way, but the practitioner often will have to probe more specifically to refine the diagnosis and assess the severity of the condition. Diabetes mellitus is used to illustrate the types of questions that can be used to gather important health information

and assess drug therapy. The following questions should generate information that will help to determine whether P.J. has type 1 or type 2 diabetes mellitus.

- How old were you when you were told you had diabetes?
- Do any of your relatives have diabetes mellitus? What do you know of their diabetes?
- Do you remember your symptoms? Please describe them to me.
- What medications have you used to treat your diabetes?

When questions such as these are combined with knowledge of the pathophysiology of diabetes, appreciation of the typical presenting signs and symptoms of the disease, and understanding of the drugs generally used to treat both forms of diabetes, meaningful MTM can be provided. Even simple assessments such as the observation of a patient's body size can provide information useful for therapeutic interventions. For example, a person with type 2 diabetes is more likely to be an overweight adult (see Chapter 53, Diabetes Mellitus).

Medication History

In the community pharmacy setting, patients generally present themselves in one of four ways: (a) with a self-diagnosed condition for which nonprescription drug therapy is sought, (b) with a newly diagnosed condition for which a drug has been prescribed, (c) with a chronic condition that requires refill of a previously prescribed drug or the initiation of a new drug, or (d) on referral from their health plan or provider, or self-referral for focused medication therapy review (MTR). In the first and second situations, the practitioner must confirm the diagnosis by using disease-specific questions as illustrated in Question 1. In the third situation, the practitioner uses the same type of questioning as in the first two situations; however, this time the practitioner needs to evaluate whether the desired therapeutic outcomes have been achieved. The practitioner must evaluate the information gleaned during follow-up visits in the context of the history and incorporate it into his or her assessment and medication action plan (MAP). In the fourth situation, in which patients require a focused MTR, the medication and medical history information are equally important. Without the medical history, it is not possible to evaluate whether the drug therapy is appropriate, and without an accurate medication history, it is not possible to determine whether the patient has reached the desired goals of therapy for her condition. The goal of the medication history is to obtain and assess the following information: the specific prescription and nonprescription drugs that the patient is taking (the latter includes OTC medications, botanicals, dietary supplements, recreational drugs, alcohol, tobacco, and home remedies); the intended purpose or indications for each of these medications; how taken (e.g., route, ingestion in relation to meals), how much, and how often these medications are used; how long these agents have been taken or used (start and stop dates); whether the patient believes that any of these agents are providing therapeutic benefit; whether the patient is experiencing or has experienced any adverse effects that could be caused by each of these agents (idiosyncratic reactions, toxic effects, adverse effects); whether the patient has stopped taking any of the medications for any reason; and allergic reactions and any history of hypersensitivity or other severe reactions to drugs. This information should be as specific as possible, including a description of the reaction, the treatment, and the date of its occurrence.

The approach and process by which the medication history is obtained does not necessarily change based on the setting of the encounter. A successful medication reconciliation process consists of a standardized systematic approach, with the initial step

in this process involving the collection of the best medication history possible from every patient that enters any point in the health care system. The appropriate health care professional to obtain this information varies widely from one institution to the next, and may involve an array of individuals. Although pharmacists are uniquely qualified and have demonstrated increased accuracy in acquiring the medication history,¹³ ultimately, medication reconciliation requires a multidisciplinary effort in which all available resources are integrated into each step of the process when appropriate.¹⁴ Shared accountability by using key members of the health care team such as nurses, pharmacy technicians, pharmacists, and prescribers is essential in this process. Once an accurate medication history is obtained, this information is used to ensure that as the patient moves through the health care system, any deviation from prescribed regimen is deliberate and based on acute changes in the patient's condition. If an observed discrepancy is the result of an intended therapeutic decision by the prescribing clinician, appropriate documentation with either the reason for or intention to change, hold, or discontinue the medication should be completed in a manner that is clear to all members of the health care team. Unintentional variances in the medication lists should be considered as potential medication errors pending clarification from the prescribing clinician.

Because medication errors most commonly occur during transitions of care, the essential times to conduct medication reconciliation are when a patient is admitted to or discharged from a health care facility.^{15,16} A crucial final step in the reconciliation process, and a vital piece of MTMS, occurs at discharge to avoid therapeutic duplication, drug interactions, and omissions of medications that may have been discontinued or placed on hold during hospitalization. On departure from a health care facility, a complete list of the patient's medications must be communicated to the patient and the next provider of service regardless of the setting. It is important to realize that efforts to implement a medication reconciliation process should not focus simply on fulfilling a Joint Commission standard but that this process allows for informed prescribing decisions and creates a safer environment for patients by improving the accuracy of medication administration throughout the continuum of care.

Perhaps the most important aspect of the medication history is to ensure that no assumptions related to medication use go unverified with the patient. The provider should ask questions related to how the current medication therapy is actually taken by the patient. The interviewer should then compare the use of medications as defined by the patient to the prescription information on the bottle or in the PIS/EHR. This information may identify discrepancies or misunderstandings between the prescriber and patient. As discussed previously, the patient may not have adequate health literacy, and the interpretation of the medication instructions printed on the bottle or described by a health professional may not be understandable to a patient. The review of the medication history is an opportune time to identify and clarify such misunderstandings.

CASE 1-1, QUESTION 2: P.J. has indicated that she is injecting insulin to treat her diabetes. What questions might be asked to evaluate P.J.'s use of and response to insulin?

The following types of questions, when asked of P.J., should provide the practitioner with information on P.J.'s understanding about the use of and response to insulin.

DRUG IDENTIFICATION AND USE

- What type of insulin do you use?
- How many units of insulin do you use?

- When do you inject your insulin?
- Where do you inject your insulin? (Rather than the more judgmental question, "Do you rotate your injection sites?")
- Please show me how you usually prepare your insulin for injection. (This request of the patient requires the patient to demonstrate a skill.)
- What, if anything, keeps you from taking your insulin as prescribed?

ASSESSMENT OF THERAPEUTIC RESPONSE

- How do you know if your insulin is working?
- What blood glucose levels are you aiming for?
- What foods or meals do you find affect your blood sugars most?
- How often and when during the day do you test your blood glucose concentration?
- Do you have any blood glucose records that you could share with me?
- Please show me how you test your blood glucose concentration.
- What is your understanding of the hemoglobin A_{1c} blood test?
- When was the last time you had this test done?
- What were the results of the last hemoglobin A_{1c} test?

ASSESSMENT OF ADVERSE EFFECTS

- Do you ever experience reactions from low blood glucose?
- What symptoms warn you of such a reaction?
- When do these typically occur during the day?
- How often do they occur?
- What circumstances seem to make them occur more frequently?
- What do you do when you have a low blood glucose?

The patient's responses to these questions on drug use, therapeutic response, and adverse effects will allow a quick assessment of the patient's knowledge of insulin and whether she is using it in a way that is likely to result in blood glucose concentrations that are neither too high nor too low. The responses to these questions also should provide the practitioner with insight about the extent to which the patient has been involved in establishing and monitoring therapeutic outcomes. Based on this information, the practitioner can begin to formulate the patient's therapeutic plan.

Social History

The social history is used to determine the patient's occupation and lifestyle; important family relationships or other support systems; any particular circumstances (e.g., a disability) or stresses in her life that could influence the MAP; and attitudes, values, and feelings about health, illness, and treatments.

CASE 1-1, QUESTION 3: A patient's occupation, lifestyle, insurance status, ability to pay, and attitudes often can determine the success or failure of drug therapy. Therefore, P.J.'s prescription drug coverage, nutritional history, her level of activity or exercise in a typical day or week, the family dynamics, and any particular stresses that may affect glucose control need to be documented and assessed. What questions might be asked of P.J. to gain this information?

WORK

- Describe a typical workday and a typical weekend day.

INSURANCE/COST

- What type of prescription drug coverage do you have? How much do you pay for your insulin and diabetic supplies? How often do you go without your insulin or supplies because of their cost?

EXERCISE

- Describe your exercise habits. How often, how long, and when during the day do you exercise? Describe how you change your meals or insulin when you exercise.

DIET

- How many times per day do you usually eat? Describe your usual meal times.
- What do you usually eat for each of your main meals and snacks?
- Are you able to eat at the same time each day?
- What do you do if a meal is delayed or missed?
- Who cooks the meals at home? Does this person understand foods to prepare for someone with diabetes?
- How often do you eat meals in a restaurant?
- How do you order meals in a restaurant to maintain a proper diet for your diabetes? (*Note:* This is asked of patients who frequently dine in restaurants.)

SUPPORT SYSTEMS

- Who else lives with you? What do they know about diabetes? How do they respond to the fact that you have diabetes? How do they help you with your diabetes management? Does it ever strain your relationship? What are the issues that seem to be most troublesome? (*Note:* These questions apply equally to the workplace or school setting. Often, the biggest barrier to multiple daily injections is refusal of the patient to inject insulin while at work or school.)

ATTITUDE

- How do you feel about having diabetes?
- What worries or bothers you most about having diabetes? (*Note:* Participate in the patient's care. This approach is likely to enhance the patient-provider relationship, which should translate into improved care.)

APPROACH TO AND ASSESSMENT OF PATIENT THERAPY

The provider-patient encounter will vary based on the location and type of services provided and access to necessary information. However, the general approach to the patient encounter should follow the problem-oriented medical record (POMR). Organizing information according to medical problems (e.g., diseases) helps to break down a complex situation (e.g., a patient with multiple medical problems requiring multiple drugs) into its individual parts.^{4,5} The medical community has long used a *POMR* or *SOAP note* to record information in the medical record or chart by using a standardized format (Table 1-2). Each medical problem is identified, listed sequentially, and assigned a number. *Subjective* data and *objective* data in support of each problem are delineated, an *assessment* is made, and a *plan* of action identified. The first letter of the four key words (subjective, objective, assessment, and plan) serve as the basis for the SOAP acronym.

TABLE 1-2**Elements of the Problem-Oriented Medical Record^a**

Problem name: Each “problem” is listed separately and given an identifying number. Problems may be a patient complaint (e.g., headache), a laboratory abnormality (e.g., hypokalemia), or a specific disease name if prior diagnosis is known. When monitoring previously described drug therapy, more than one drug-related problem may be considered (e.g., nonadherence, a suspected adverse drug reaction or drug interaction, or an inappropriate dose). Under each problem name, the following information is identified:

| | |
|------------|---|
| Subjective | Information that explains or delineates the reason for the encounter. Information that the patient reports concerning symptoms, previous treatments, medications used, and adverse effects encountered. These are considered nonreproducible data because the information is based on the patient's interpretation and recall of past events. |
| Objective | Information from physical examination, laboratory test results, diagnostic tests, pill counts, and pharmacy patient profile information. Objective data are measurable and reproducible. |
| Assessment | A brief but complete description of the problem, including a conclusion or diagnosis that is supported logically by the above subjective and objective data. The assessment should not include a problem or diagnosis that is not defined above. |
| Plan | A detailed description of recommended or intended further workup (laboratory tests, radiology, consultation), treatment (e.g., continued observation, physiotherapy, diet, medications, surgery), patient education (self-care, goals of therapy, medication use and monitoring), monitoring, and follow-up relative to the above assessment. |

^a Sometimes referred to as the SOAP (subjective, objective, assessment, plan) note.

The POMR is a general approach and helps to focus the encounter, which provides a structure for the documentation of the services provided. The following section will describe the POMR and SOAP note in more detail.

Problem List

Problems are listed in order of importance and are supported by the subjective and objective evidence gathered during the patient encounter. Each problem in the list can then be given an identifying number. All subsequent references to a specific problem can be identified or referenced by that number (e.g., “problem 1” or simply “1”). These generally are thought of in terms of a diagnosed disease, but they also may be a symptom complex that is being evaluated, a preventive measure (e.g., immunization, contraception), or a cognitive problem (e.g., nonadherence). Any condition that requires a unique management plan should be identified as a problem to serve as a reminder to the practitioner that treatment is needed for that problem. Different settings and activities or clinical services will determine the priority of the problems identified.

Medical problems can be *drug related*, including prescribing errors, dosing errors, adverse drug effects, adherence issues, and the need for medication counseling. Drug-related problems may be definite (i.e., there is no question that the problem exists) or possible (i.e., further investigation is required to establish whether the problem really exists). The most commonly encountered types of drug-related problems are listed in Table 1-3.^{6,11}

TABLE 1-3
Drug-Related Problems

Drug Needed

Drug indicated but not prescribed; a medical problem has been diagnosed, but there is no indication that treatment has been initiated (maybe it is not needed)

Correct drug prescribed but not taken (nonadherence)

Wrong or Inappropriate Drug

No apparent medical problem justifying the use of the drug

Drug not indicated for the medical problem for which it has been prescribed

Medical problem no longer exists

Duplication of other therapy

Less expensive alternative available

Drug not covered by formulary

Failure to account for pregnancy status, age of patient, or other contraindications

Incorrect nonprescription medication self-prescribed by the patient

Recreational drug use

Wrong Dose

Prescribed dose too high (includes adjustments for renal and hepatic function, age, body size)

Correct prescribed dose but overuse by patient (overadherence)

Prescribed dose too low (includes adjustments for age, body size)

Correct prescribed dose but underuse by patient (underadherence)

Incorrect, inconvenient, or less-than-optimal dosing interval (consider use of sustained-release dosage forms)

Adverse Drug Reaction

Hypersensitivity reaction

Idiosyncratic reaction

Drug-induced disease

Drug-induced laboratory change

Drug Interaction

Drug–drug interaction

Drug–food interaction

Drug–laboratory test interaction

Drug–disease interaction

The distinction between medical problems and drug-related problems sometimes is unclear, and considerable overlap exists. For example, a medical problem (i.e., a disease, syndrome, symptom, or health condition) can be prevented, cured, alleviated, or exacerbated by medications. When assessing drug therapy, several situations could exist: treatment is appropriate and therapeutic outcomes have been achieved; drugs that have been selected are ineffective or therapeutic outcomes are partially achieved; dosages are subtherapeutic or medication is taken improperly; an inappropriate drug for the medical condition being treated has been prescribed or is being used; or the condition is not being treated.

Likewise, a drug-related problem can cause or aggravate a medical problem. Such drug-related problems could include hypersensitivity reactions; idiosyncratic reactions; toxic reactions secondary to excessive doses; adverse reactions (e.g., insulin-induced hypoglycemia or weight gain); drug–drug, drug–disease, drug–laboratory test, and drug–lifestyle interactions; or polypharmacy (using multiple medications), which may increase the risk of adverse drug events.¹⁷

Subjective and Objective Data

Subjective and objective data in support of a problem are important because assessment of patients and therapies requires the gathering of specific information to verify that a problem continues to exist or that therapeutic objectives are being achieved.

Subjective data refer to information provided by the patient or another person that cannot be confirmed independently. This is the data most commonly obtained during a patient interview. Objective data refer to information observed or measured by the practitioner (e.g., laboratory tests, blood pressure [BP] measurements). The objective data are most commonly obtained from the EMR or paper chart (data-rich environment). However, some objective data can be obtained in data-poor environments. In the absence of a medical record, weight, height, pulse, BP, blood glucose readings, and other objective information can be gathered during the provider–patient encounter.

CASE 1-2

QUESTION 1: P.N., a 28-year-old man, has a BP of 140/100 mm Hg. What is the primary problem? What subjective and objective data support the problem, and what additional subjective and objective data are not provided but usually are needed to define this particular problem?

The primary problem is hypertension. No subjective data are given. The objective data are the patient's age, sex, and BP of 140/100 mm Hg. Each of these is important in designing a patient-specific therapy plan. Because hypertension often is an asymptomatic disease (see Chapter 14, Essential Hypertension), subjective complaints such as headache, tiredness or anxiety, shortness of breath (SOB), chest pain, and visual changes usually are absent. If long-term complications such as rupturing of blood vessels in the eye, glomerular damage, or encephalopathy were present, subjective complaints might be blurring or loss of vision, fatigue, or confusion. Objective data would include a report by the physician on the findings of the chest examination (abnormal heart or lung sounds if secondary heart failure [HF] has developed), an ocular examination (e.g., presence of retinal hemorrhages), and laboratory data on renal function (blood urea nitrogen, creatinine, or creatinine clearance). To place these complications in better perspective, the rate of change should be stated. For example, the serum creatinine has increased from a level of 1 mg/dL 6 months ago to a value of 3 mg/dL today. Vague descriptions such as “eye changes” or “kidney damage” are of little value, because progressive damage to these end organs results from uncontrolled high BP, and disease progression needs to be monitored more precisely.

CASE 1-3

QUESTION 1: D.L., a 36-year-old construction worker, tripped on a board at the construction site 2 days ago, sustaining an abrasion of his left shin. He presents to the emergency department with pain, redness, and swelling in the area of the injury. He is diagnosed as having cellulitis. What is the primary problem? What subjective and objective data support the problem? What additional subjective and objective data are not provided but usually are needed to define this particular problem?

The primary problem is cellulitis of the left leg. Useful pieces of subjective information are D.L.'s description of how he injured his shin at a construction site and his current complaints of pain, redness, and swelling. The fact that he was at a construction site is indirect evidence of a possible dirty wound. Further information must be obtained about how he cleaned the wound after the injury and whether he has received a booster dose of tetanus toxoid within the past 10 years. Objectively, the wound is on the left shin. No other objective data are given. Additional data to obtain would be to document the intensity of the redness on a one-to-four-plus scale, the size of the inflamed area as

described by an area of demarcation, the circumference of his left shin compared with his right shin, the presence or absence of pus and any lymphatic involvement, his temperature, and a white blood cell count with differential.

CASE 1-4

QUESTION 1: C.S., a 58-year-old woman, has had complaints of fatigue, ankle swelling, and SOB, especially when lying down, for the past week. Physical examination shows distended neck veins, bilateral rales, an S₃ gallop rhythm, and lower extremity edema. A chest radiograph shows an enlarged heart. She is diagnosed as having HF and is being treated with furosemide and digoxin. What is/are the primary problem(s)? What subjective and objective data support the problem(s)? What additional subjective and objective data are not provided but usually are needed to define this (these) particular problem(s)?

The primary problem is systolic HF. Subjectively, C.S. claims to be experiencing fatigue, ankle swelling, and SOB, especially when lying down. She claims to have been taking furosemide and digoxin. An expanded description of these symptoms and her medication use would be helpful. The findings on physical examination and the enlarged heart on chest radiograph are objective data in support of the primary problem of HF. In addition, other objective findings that would help in her assessment would be the pulse rate, BP, serum creatinine, serum potassium concentration, digoxin blood level, a more thorough description of the rales on lung examination, extent of neck vein distension, and degree of leg edema. Pharmacy records could be screened to determine current dosages and refill patterns of the medications.

In this case, a second primary problem may be present. Current recommendations for the management of HF include use of an angiotensin-converting enzyme (ACE) inhibitor before or concurrent with digoxin therapy. Thus, a possible drug-related problem is the inappropriate choice of drug therapy (“wrong drug”). The patient or prescriber should be consulted to ascertain whether an ACE inhibitor has been used previously, any contraindications exist, or possible adverse effects were encountered.

Assessment

After the subjective and objective data have been gathered in support of specific listed problems, the practitioner should assess the acuity, severity, and importance of these problems. He or she should then identify all factors that could be causing or contributing to the problem. The assessment of the severity and acuity is important because the patient expects relief from the symptoms that are of particular concern at this time. During the initial encounter with a patient, it might be discovered that the medical problem is only a symptom complex and that a diagnosis is needed to more accurately identify the problem and further define its severity.

The assessment is usually performed during or immediately after the data gathering while the provider keeps in mind evidence-based practices. For example, if diabetes is assessed and pertinent subjective data (medication history, social history, diet, and exercise, etc.) and objective data exist (laboratory test results like hemoglobin A_{1c}, low-density lipoprotein cholesterol [LDL-C], BP, etc.), then the assessment of diabetes may be to determine whether the patient is meeting the goals for the disease as defined by the ADA. If the patient is not at goal, then the explanation of the reasons why would be described in the assessment, and the plan would then be centered on helping that patient get to goal. Sometimes, the distinction between subjective

information provided by the patient and assessments made by the practitioner are confused in the POMR. What the patient reveals belongs in the subjective data, and how the provider interprets it belongs in the assessment. For example, a patient stating that she is having difficulty affording her medications belongs in the subjective information. However, a patient appearing to have cost-related nonadherence belongs in the assessment, as it is the provider’s interpretation of what the patient has stated.

DRUG THERAPY ASSESSMENT

A responsibility of the practitioner is to monitor the response of patients to prescribed therapeutic regimens. The purpose of drug therapy monitoring is to identify and solve drug-related problems and to ensure that all therapeutic objectives are being achieved. Unless proven otherwise, the medical diagnosis should be assumed to be correct. On occasion, the diagnosis may not be readily apparent, or a drug-induced problem may have been diagnosed incorrectly as being a disease entity.

Nurses, pharmacists, physicians, physician assistants, and other health care practitioners share the responsibility to assess and monitor patient drug therapy. For the pharmacist, medication reconciliation and the drug therapy assessment may occur in many practice settings, including the community pharmacy while dispensing or refilling prescriptions or counseling patients, during MTMS encounters in the home or in the clinic, while assessing therapy for the hospitalized patient, or as part of routine monthly evaluations of patients residing in long-term care facilities. Many states have enacted legislation allowing pharmacists to develop collaborative drug therapy agreements with physicians for disease state management of common disorders such as asthma, diabetes, dyslipidemia, and hypertension. Additional services commonly provided by pharmacists through collaborative drug therapy agreements include anticoagulation monitoring, emergency contraception, and immunizations.⁷ These services often involve more detailed drug therapy evaluation and assessment and may occur within or outside the traditional pharmacy setting. Regardless, the patient’s need (this should be the primary consideration), time constraints, working environment (a determinant of the amount of patient information that is available), and practitioner’s skill level govern the extent of monitoring. Similarly, the exact steps used to monitor therapy and the order in which they are executed need to be adapted to a practitioner’s personal style. Thus, the examples given in this chapter should be used by the reader as a guide rather than as a recipe in a cookbook.

Plan

After the problem list is generated, subjective and objective data are reviewed, and the severity and acuity of the problems are assessed and prioritized, the next step in the problem-oriented (i.e., SOAP) approach is to create a plan, which at the minimum should consist of a diagnostic plan and an MAP that includes patient education. The plan is the action that was justified in the assessment. The plan is clear and direct and does not require explanation (this should be explained in the assessment). For example, if a patient is experiencing constipation while taking an opioid pain reliever, the plan would be to recommend a stool softener and stimulant laxative such as docusate sodium and bisacodyl. The plan should also include any follow-up that would be necessary as a result of to the action taken.

Patient Education

Educating patients to better understand their medical problem(s) and treatment is an implied goal of all treatment plans. This

process is categorized as the development of a patient education plan. The level of teaching has to be tailored to the patient's needs, health literacy, willingness to learn, and general state of health and mind. The patient should be taught the knowledge and skills needed to achieve and evaluate his or her therapeutic outcome. An important component of the patient education plan emphasizes the need for patients to follow prescribed treatment regimens.

The POMR will allow the provider to focus the interview and encounter independent of the site or service offered. The POMR facilitates documentation of the provision of MTMS across multiple sites and services (across the continuum of care).

The next few sections will discuss how to approach MTMS in various clinical settings.

MEDICATION THERAPY MANAGEMENT SERVICES IN THE COMMUNITY PHARMACY OR AMBULATORY SETTING

The core elements of MTMS have been described by the American Pharmacists Association (APhA) and the National Association of Chain Drug Stores.¹⁸ According to these organizations, the core elements of MTMS should include the following components:

1. Medication therapy review (MTR)
2. Personal medication record (PMR)
3. Medication action plan (MAP)
4. Intervention or referral
5. Documentation and follow-up

Medication Therapy Review (MTR)

The MTR may be a comprehensive review, including medication reconciliation, in which the provider reviews all of the medications the patient is currently taking, or it may be a focused review of one medication-related issue such as an adverse event. Examples of services provided during the MTR are described in Table 1-4. MTR is dependent on the information that is available

TABLE 1-4

Examples of Services Provided During a Medication Therapy Review

- Assess the patient's health status
- Assess cultural issues, health literacy, language barriers, financial status, and insurance coverage or other patient characteristics that may affect the patient's ability to take medications appropriately
- Interview the patient or caregiver to assess, identify, and resolve actual or potential adverse medication events, therapeutic duplications, untreated conditions or diseases, medication adherence issues, and medication cost considerations
- Monitor medication therapy, including response to therapy, safety, and effectiveness
- Monitor, interpret, and assess patient laboratory values, especially as they relate to medication use/misuse
- Provide education and training on the appropriate use of medications
- Communicate appropriate information to other health professionals, including the use and selection of medication therapy

Source: American Pharmacists Association; National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). *J Am Pharm Assoc* (2003). 2008;48(3):341–353.

from the patient or other data sources. Community pharmacies may be a data-poor environment, and access to necessary information may be limited. In some ambulatory clinics, the provider may have access to the EHR (data-rich environment).

Personalized Medication Record (PMR)

Regardless of the setting, a necessary tool to help with the gathering of the medication information is the PMR. This medication record should be updated after any change in medication therapy and should be shared with other health care providers. The patient is responsible for the upkeep of the PMR, but the PMR requires periodic review by the pharmacist or other provider. The goal of this record is to promote self-care and ownership of the medication regimen.¹⁸ The PMR should be used at all levels of care, thereby facilitating the medication reconciliation process required across the continuum of care. An example of a PMR is shown in Figure 1-2.

Once the patient interview has occurred and the PMR has been updated, the provider may still require information to make an assessment. In such cases, the provider must do his or her best with the available information, or may obtain missing information such as the medical history or objective data from other providers. Lack of objective information is common in the community pharmacy setting, and the ability to address all problems effectively may be limited in this data-poor environment. In some encounters, obtaining the necessary information and medication reconciliation may take the entire visit, necessitating a follow-up encounter.

Medication Action Plan (MAP)

If adequate information is available to assess the current problem, an MAP should be developed. Because the MAP is patient centered and is prioritized according to the urgency of need, the provider and the patient should develop the plan together. An example of an MAP can be seen in Figure 1-3.

Intervention and Referral

The MAP often describes the intervention performed in an MTM encounter and may serve as documentation that can be shared with the patient and other health care providers (like the PMR). The primary purpose of the MAP is to make the action plan patient centered and to provide the patient with documentation of what they need to do next in the action plan. It also provides space for the patient to document what he or she did related to this action and when it was done. In some instances, the MAP may involve referral to another provider (a physician or pharmacist with additional qualifications) if the issue is beyond the scope of the intervening pharmacist. Some reasons for referral may include diabetes education by a certified diabetes educator, diagnosis of a new or suspected medical condition, or laboratory testing that may be beyond the scope of the pharmacist.

Coordination of care is a key element of MTMS and MTR.⁴ This may include improving the communication between the patient and other health care providers, enhancing the patient's understanding of his or her health issues or concerns, maximizing health insurance coverage, advocating on behalf of the patient to get needed medications using available resources and programs, and various other functions that will improve the patient's understanding of his or her health care environment and promote self-care. Coordination of care may be the primary action taken on behalf of the patient and may be included in the MAP.

| Patient: M.C. ALLERGIES: None Type of reaction: N/A | | Primary Physician: Dr. Sara Smith (555-3971) | | | Pharmacist: Mary Doe (555-5551) | | Date Prepared: 4/2/12 | | Date Updated: 5/2/12 |
|---|-------------------------|--|----------|-----------------------------|---------------------------------------|---------------------|---|---------------------------|-------------------------|
| Start Date | Medication (generic) | Dosage | Route | Times per Day | Scheduled Times | Purpose for Use | Remarks | Prescriber (Phone) | Stop Date |
| 1/2/12 | (lisinopril) | 40 mg | By mouth | Once | 9 a.m. | High blood pressure | | Sara Smith, MD (555-3971) | |
| 1/2/12 | (metoprolol) | 50 mg | By mouth | Twice | 9 a.m. and 9 p.m. | High blood pressure | | Sara Smith, MD (555-3971) | |
| 1/2/12 | (glipizide) | 5 mg | By mouth | Once | 9 a.m. | Diabetes | Take 30 minutes before breakfast | Sara Smith, MD (555-3971) | |
| 1/2/12 | (indomethacin) | 50 mg | By mouth | Up to three times if needed | 9 a.m., 4 p.m., 11 p.m. | Back pain | Take with food. Do not take this medicine with other anti-inflammatory medicines (e.g., ibuprofen, naproxen). Do not take this medication unless you have pain. | Sara Smith, MD (555-3971) | |
| 4/2/12 | Crestor® (rosuvastatin) | 40 mg | By mouth | Once | 9 a.m. | Cholesterol | | Ted Hart, MD (555-1234) | |

Bring this Personal Medication Record with you to all visits with health care providers and if you are admitted to a hospital. Contact your pharmacist regarding questions or updates.

FIGURE 1-2 Example of a Personal Medication Record (PMR).

Documentation and Follow-up

The development of a documentation process is a necessary component of MTMS.¹⁸ Documentation should be standardized and based on the POMR format. All appropriate records, including the PMR and MAP, should be shared with other providers to promote communication and continuity of care. If the encounter

requires follow-up, the documentation should reflect the timing of the follow-up care, and any expectations of the patient and providers should be included. Thorough documentation of the encounter allows all providers to quickly assess the progress of the patient and determine that the desired outcome has been achieved.

| My Medication–Related Action Plan | |
|---|--------------------------------------|
| Patient: | M.C. |
| Provider (Phone): | Dr. Sara Smith (555-3971) |
| Pharmacy/Pharmacist (Phone): | RiteMart/Mary Doe, PharmD (555-5551) |
| Date Prepared: | May 2, 2012 |
| <p>The list below has important Action Steps to help you get the most from your medications. Follow the checklist to help you work with your pharmacist and providers to manage your medications AND make notes of your actions next to each item on your list</p> | |
| Action Steps → What I need to do... | Notes → What I did when I did it... |
| <input type="checkbox"/> For your muscle weakness and soreness Stop Crestor® (rosuvastatin) 40 mg. We asked Dr. Hart to change to a lower dose or different agent such as simvastatin. Obtain blood test from Dr. Hart's office. Follow-up with Dr. Hart in 2 days. | |
| <input type="checkbox"/> Medicine Cost We have asked Dr. Hart to stop Crestor (rosuvastatin) as it is too expensive. A generic medicine such as simvastatin will cost you less and was recommended to Dr. Hart as an alternative. Continue to ask your pharmacist and doctor whether the medications you are taking are covered by your Medicare Part D plan and whether there are any alternatives that might be less expensive for you. | |
| <input type="checkbox"/> For Pain Talk to Dr. Sara Smith about other pain medicines because the indomethacin may not be the best choice for you because of side effects. Some choices might include other medicines such as Vicodin (hydrocodone and acetaminophen), over-the-counter acetaminophen, or medicines like naproxen or ibuprofen. | |
| My next appointment with my pharmacist is on: _____ (date) at _____ <input type="checkbox"/> AM <input type="checkbox"/> PM | |

This form is based on forms developed by the American Pharmacist Association and the National Association of Chain Drug Store Foundation. Reproduced with permission from APhA and NACDS Foundation.

FIGURE 1-3 Example of a Medication Action Plan (MAP).

An important aspect of documenting the encounter is to submit billing for the encounter when appropriate. Although billing for MTMS is not universally accepted by all payers, the introduction of the national provider identifier (NPI) and pharmacist-specific CPT codes may soon make this a reality.^{7,19} The implementation of Medicare Part D in 2006 allowed pharmacists in pharmacies contracted with prescription drug plans to provide MTMS to plan-identified Medicare recipients. Pharmacists bill these plans through the contracted pharmacy by using an NPI and one of three CPT codes. The NPI number designates the provider to be paid, and the CPT determines the amount of payment based on the services rendered. The CPT codes specific to pharmacists providing MTMS include the following:

- CPT 99605:** Initial face-to-face assessment or intervention by a pharmacist with the patient for 1 to 15 minutes
- CPT 99606:** Subsequent face-to-face assessment or intervention by a pharmacist with the patient for 1 to 15 minutes
- CPT 99607:** Each additional 15 minutes spent face-to-face by a pharmacist with the patient; used in addition to 99605 or 99606

Although the NPI number and CPT codes allow pharmacists to bill for MTMS, the reimbursement varies by plan and negotiated contract and is beyond the scope of this text. Pharmacists have also developed patient self-pay reimbursement strategies as well as contracts with self-insured employers and state-run Medicaid programs to provide services.^{20,21}

The Patient Protection and Affordable Care Act of 2010 and the Health Care and Education Reconciliation Act of 2010 describe the need for payment reform that promotes improved quality of care. Other providers also see these laws providing new opportunities for pharmacists to participate in care teams such as the patient-centered medical home and pay-for-performance programs to improve medication-related care coordination, quality scores, and patient outcomes.^{22,23} The enhanced payment for improving quality in medication-related areas could be used to fund the pharmacist in this activity.

CASE 1-5

QUESTION 1: M.C. is a 76-year-old woman who comes to an appointment at the community pharmacy with her daughter for a focused MTR. She has a Medicare Part D prescription drug plan and is asking for help with her medication costs. She indicates that she has type 2 diabetes, hypertension, back pain, and hyperlipidemia. Her medications include lisinopril 40 mg once daily, metoprolol 50 mg twice daily, glipizide 5 mg once daily, indomethacin 50 mg up to three times daily as needed for pain, and rosuvastatin 40 mg once daily. M.C. tells you that she has trouble paying for her rosuvastatin (tier 3, \$60 copayment) and would rather have something generic that costs less (tier 1, \$5 copayment). Further, she complains of muscle soreness and weakness during the last 3 weeks. What objective information can be obtained in a community pharmacy setting? What is the primary problem? What additional information is necessary to determine the cause of her problem? How would a clinician assess and document her problem(s) in a SOAP format?

Although generally not considered a data-rich environment, increasing amounts of objective information can be gathered during the patient encounter at a community pharmacy. Specifically, information such as weight, BP, temperature, and finger-stick glucose and cholesterol levels can be measured if indicated for this patient. This information may be useful to the community

pharmacist when performing the MTR to determine whether the medications are achieving the desired therapeutic outcomes. Although the patient presented for MTR, the primary complaint is the patient's self-reported muscle weakness and soreness during the last 3 weeks. Assuming that M.C. is a patient of this pharmacy, the practitioner could gather the necessary medication history from the PIS. Because the patient is present, this is a good opportunity to develop a PMR with M.C. While developing the PMR with the patient, the practitioner should gather additional information from M.C. about her medication use. For example, the name of one of M.C.'s medicines could be read with the practitioner continuing to ask open-ended questions such as, "How do you take this medication?" "What is your routine for taking your medication?" and "What types of problems, if any, have you had while using this medication?" This process will help to quickly identify any medication discrepancies between the pharmacy computer system and the patient's understanding of medication administration. If discrepancies are noted, the practitioner can clarify them with M.C. right away as part of the intervention. The PMR should also include a section to list medication allergies. The type of reaction should also be included on the PMR so that other providers will know the severity of the medication allergy (i.e., intolerance vs. anaphylactic reaction). Based on data gathered from the pharmacy computer and M.C., a PMR (depicted in Fig. 1-3) could be developed.

Reviewing the medications alone often does not provide enough information to determine whether M.C. is experiencing a medication-related event. Further questioning may be necessary. M.C. should be asked questions such as "What other medications have you tried in the past?" "How often do you experience muscle weakness and soreness?" "Which muscles are hurting?" "Show me where the problem is," "What do you think is causing the problem?" or "Describe the problem you are experiencing in more detail." Asking questions related to the onset of her symptoms of muscle soreness and weakness will help to determine whether this is a medication-related problem.

The practitioner can develop an assessment from this questioning and the PMR of the current problem that she is experiencing. As indicated on the PMR, M.C. started rosuvastatin most recently. The initiation of this medication corresponds to the onset of her recent soreness and weakness. β -Hydroxy- β -methylglutaryl-CoA (HMG-CoA) reductase inhibitors like rosuvastatin are known to cause myositis, or muscle breakdown, which may lead to weakness and muscle soreness. Furthermore, the prescribed dose is high for a woman of M.C.'s age. Based on this information, an assessment of the problem can be pursued. If rosuvastatin is the suspected agent, the plan would include actions necessary to solve the problem or to determine whether rosuvastatin is the cause of her muscle soreness and weakness. Unfortunately, not all of the necessary information is available (e.g., her baseline cholesterol, serum creatinine, liver function tests, or creatine kinase levels) to develop a formal plan of action to resolve the adverse medication event. However, part of the plan may be to obtain the laboratory test results necessary to identify or act on the adverse medication event. An example of the documentation of the SOAP note follows.

PRIMARY PROBLEM:

Muscle soreness and weakness (possible adverse medication event)

SUBJECTIVE:

M.C. reports weakness and soreness, predominantly in her legs during the past 3 weeks. She has difficulty rising from her chair after sitting for long periods and describes the pain as aching. The patient reports taking her medications as prescribed and rarely misses a dose.

OBJECTIVE:

Total Cholesterol: 137 mg/dL; LDL-C: 56 mg/dL; HDL: 54 mg/dL;
Triglycerides: 136 mg/dL
Temperature: 98.5°F

ASSESSMENT:

M.C. has muscle weakness and soreness in her large muscle groups. She is currently at the recommended LDL-C goal level for a person with diabetes and hypertension per NCEP ATP III guidelines (very-high-risk LDL-C goal is <70 mg/dL).²⁴ Her current lipid therapy is rosuvastatin 40 mg once daily, which was started by her cardiologist 6 weeks ago. The initiation of rosuvastatin 40 mg correlates to the timing of her muscle soreness and weakness. HMG-CoA reductase inhibitors (i.e., rosuvastatin) are known to cause myositis or myalgias, and this patient is at particular risk given her age, sex, and starting dose. It is possible that the rosuvastatin could be causing her muscle soreness and weakness. Other lipid-lowering agents could be tried or the dose of rosuvastatin could be reduced, which might eliminate or reduce this adverse event. A creatine kinase level should be obtained to determine the severity of the myositis. A serum creatinine should also be measured, as myositis can lead to renal damage and rhabdomyolysis in severe cases; however, this is usually accompanied by fever and other symptoms that the patient is not currently experiencing.

PLAN:**1. DRUG-RELATED ADVERSE EVENT:**

- Discussed the possibility of an adverse medication event with the patient, which included the signs and symptoms of myalgias and myositis.
- Contacted Dr. Hart (M.C.'s cardiologist) to discuss the current problem with rosuvastatin.
- Per discussion with Dr. Hart, will obtain a creatine kinase level and serum creatinine.
- Discontinue rosuvastatin per the pharmacist's recommendation. Dr. Hart agreed that M.C. should temporarily stop her rosuvastatin until her laboratory values are reviewed.
- Alternative dosing of rosuvastatin 5 mg or another equivalent agent (atorvastatin 10 mg or simvastatin 20 mg) was discussed with Dr. Hart.
- M.C. is to see Dr. Hart in the cardiology clinic in 2 days to discuss the laboratory values and alternative therapies.
- Discussed the entire plan with M.C., and she verbalized understanding of steps that she is to take with respect to her current medication-induced problem.

CASE 1-5, QUESTION 2: From M.C.'s medication profile, what other problems can be identified with her medication therapy? What can be done to address these issues?

There are three remaining issues that may need to be addressed. The first issue relates to the pain medicine (indomethacin) that M.C. is taking. It is suggested that indomethacin may have a higher rate of central nervous system side effects in the elderly compared with other agents in the same class.²⁵ Furthermore, the American Geriatric Society guidelines on the management of mild to moderate persistent pain caution the use of nonsteroidal anti-inflammatory agents in older adults, preferring acetaminophen as a first-line agent.²⁶ Other prescription medications such as hydrocodone/acetaminophen or nonprescription medication such as acetaminophen alone could be used to help treat M.C.'s pain (see Chapter 7, Pain and Its Management, and Chapter 102, Geriatric Drug Use). Second, it is not clear from the current information whether the various providers are communicating. It is the responsibility of the pharmacist to help coordinate care among multiple prescribers as described by the APhA MTMS consensus document.⁴ Therefore, it is important to be sure that both providers (Drs. Smith and Hart) receive a copy of the documentation of the issues addressed during the visit (SOAP note).

Finally, M.C. came into the pharmacy asking for help with her medication costs. To assess this problem, it is important to ask whether there are specific cost issues with a particular drug or whether it is her overall medication regimen that causes her concern. Another important question to ask is whether she has stopped taking any medications or changed the way that she

TABLE 1-5**Cost Containment Strategies****Patient With Prescription Drug Coverage**

- Maximize generic drugs
- Maximize formulary coverage
- Switch to agents covered on the least expensive formulary tier
- If patient has Medicare Part D, determine eligibility for low-income subsidy through the Social Security Administration
- Consider mail-order prescription programs

Uninsured Patient

- Use low-cost generic programs (e.g., Rx Outreach, Costco, Wal-Mart, Target generic programs)
- Switch to therapeutically equivalent lower-cost brand name drugs when generics are unavailable
- Consider tablet splitting, if appropriate
- Consider pharmaceutical industry-sponsored patient assistance programs or foundation-sponsored copay-assistance programs
- Determine whether the patient is eligible for Medicaid, Medicare, Medicare Part D, or other assistance programs

takes her medications because of cost. Many patients will discuss cost and adherence issues with their pharmacist, because the point of sale for medications occurs at the pharmacy. However, they may not discuss this problem with the prescriber. Cost and nonadherence due to cost may be medication-related problems that the pharmacist must communicate to the prescriber on behalf of the patient. In assessing drug cost, there are several steps that can be taken. First, determine the patient's ability to pay for medications; implement low-cost, medically appropriate interventions targeted to patient needs; facilitate enrollment into relevant benefit programs; and confirm medication changes with the patient and prescribers (Table 1-5).

For M.C., the rosuvastatin is her biggest concern, as it costs \$60 per month and her Medicare Part D plan lists it as a nonpreferred (tier 3) agent on the formulary. With the possible discontinuation of her rosuvastatin, it is important for the pharmacist to anticipate her need for an alternative lipid-lowering agent and to determine whether there are cost-effective formulary alternatives that may be appropriate. This information can then be relayed to the prescriber. Furthermore, the alternative lipid-lowering formulary choice can be integrated into the plan developed for the primary issue of muscle soreness and weakness (see Case 1-5, Question 1). The integration of multiple problems is a complicated but important aspect of the MAP.

CASE 1-5, QUESTION 3: What additional information can be provided to M.C. at this time?

As discussed previously, an important part of MTMS involves the MAP. The MAP is a document that may empower the patient and promote self-care. The information on the MAP is important for both the patient and provider and facilitates communication among multiple providers. When a patient presents the PMR and MAP to all providers, complex medication information can be shared across the continuum of care. An example of M.C.'s MAP is included in Figure 1-3.

Because extensive information was communicated to the patient and other providers, follow-up (phone or face-to-face) would be appropriate and necessary to determine the resolution to the medication-related issues identified. Follow-up should occur in a timely manner, likely after M.C. has obtained the necessary laboratory test results and has been evaluated by her cardiologist as outlined in the plan. The follow-up should include questions related to the changes that were (or were not) made based on the practitioner recommendations and any new issues that have